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ABSTRACT
The paraventricular nucleus of the hypothalamus (PVN) is an important
cardiovascular and autonomic regulatory center. Activation of PVN neurons projecting
to the brainstem and spinal cord elevates sympathetic activity and blood pressure. Brain
derived neurotrophic factor (BDNF) plays a key role in stress-induced cardiovascular
responses within the PVN and is also known to be upregulated in the PVN in response to
stress and hyperosmolality. PVN overexpression or acute injection of BDNF also
elevates blood pressure chronically. However, the mechanism behind BDNF-mediated
cardiovascular regulation is not fully understood. BDNF is known to modulate
excitatory/inhibitory signaling by altering the expression and membrane trafficking of
neurotransmitter receptors. Further, changes in the excitatory/inhibitory signaling in the
PVN have been shown to elevate blood pressure and sympathetic activity chronically in
various hypertensive models. Thus, we set out to examine the long‐term effects of BDNF
overexpression within the PVN on NMDA‐, GABAA‐ and catecholaminergic receptor‐
mediated blood pressure mechanisms. We tested the hypothesis that BDNF increases
blood pressure, in part by diminishing catecholaminergic inhibitory input from the
nucleus of the solitary tract (NTS) to the PVN, while also enhancing NMDA and
diminishing GABAA-signaling in the PVN. Sprague-Dawley (SD) rats received bilateral
PVN injections of viral vectors expressing either green fluorescent protein (GFP) or
BDNF and bilateral NTS injections of vehicle or anti-dopamine-β-hydroxylaseconjugated saporin (DSAP), which selectively lesions catecholaminergic neurons. BDNF
overexpression in the PVN without NTS lesioning significantly increased mean arterial
pressure in awake animals (p < 0.001). DSAP treatment also increased blood pressure in
the GFP group but failed to affect blood pressure in the BDNF group. In addition,
hypotensive responses to PVN injections of a β-adrenergic agonist were significantly
attenuated by BDNF overexpression, while BDNF treatment also significantly reduced
β1-adrenergic receptor mRNA expression in the PVN (p < 0.01). Cardiovascular
responses to PVN injections of NMDA and GABAA agonists and antagonists were also
recorded in GFP and BDNF rats. NMDA inhibition led to greater decreases in blood
pressure in the BDNF group (p<0.05), while NMDA activation did not significantly alter
blood pressure in the two groups (p=0.31, n.s.). NMDA-signaling is elevated in the PVN
in response to BDNF, which may be due to an increase in presynaptic release of
glutamate or an increase in glutamatergic innervation. Meanwhile, GABAA inhibition
led to greater increases in blood pressure in the GFP group, while GABAA activation led
to a greater decrease in blood pressure in the GFP group. GABAergic signaling is reduced
in the PVN in response to BDNF, potentially due to a decrease in both presynaptic and
postsynaptic GABAA signaling mechanisms. Protein expression of NMDAR1 in the
PVN was also significantly elevated in the BDNF group (p<0.05) while GABAA-alpha1
expression in the PVN was diminished in the BDNF group (p<0.01). In summary,
increased BDNF expression in the PVN elevates blood pressure, in part by
downregulating β-receptor signaling and diminishing hypotensive catecholaminergic
input from the NTS to the PVN, while also promoting NMDA-mediated excitatory
activity and diminishing GABAA-mediated inhibitory activity in the PVN.

CITATIONS
Material from this dissertation has been published in the following form:
Thorsdottir, D., Cruickshank, N. C., Einwag, Z., Hennig, G. W., Erdos, B.. (2019).
BDNF Downregulates Adrenergic β-Receptor-Mediated Hypotensive Mechanisms in the
Paraventricular Nucleus of the Hypothalamus. American Journal of Physiology – Heart
and Circulatory Physiology, 317(6), H1258-H1271.

ii

ACKNOWLEDGEMENTS
I would like to express my sincere appreciation and thanks to my advisor: Benedek
Erdos, M.D., Ph.D., and to my dissertation committee: Tony Morielli, Ph.D., Margaret
Vizzard, Ph.D., and George Wellman, Ph.D., for their endless patience, support and
encouragement throughout my time in the Neuroscience Graduate Program.
I would also like to thank my current and former co-workers from the Erdos lab: Nick
Cruickshank, M.S., Terry Wellman, Friederike Uhlig, Ph.D., and Zach Einwag, M.S., as
well as NGP administrators Carrie Perkins and Haley Olszewski, and all my fellow NGP
students. I am grateful to all of you for your support and guidance during my time at the
University of Vermont.
Finally, I am especially thankful to my family and friends who have been a source of
endless love and support. This would not have been possible without you. Thank you.

iii

TABLE OF CONTENTS
ACKNOWLEDGEMENTS ............................................................................................... iii
LIST OF TABLES ........................................................................................................... viii
LIST OF FIGURES ........................................................................................................... ix
LIST OF ABBREVIATIONS ......................................................................................... xvii
CHAPTER 1: LITERATURE REVIEW ............................................................................ 1
1.1.
1.1.1.

Introduction: Hypertension and Sympathetic Control of Blood Pressure ............ 1
Hypertension Etiology and Prevalence............................................................. 1

1.1.2. Sympathetic and Neural Control of Blood Pressure Regulation ........................... 4
1.2.

Brain Regions Involved in Sympathetic and Cardiovascular Regulation ............ 7

1.2.1.

Paraventricular Nucleus of the Hypothalamus (PVN) ..................................... 7

1.2.2.

Rostral Ventrolateral Medulla (RVLM) ......................................................... 11

1.2.3.

Caudal Ventrolateral Medulla (CVLM) ......................................................... 12

1.2.4.

Nucleus of the Solitary Tract (NTS)............................................................... 13

1.2.5.

Baroreflex ....................................................................................................... 15

1.3. Neurotransmitter and Neuromodulator Signaling Mechanisms Involved in
the Regulation of Sympathetic, Cardiovascular and Neural activity in the PVN ......... 16
1.3.1. Glutamatergic signaling in the PVN ................................................................... 16
1.3.2. GABAergic signaling in the PVN ....................................................................... 18
1.3.3. Catecholaminergic signaling in the PVN ............................................................ 21
1.3.4. Angiotensinergic signaling in the PVN............................................................... 23
1.3.5. Vasopressinergic, Oxytocinergic and Corticotrophin Signaling in the PVN ...... 25
1.4.

BDNF Signaling in the Central Nervous System ............................................... 28

1.4.1.

BDNF Synthesis, Transport and Secretion ..................................................... 28

1.4.2.

BDNF and Catecholaminergic Signaling ....................................................... 32

1.4.3.

BDNF and Glutamatergic Signaling............................................................... 33

1.4.4.

BDNF and GABAergic Signaling .................................................................. 35
iv

1.4.5.
1.5.
1.5.1.

BDNF-mediated Neuroplasticity .................................................................... 37
BDNF Signaling in the Hypothalamus............................................................... 41
BDNF-mediated Cardiovascular and Sympathetic Regulation ...................... 41

1.5.2. BDNF-mediated Regulation of the Hypothalamic-Pituitary-Adrenal
(HPA) Axis .................................................................................................................... 43
1.5.3.

BDNF-mediated AVP Secretion and Osmoregulation ................................... 46

1.5.4.

BDNF-mediated Regulation of Metabolism and Food Intake........................ 48

CHAPTER 2: BDNF Downregulates Beta-Adrenergic Receptor-Mediated
Hypotensive Mechanisms in the Paraventricular Nucleus of the Hypothalamus ............. 53
2.1. Introduction ............................................................................................................ 53
2.2. Methods .................................................................................................................. 56
2.2.1. Experimental Design ........................................................................................... 57
2.2.2. Surgical Procedures ............................................................................................. 59
2.2.2.1. Telemetry Transmitter Implantation ................................................................ 59
2.2.2.2. Stereotaxic Viral Vector and DSAP Injections ................................................ 59
2.2.2.3. Assessment of Cardiovascular Responses to Adrenergic Receptor Agonists .. 60
2.2.3. Viral Vector-mediated Gene Transfer into the PVN and DSAP Lesioning of
NTS Neurons ................................................................................................................. 61
2.2.4. Analysis of Resting Radiotelemetric Cardiovascular Data ................................. 62
2.2.5. Acute Stress Procedures ...................................................................................... 63
2.2.6. Analysis of Cardiovascular Data from Anesthetized Animals............................ 64
2.2.7. Immunofluorescence ........................................................................................... 64
2.2.8. Confocal Microscopy and Image Analysis ......................................................... 68
2.2.9. Real-Time RT-PCR ............................................................................................. 68
2.2.10. Statistics ............................................................................................................ 69
2.3. Results .................................................................................................................... 70
2.3.1. Effects of BDNF and DSAP Treatments ............................................................ 70
2.3.2. Acute Water and Restraint Stress ........................................................................ 76
v

2.3.3. Effect of BDNF on Adrenergic Receptor Signaling in the PVN ........................ 80
2.3.4. Expression of Components of Catecholaminergic Signaling .............................. 83
2.4. Discussion .............................................................................................................. 85
2.5. Conclusion.............................................................................................................. 93
CHAPTER 3: BDNF Augments NMDA-signaling and Reduces GABAA-signaling in
the Paraventricular Nucleus of the Hypothalamus (PVN) to Elevate Blood Pressure ..... 94
3.1. Introduction ............................................................................................................ 94
3.2. Methods .................................................................................................................. 98
3.2.1. Experimental Design ........................................................................................... 98
3.2.2. Surgical Procedures ........................................................................................... 100
3.2.3. Assessment of cardiovascular responses to NMDA and GABAA agonists
and antagonists ............................................................................................................ 100
3.2.4.

Viral Vector-Mediated Gene Transfer into the PVN.................................... 101

3.2.5.

Analysis of Cardiovascular Data from Anesthetized Animals ..................... 103

3.2.6.

Immunofluorescence .................................................................................... 103

3.2.7.

Confocal Microscopy and Image Analysis ................................................... 104

3.2.8.

Real-Time RT-PCR ...................................................................................... 105

3.2.9.

Statistics ........................................................................................................ 106

3.3.

Results .............................................................................................................. 106

3.3.1. Effect of BDNF on NMDA-mediated signaling in the PVN ............................ 106
3.3.2. Effect of BDNF on GABAA-mediated signaling in the PVN .......................... 113
3.4.

Discussion ........................................................................................................ 125

3.5.

Conclusion........................................................................................................ 135

CHAPTER 4: SIGNIFICANCE OF FINDINGS ............................................................ 136
4.1. Hypertension and Sympathetic Cardiovascular Regulation ................................. 136
4.2. The Importance of BDNF Signaling .................................................................... 140
4.3. Potential Applications of Findings ....................................................................... 143
4.4. Experimental Limitations and Future Directions ................................................. 145
vi

CHAPTER 5: REFERENCES ........................................................................................ 151

vii

LIST OF TABLES
Table

Page

Table 1. Radiotelemetric parameters. Values are means ± SE. HR, heart rate; DIA,
diastolic pressure; SYS, systolic pressure; ACT, activity; sBRS, spontaneous
baroreflex sensitivity; AU, arbitrary units; BDNF, brain-derived neurotrophic
factor; DSAP, anti-dopamine-β-hydroxylase-conjugated saporin; GFP, green
fluorescent protein; PBS, phosphate-buffered saline; D, daytime; N, nighttime;
week 0 values represent average of parameters measured during the week
preceding vector injections; week 3 values represent average of parameters
measured during week 3 after vector injections. GFP+PBS, n = 6; GFP+DSAP,
n = 7; BDNF+PBS, n = 6; BDNF+DSAP, n = 7. †P < 0.05 GFP+PBS vs.
GFP+DSAP; *P < 0.05 GFP+PBS vs. BDNF+PBS; **P < 0.01 GFP+PBS vs.
BDNF+PBS; ***P < 0.001 GFP+PBS vs. BDNF+PBS (2-way repeated-measures
ANOVA for MAP and HR, and 1-way ANOVA for sBRS). .................................... 73

viii

LIST OF FIGURES
Figure

Page

Figure 1. Presympathetic neurons within the PVN stimulate spinal sympathetic
preganglionic neurons in the intermediolateral (IML) cell column directly or via
the rostral ventrolateral medulla (RVLM). Sympathetic preganglionic neurons
innervate the heart, blood vessels and kidneys to elevate blood pressure, heart rate
and sympathetic nervous system activity which in turn activates baroreceptors. The
baroreceptors activate sensory afferents via the vagus and glossopharyngeal nerves
that project to the nucleus of the solitary tract (NTS), where they excite the caudal
ventrolateral medulla (CVLM), which in turn inhibits the RVLM from increasing
sympathetic output. This negative feedback loop between the NTS, CVLM and
RVLM, is known as the baroreflex. The NTS also sends inhibitory
catecholaminergic projections to the PVN to inhibit PVN neuron activity. ............... 6
Figure 2. A: Timeline of experiment 1. B and C: representative fluorescent images of
coronal brain sections ~1.8 mm posterior from bregma showing PVN expression
of GFP and BDNFmyc, respectively. BDNFmyc expression was detected with an
anti-myc tag antibody and immunofluorescence; scale bars = 100 µm. D and E:
representative fluorescence images showing DβH expression in the NTS in coronal
brain sections at the level of the calamus scriptorius following PBS and DSAP
injections, respectively; scale bars, 100 µm. F and G: number of GFP- and mycpositive cells was assessed in subnuclei of the PVN; dorsal parvocellular nuclei
(dp), medial parvocellular nuclei (mp), ventrolateral parvocellular nuclei (vlp),
and posterior magnocellular nuclei (pm) following AAV2-GFP or
AAV2-BDNFmyc injections in the PVN and PBS or DSAP injections in the
NTS. DSAP had no significant effect on vector mediated gene transduction in
GFP or BDNF rats. GFP+PBS (n = 12), GFP+DSAP (n = 14), BDNF+PBS
(n = 12), BDNF+DSAP (n = 14); n refers to number of PVN sides. H: number of
DβH-positive neurons in the NTS following AAV2-GFP or AAV2-BDNFmyc
injections in the PVN and PBS or DSAP injections in the NTS. DSAP
significantly reduced the number of DβH-positive neurons in both the GFP and
BDNF groups. 3V, third ventricle; PVN, paraventricular nucleus; NTS, nucleus of
the solitary tract; GFP, green fluorescent protein; PBS, phosphate-buffered saline;
BDNF, brain-derived neurotrophic factor; BDNFmyc, myc epitope-tagged BDNF;
DβH, dopamine β-hydroxylase; DSAP, anti-dopamine-β-hydroxylase-conjugated
saporin; AAV2, adeno-associated viral vector 2. ***P < 0.001 for DSAP (1-way
ANOVA). .................................................................................................................. 65
Figure 3. A: Representative fluorescent image of a coronal brain section ~1.8 mm
posterior to bregma showing PVN expression of GFP and the red fluorescent
microbead solution that was mixed with injected drug solution to verify injection
ix

sites; scale bars, 250 µm. B and C: diagrams of the PVN ~1.8 mm and ~1.9 mm
posterior to bregma showing locations of isoprenaline injections in rats previously
injected with AAV2-GFP (gray circles) or AAV2-BDNFmyc (filled circles), and
phenylephrine (open circles) and aCSF (open triangles) injections in untreated
rats. 3V, third ventricle; lm, lateral magnocellular nuclei; dp, dorsal parvocellular
nuclei; mp, medial parvocellular nuclei; vlp, ventrolateral parvocellular nuclei;
PVN, paraventricular nucleus; GFP, green fluorescent protein; BDNF,
brain-derived neurotrophic factor; BDNFmyc, myc epitope-tagged BDNF; AAV2,
adeno-associated viral vector 2; aCSF, artificial cerebrospinal fluid. ....................... 67
Figure 4. Radiotelemetric recordings of daytime mean arterial pressure (MAP) and
heart rate [HR, in beats/min (bpm)]. Radiotelemetric parameters were recorded for
6 days before brain injections and during weeks 2–4 after brain injections.
Recording was turned off during the postsurgical recovery phase (between days 6
and 14), and data from day 28 are omitted because animals were subjected to water
stress on that day. Since viral vector and DSAP treatments had similar effects on
daytime and nighttime parameters, only daytime parameters are shown (nighttime
data are summarized in Table 1). A: daytime MAP (top) and HR (bottom) in
GFP+PBS (n = 6), GFP+DSAP (n = 7), BDNF+PBS (n = 6), and BDNF+DSAP
(n = 7) rats. B: average changes in daytime MAP (top) and HR (bottom) during
weeks 2, 3, and 4 from pretreatment baseline period. PVN, paraventricular
nucleus; NTS, nucleus of the solitary tract; GFP, green fluorescent protein; PBS,
phosphate-buffered saline; BDNF, brain-derived neurotrophic factor; DSAP,
anti-dopamine-β-hydroxylase-conjugated saporin. Results represent means ± SE.
Two-way repeated-measures ANOVA on weekly averages indicated significant
treatment effect for MAP and HR (P < 0.001), significant time effect for HR
(P < 0.05), and significant treatment × time interaction for both MAP and HR
(P < 0.01). Post hoc analysis indicated *P < 0.05 for GFP+PBS vs. BDNF+PBS,
**P < 0.01 for GFP+DSAP vs. BDNF+DSAP, ***P < 0.001 for GFP+PBS vs.
BDNF+PBS, ****P < 0.0001 for GFP+PBS vs. BDNF+PBS; #P < 0.05 for
GFP+PBS vs. GFP+DSAP, ##P < 0.01 for GFP+PBS vs. GFP+DSAP. .................. 72
Figure 5. DβH-positive vesicles in the PVN of rats previously injected with
AAV2-GFP or AAV2-BDNFmyc in the PVN and with PBS or DSAP in the NTS.
Top: representative confocal images of DβH expression within the PVN in all
experimental groups as detected with an anti-DβH antibody and
immunofluorescence; scale bars, 100 µm. Bottom: maximum percent volumetric
density of DβH-positive vesicles within the PVN, averaged for each experimental
group; n refers to number of PVN sides [GFP+PBS (n = 6), GFP+DSAP (n = 12),
BDNF+PBS (n = 8), BDNF+DSAP (n = 8)]. 3V, third ventricle; PVN,
paraventricular nucleus; NTS, nucleus of the solitary tract; GFP, green fluorescent
protein; PBS, phosphate-buffered saline; BDNF, brain-derived neurotrophic factor;
DBH, dopamine β-hydroxylase; DSAP, anti-dopamine-β-hydroxylase-conjugated
x

saporin; AAV2, adeno-associated viral vector 2. Results represent means ± SE.
P = 0.06 for GFP+PBS vs. GFP+DSAP; &P < 0.05 for GFP+DSAP vs.
BDNF+DSAP (1-way ANOVA) ............................................................................... 75
Figure 6. Radiotelemetric recordings of mean arterial pressure (MAP) and heart rate
(HR) during acute water stress and poststress recovery in GFP+PBS (n = 6),
GFP+DSAP (n = 7), BDNF+PBS (n = 6) and BDNF+DSAP (n = 7) rats. A: MAP
(top) and HR (bottom) traces with 3-min moving average during stress (15 min,
indicated by arrow) and during poststress recovery (60 min). B: amplitude and
delay of peak MAP and HR responses. C: MAP and HR increases averaged during
stress and poststress recovery. Prestress MAP and HR were 94 ± 3 mmHg and
308 ± 11 beats/min (bpm) in the GFP+PBS group, 101 ± 4 mmHg and 327 ± 9
beats/min in the GFP+DSAP group, 121 ± 4 mmHg and 366 ± 19 beats/min in the
BDNF+PBS group, and 113 ± 5 mmHg and 378 ± 11 beats/min in the
BDNF+DSAP group. GFP, green fluorescent protein; PBS, phosphate-buffered
saline; BDNF, brain-derived neurotrophic factor; DSAP, anti-dopamine-βhydroxylase-conjugated saporin. Results represent means ± SE. **P < 0.01 for
GFP+PBS vs. BDNF+PBS (1-way ANOVA). .......................................................... 77
Figure 7. Radiotelemetric recordings of mean arterial pressure (MAP) and heart rate
(HR) during acute restraint stress and poststress recovery in GFP+PBS (n = 6),
GFP+DSAP (n = 7), BDNF+PBS (n = 6), and BDNF+DSAP (n = 7) rats. A: MAP
(top) and HR (bottom) traces with 3-min moving average during stress (60 min,
indicated by arrow) and during poststress recovery (60 min). B: amplitude and
delay of peak MAP and HR responses. C: MAP and HR increases averaged
during stress and poststress recovery. Prestress MAP and HR were 92 ± 3 mmHg
and 311 ± 11 beats/min (bpm) in the GFP+PBS group, 101 ± 4 mmHg and
351 ± 14 beats/min in the GFP+DSAP group, 120 ± 2 mmHg and 372 ± 18
beats/min in the BDNF+PBS group, and 114 ± 3 mmHg and 380 ± 13 beats/min
in the BDNF+DSAP group. GFP, green fluorescent protein; PBS, phosphatebuffered saline; BDNF, brain-derived neurotrophic factor; DSAP,
anti-dopamine-β-hydroxylase-conjugated saporin. Results are represented as
means ± SE. *P < 0.05, for GFP+PBS vs. BDNF+PBS, ##P < 0.01, GFP+PBS vs.
GFP+DSAP (1-way ANOVA). ................................................................................. 79
Figure 8. Changes in mean arterial pressure (MAP; top) and heart rate (HR; bottom)
in response to PVN injections of adrenergic receptor agonists and vehicle in
anesthetized rats previously treated with AAV2-GFP (n = 6) or AAV2-BDNFmyc
(n = 7). A: MAP and HR obtained with 10-s moving average over 120 s following
isoprenaline (ISO) injection in GFP and BDNFmyc treated rats, and phenylephrine
(PE; n = 3) or aCSF, artificial cerebrospinal fluid (aCSF; n = 3) injections in
untreated rats. B: average peak MAP and HR responses to ISO, PE, and aCSF
injections. Baseline MAP and HR were 89 ± 6 mmHg and 351 ± 15 beats/min
(bpm) in GFP and 108 ± 4 mmHg and 398 ± 15 beats/min in BDNF rats, and
xi

105 ± 3 mmHg and 353 ± 7 beats/min in untreated rats. PVN, paraventricular
nucleus; GFP, green fluorescent protein; BDNF, brain-derived neurotrophic
factor; BDNFmyc, myc epitope-tagged BDNF; AAV2, adeno-associated viral
vector 2. Results represent means ± SE. Statistical analysis was done on peak
changes in MAP and HR. #P < 0.05 for 250 µM ISO vs. aCSF, *P < 0.05, for
GFP vs. BDNF (1-way ANOVA).............................................................................. 81
Figure 9. Expression of BDNF, CRH, and adrenergic receptor mRNA in the PVN, and
TH and DβH mRNA in the NTS of rats previously injected with AAV2-GFP
(n = 6) or AAV2-BDNFmyc (n = 6) in the PVN. A: significant increases in BDNF
and CRH mRNA expressions verify successful vector mediated BDNF
transduction and activation of BDNF-mediated signaling mechanisms. B:
expressions of α1a-, α1b-, and α2a- and β1- and β2-adrenergic receptor mRNAs
in GFP and BDNF rats. C: expressions of TH and DβH mRNAs in the NTS of
AAV2-GFP (n = 7) and AAV2-BDNFmyc (n = 7) rats. PVN, paraventricular
nucleus; NTS, nucleus of the solitary tract; GFP, green fluorescent protein;
BDNF, brain-derived neurotrophic factor; BDNFmyc, myc epitope-tagged
BDNF; TH, tyrosine hydroxylase; DBH, dopamine β-hydroxylase; AAV2,
adeno-associated viral vector 2; CRH, corticotropin-releasing hormone. Results
are expressed as 2−ΔΔCT (where CT is threshold cycle) normalized to the
control group and presented as means ± SE. **P < 0.01 GFP vs. BDNF
(unpaired t test). ......................................................................................................... 84
Figure 10. Representative fluorescent image of a coronal brain section ~1.8 mm
posterior to bregma showing PVN expression of AAV2-GFP (A) or AAV2BDNFmyc (B) and the red fluorescent microbead solution that was mixed with
injected drug solution to verify injection sites (C); scale bars, 250 µm. D.
diagrams of the PVN ~1.8 mm and ~1.9 mm posterior to bregma showing
locations of drug injections in rats previously injected with AAV2-GFP (circle,
shown aggregated on the left side of the PVN) or AAV2-BDNFmyc (rectangle,
shown aggregated on the right side of the PVN). E. number of GFP- and mycpositive cells was assessed in subnuclei of the PVN; dorsal parvocellular nuclei
(DP), medial parvocellular nuclei (MP), ventrolateral parvocellular nuclei (VLP),
and posterior magnocellular nuclei (PM) following AAV2-GFP or AAV2BDNFmyc injections in the PVN. 3V, third ventricle; PVN, paraventricular
nucleus; GFP, green fluorescent protein; BDNF, brain-derived neurotrophic
factor; BDNFmyc, myc epitope-tagged BDNF; AAV2, adeno-associated viral
vector 2. ................................................................................................................... 102
Figure 11. Changes in mean arterial pressure (MAP; top) and heart rate (HR; bottom)
in response to PVN injections of the NMDA receptor antagonist AP5 (A, B) and
NMDA-receptor agonist NMDA (C, D) in anesthetized rats previously treated
with AAV2-GFP or AAV2-BDNFmyc. A: MAP and HR obtained with 10-s
moving average over 180 seconds following AP5 injection in GFP (n=5) and
xii

BDNFmyc (n=7) treated rats. B: Average max decrease in MAP and heart rate
responses to AP5 injections. C: MAP and HR obtained with 20-s moving
average over 180 seconds following NMDA injection in GFP (n=5) and
BDNFmyc (n=7) treated rats. D: Average max decrease and increase in MAP
and average max decrease in heart rate responses to NMDA injections.
Statistical analysis was done on max changes in MAP and heart rate. PVN,
paraventricular nucleus; GFP, green fluorescent protein; BDNF, brain-derived
neurotrophic factor; BDNFmyc, myc epitope-tagged BDNF; AAV2, adenoassociated viral vector 2. Results represent means ± SE. Statistical analysis was
done on peak changes in MAP and HR. *P < 0.05 for GFP vs. BDNF (unpaired
t-test). ....................................................................................................................... 108
Figure 12. NMDAR1 fluorescent expression in the PVN of rats previously injected
with AAV2-GFP (A) or AAV2-BDNFmyc (B) in the PVN. Representative
confocal images of NMDAR1 expression within the PVN in GFP (A) and
BDNFmyc (B) groups as detected with an NMDAR1 antibody and
immunofluorescence; scale bars, 100 µm. C-D. ROI mean (C) and ROI max (D)
NMDAR1 in the PVN, averaged for each experimental group; n refers to number
of PVN sides [GFP (n = 11) and BDNFmyc (n = 7)]. E: PVN mean NMDAR1
expression [GFP (n = 11) and BDNFmyc (n = 7)]. 3V, third ventricle; PVN,
paraventricular nucleus; GFP, green fluorescent protein; BDNF, brain-derived
neurotrophic factor; AAV2, adeno-associated viral vector 2. Results represent
means ± SE. *P < 0.05 for GFP vs. BDNF; ***P < 0.001 for GFP vs. BDNF
(unpaired t test). ....................................................................................................... 109
Figure 13. A: NMDAR1 fluorescent expression in the PVN of rats previously
injected with AAV2-GFP, showing a rectangular area which is magnified in B-D,
scale bar 100 uM. B-D: Representative 60X magnification confocal images
showing NMDAR1 and GFP expression in the PVN. Arrows show overlap of
NMDAR1 staining with GFP infected cell bodies and fibers, scale bar 50 µM. E:
NMDAR1 fluorescent expression in the PVN of rats previously injected with
AAV2-BDNFmyc, showing a rectangular area which is magnified in F-H, scale
bar 100 uM. F-H: Representative 60X magnification confocal images showing
NMDAR1 and BDNFmyc expression in the PVN. Arrows show overlap of
NMDAR1 staining with BDNFmyc infected cell bodies and fibers, scale bar
50 µM. ..................................................................................................................... 110
Figure 14. Synapsin 1a/b fluorescent expression in the PVN of rats previously injected
with AAV2-GFP or AAV2-BDNFmyc in the PVN. A-B. Representative confocal
images of NMDAR1 expression within the PVN in GFP (A) and BDNFmyc (B)
groups as detected with a synapsin 1a/b antibody and immunofluorescence; scale
bars, 100 µm. C-D. ROI mean (C) and ROI max (D) synapsin 1a/b expression in
the PVN, averaged for each experimental group; n refers to number of PVN sides
[GFP (n = 8) and BDNFmyc (n = 8)]. E: PVN mean synapsin 1a/b expression
xiii

[GFP (n = 8) and BDNFmyc (n = 8)]. 3V, third ventricle; PVN, paraventricular
nucleus; GFP, green fluorescent protein; BDNF, brain-derived neurotrophic
factor; AAV2, adeno- associated viral vector 2. Results represent means ± SE. .... 111
Figure 15. A: Synapsin 1a/b fluorescent expression in the PVN of rats previously
injected with AAV2-GFP, showing a rectangular area which is magnified in B-D,
scale bar 100 uM. B-D: Representative 60X magnification confocal images
showing synapsin 1a/b and GFP expression in the PVN. Arrows show overlap of
synapsin 1a/b staining with GFP infected cell bodies and fibers, scale bar 50 µM.
E: Synapsin 1a/b fluorescent expression in the PVN of rats previously injected
with AAV2-BDNFmyc, showing a rectangular area which is magnified in F-H,
scale bar 100 uM. F-H: Representative 60X magnification confocal images
showing synapsin 1a/b and BDNFmyc expression in the PVN. Arrows show
overlap of synapsin 1a/b staining with BDNFmyc infected cell bodies and
fibers, scale bar 50 µM. ........................................................................................... 112
Figure 16. Changes in mean arterial pressure (MAP; top) and heart rate (HR; bottom)
in response to PVN injections of the GABAA receptor antagonist gabazine (A, B)
and GABAA-receptor agonist muscimol (C, D) in anesthetized rats previously
treated with AAV2-GFP or AAV2-BDNFmyc. A: MAP and HR obtained with
20-s moving average over 600 seconds following gabazine injection in GFP (n=6)
and BDNFmyc (n=7) treated rats. B: Average max increase in MAP and HR
responses to gabazine injections. C: MAP and HR obtained with 20-s moving
average over 900 seconds following muscimol injection in GFP (n=5) and
BDNFmyc (n=7) treated rats. D: Average max decrease in MAP and HR
responses to muscimol injections. Statistical analysis was done on average max
changes in MAP and HR. PVN, paraventricular nucleus; GFP, green fluorescent
protein; BDNF, brain-derived neurotrophic factor; BDNFmyc, myc
epitope-tagged BDNF; AAV2, adeno-associated viral vector 2. Results represent
means ± SE. Statistical analysis was done on peak changes in MAP and HR.
*P < 0.05 for GFP vs. BDNF (unpaired t test). ....................................................... 114
Figure 17. GABAA-alpha1 fluorescent expression in the PVN of rats previously
injected with AAV2-GFP or AAV2-BDNFmyc in the PVN. A-B. Representative
confocal images of GABAA-alpha1 expression within the PVN in GFP (A) and
BDNFmyc (B) groups as detected with an GABAA-alpha1 antibody and
immunofluorescence; scale bars, 100 µm. C-D. ROI mean (C) and ROI max (D)
GABAA-alpha1 expression in the PVN, averaged for each experimental group;
n refers to number of PVN sides [GFP (n = 8) and BDNFmyc (n = 7)]. E: PVN
mean GABAA-alpha1 expression [GFP (n = 8) and BDNFmyc (n = 7)]. F: Area
mean of GABAA-alpha1 within the peri-PVN and the parvocellular PVN [GFP
(n = 8) and BDNFmyc (n = 7)]. 3V, third ventricle; PVN, paraventricular nucleus;
GFP, green fluorescent protein; BDNF, brain-derived neurotrophic factor; AAV2,
adeno-associated viral vector 2. Results represent means ± SE. *P < 0.05 for GFP
xiv

Peri-PVN vs. BDNFmyc Peri-PVN; **P < 0.05 for BDNF PVN vs. BDNF PeriPVN; **P < 0.01 for GFP vs. BDNF (unpaired t test). ........................................... 116
Figure 18. A: GABAA-alpha1 fluorescent expression in the PVN of rats previously
injected with AAV2-GFP, showing a rectangular area which is magnified in
B-D, scale bar 100 uM. B-D: Representative 60X magnification confocal images
showing GABAA-alpha1 and GFP expression in the PVN. Arrows show overlap
of GABAA-alpha1 staining with GFP infected cell bodies and fibers, scale bar 50
µM. E: GABAA-alpha1 fluorescent expression in the PVN of rats previously
injected with AAV2-BDNFmyc, showing a rectangular area which is magnified
in F-H, scale bar 100 µM. F-H: Representative 60X magnification confocal
images showing GABAA-alpha1 and BDNFmyc expression in the PVN. Arrows
show overlap of GABAA-alpha1 staining with BDNFmyc infected cell bodies
and fibers, scale bar 50 µM. .................................................................................... 117
Figure 19. GAD67 fluorescent expression in the PVN of rats previously injected with
AAV2-GFP or AAV2-BDNFmyc in the PVN. A-B. Representative confocal
images of GAD67 expression within the PVN in GFP (A) and BDNFmyc (B)
groups as detected with a GAD67 antibody and immunofluorescence; scale bars,
100 µm. C-D. ROI mean (C) and ROI max (D) GAD67 in the PVN, averaged for
each experimental group; n refers to number of PVN sides [GFP (n = 9) and
BDNFmyc (n = 8)]. E: PVN mean GAD67 expression [GFP (n = 9) and
BDNFmyc (n = 8)]. 3V, third ventricle; PVN, paraventricular nucleus; GFP,
green fluorescent protein; BDNF, brain-derived neurotrophic factor; AAV2,
adeno-associated viral vector 2. Results represent means ± SE. ............................. 119
Figure 20. A: GAD67 fluorescent expression in the PVN of rats previously injected
with AAV2-GFP, showing a rectangular area which is magnified in B-D, scale
bar 100 uM. B-D: Representative 60X magnification confocal images showing
GAD67 and GFP expression in the PVN. Arrows show overlap of GAD67
staining with GFP infected cell bodies and fibers, scale bar 50 µM. E: GAD67
fluorescent expression in the PVN of rats previously injected with AAV2BDNFmyc, showing a rectangular area which is magnified in F-H, scale bar 100
uM. F-H: Representative 60X magnification confocal images showing GAD67
and BDNFmyc expression in the PVN. Arrows show overlap of GAD67 staining
with BDNFmyc infected cell bodies and fibers, scale bar 50 uM. .......................... 120
Figure 21. KCC2 fluorescent expression in the PVN of rats previously injected with
AAV2-GFP or AAV2-BDNFmyc in the PVN. A-B. Representative confocal
images of KCC2 expression within the PVN in GFP (A) and BDNFmyc (B)
groups as detected with a KCC2 antibody and immunofluorescence; scale bars,
100 µm. C-D. ROI mean (C) and ROI max (D) KCC2 in the PVN, averaged for
each experimental group; n refers to number of PVN sides [GFP (n = 8) and
BDNFmyc (n = 9)]. E: PVN mean KCC2 expression [GFP (n = 8) and
BDNFmyc (n = 9)]. 3V, third ventricle; PVN, paraventricular nucleus; GFP,
xv

green fluorescent protein; BDNF, brain-derived neurotrophic factor; AAV2,
adeno-associated viral vector 2. Results represent means ± SE. *P < 0.05 for GFP
vs. BDNFmyc; ***P < 0.001 for GFP vs. BDNFmyc (unpaired t test). ................. 121
Figure 22. A: KCC2 fluorescent expression in the PVN of rats previously injected
with AAV2-GFP, showing a rectangular area which is magnified in B-D, scale
bar 100 µM. B-D: Representative 60X magnification confocal images showing
KCC2 and GFP expression in the PVN. Arrows show overlap of KCC2 staining
with GFP infected cell bodies and fibers, scale bar 50 uM. E: KCC2 fluorescent
expression in the PVN of rats previously injected with AAV2-BDNFmyc,
showing a rectangular area which is magnified in F-H, scale bar 100 uM. F-H:
Representative 60X magnification confocal images showing KCC2 and
BDNFmyc expression in the PVN. Arrows show overlap of KCC2 staining with
BDNFmyc infected cell bodies and fibers, scale bar 50 µM. .................................. 122
Figure 23. Expression of NMDAR1 and GABAA-delta receptor mRNA in the PVN
of rats previously injected with AAV2-GFP (n = 6) or AAV2-BDNFmyc (n = 7)
in the PVN. A: Expression of NMDAR1 mRNA in the PVN of AAV2-GFP
(n = 12 sides of PVN) and AAV2-BDNFmyc (n = 13 sides of PVN) rats. B:
Expression of GABAA-delta receptor mRNAs in the PVN of AAV2-GFP
(n = 13 sides of PVN) and AAV2-BDNFmyc (n = 12 sides of PVN) rats. PVN,
paraventricular nucleus; GFP, green fluorescent protein; BDNF, brain-derived
neurotrophic factor; BDNFmyc, myc epitope-tagged BDNF; AAV2, adenoassociated viral vector 2. Results are expressed as 2−ΔΔCT (where CT is
threshold cycle) normalized to the control group and presented as means ± SE. .... 123
Figure 24. Mean area of neuronal soma of AAV2-GFP (n=18 sides of PVN) and
AAV2-BDNFmyc (n=15 sides of PVN) infected cells in the PVN. PVN,
paraventricular nucleus; GFP, green fluorescent protein; BDNF, brain-derived
neurotrophic factor; BDNFmyc, myc epitope-tagged BDNF; AAV2, adenoassociated viral vector 2. ......................................................................................... 124

xvi

LIST OF ABBREVIATIONS
ACE Angiotensin Converting Enzyme
ACTH Adrenocorticotropic Hormone
AGRP Agouti-Related Protein
Alpha-MSH Alpha Melanocyte-Stimulating Hormone
AMPA α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid
ANA-12 [N2-2-2-oxoazepan-3-yl amino] carbonyl phenyl benzo (b)thiophene-2carboamide
Ang II Angiotensin II
AT1R Angiotensin Type 1 Receptor
AVP Arginine Vasopressin
BDNF Brain-Derived Neurotrophic Factor
BNST Bed Nucleus of the Stria Terminalis
cAMP Cyclic Adenosine Monophosphate
CNS Central Nervous System
CPA Caudal Pressor Area
CRH Corticotropin Releasing Hormone
CRHR1 Corticotropin-Releasing Hormone Receptor 1
CRHR2 Corticotropin-Releasing Hormone Receptor 2
CVLM Caudal Ventrolateral Medulla
DBH Dopamine Beta Hydroxylase
DMH Dorsomedial Nucleus of the Hypothalamus
DMV Dorsal Motor Nucleus of the Vagus
DVC Dorsal Vagal Complex
DSAP DBH-Conjugated Saporin
EAAT Excitatory Amino Acid Transporter
Erk Extracellular Signal-related Kinase
GABA γ-Aminobutyric Acid
GAD Glutamic Acid Decarboxylase
xvii

GAT GABA Transporter
GPCR Guanine Nucleotide-Binding protein-Coupled Receptors
GR Glucocorticoid Receptor
HPA Hypothalamic-Pituitary-Adrenal Axis
HPT Hypothalamic-Pituitary-Thyroid Axis
ICV Intracerebroventricular
IML Intermediolateral Cell Column of the Thoraco Lumbar Spinal Cord
KCC2 K+- Cl− cotransporter 2
KO Knockout
LH Lateral Hypothalamic Area
LFS Low Frequency Stimulation
LTD Long-Term Depression
LTP Long-Term Potentiation
MAP Mean Arterial Pressure
MC4r Type 4 Melanocortin Receptor
mEPSC Miniature Excitatory Postsynaptic Current
mIPSC Miniature Inhibitory Postsynaptic Current
MnPO Median Preoptic Nucleus
mGluR Metabotropic Glutamate Receptor
MAPK Mitogen-activated Protein Kinase
MR Mineralocorticoid Receptor
NADPH Nicotinamide Adenine Dinucleotide Phosphate
NGF Nerve Growth Factor
NKCC1 Sodium Potassium Chloride Co-Transporter
NMDA N-Methyl-D-Aspartate Receptor
NPY Neuropeptide Y
NT-3 Neurotrophin 3
NT-4/5 Neurotrophin 4/5
xviii

NTS Nucleus of the Solitary Tract
OVLT Organum Vasculosum Lamina Terminalis
OXT Oxytocin
p75NTR Pan Neurotrophin Receptor 75
PAG Periaqueductal Gray
PI3K Phosphoinositide 3-Kinase
PLC-y Phospholipase C-y
PKC Protein kinase C
POMC Proopiomelanocortin
PVN Paraventricular Nucleus of the Hypothalamus
ROS Reactive Oxygen Species
RVLM Rostral Ventrolateral Medulla
SD Sprague Dawley
SFO Subfornical Organ
SHR Spontaneously Hypertensive Rat
SNP Single Nucleotide Polymorphism
STAT3 Signal Transduced and Activator of Transcription 3
TH Tyrosine Hydroxylase
TRH Thyroid Releasing Hormone
Trk Tyrosine Kinase Receptor
TRPC3 Transient Receptor Potential Cation Channel Subfamily C Member 3
VGLUT Vesicular Glutamate Transporter
VLM Ventrolateral Medulla
VTA Ventral Tegmental Area
VMN Ventromedial Nucleus of the Hypothalamus
WKY Wistar-Kyoto Rat

xix

CHAPTER 1: LITERATURE REVIEW
1.1. Introduction: Hypertension and Sympathetic Control of Blood Pressure
1.1.1. Hypertension Etiology and Prevalence
Hypertension is a chronic medical condition characterized by persistent long-term
elevation of blood pressure in arteries measured on two or more occasions, where systolic
pressure measured is at ≥130 mmHg and the diastolic pressure is measured at ≥80 mmHg
(Muntner et al., 2018). Primary hypertension is a chronic elevation of blood pressure
without a direct causal factor, and accounts for more than 90% of hypertension cases.
Secondary hypertension occurs due to an identifiable cause, such as renal failure,
pheochromocytoma or pregnancy (Carretero & Oparil, 2000; Lindheimer, Taler, &
Cunningham, 2010; Oparil, Zaman, & Calhoun, 2003). Several factors have been
implicated in the development of primary hypertension. Familial and twin studies have
suggested that 30%-50% of blood pressure variance can be attributed to genetic heritability,
while roughly 50-70% can be attributed to environmental factors (Butler, 2010;
Jeunemaitre et al., 1992). Specific environmental factors that have been shown to increase
the risk for the development of hypertension include high stress (Hamer, Molloy, &
Stamatakis, 2008; McEwen & Gianaros, 2010), high caloric (Kannel, Brand, Skinner,
Dawber, & McNamara, 1967) and high salt diets (Denton et al., 1995; F. J. He &
MacGregor, 2002; "Intersalt: an international study of electrolyte excretion and blood
pressure. Results for 24 hour urinary sodium and potassium excretion. Intersalt
Cooperative Research Group," 1988; M. Zhang et al., 2015). A diagnosis of hypertension
is also a risk factor for the development of other cardiovascular diseases (Flint et al., 2019;
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Rapsomaniki et al., 2014; Whelton et al., 2018), such as stroke, myocardial infarction,
coronary heart disease, congestive heart failure, atrial fibrillation and chronic kidney
disease (Angeli, Reboldi, & Verdecchia, 2014; B. M. Egan, Zhao, Axon, Brzezinski, &
Ferdinand, 2011; J. He & Whelton, 1997; Lawes, Vander Hoorn, & Rodgers, 2008; Persell,
2011; Sarafidis et al., 2012; Whelton, 1994). Additionally, over 80% of hypertensive
patients present with various co-morbidities such as glucose intolerance, hyperinsulinemia,
lipid disorders, and obesity (Kannel, 2000; Kannel et al., 1967).
Primary hypertension is estimated to effect approximately 31% of the world’s adult
population (Kearney et al., 2005; D. Lloyd-Jones et al., 2010; Mills et al., 2016), with
roughly 66% of those cases occurring in developing countries (Kearney et al., 2005).
Prevalence of hypertension is estimated to be highest among older adults, aged 70 and
above (Buford, 2016; Muntner et al., 2018; Vasan et al., 2002), as well as among adults
with diabetes and non-Hispanic black adults (Gillespie & Hurvitz, 2013). Within the
United States the crude prevalence of hypertension among adults has been estimated at
45.6%, where antihypertensive medication was recommended for 36.2% and
nonpharmacological treatment was advised for 9.4% of adults diagnosed with hypertension
(Muntner et al., 2018). Studies have further indicated that hypertension is inadequately
controlled in the United States (Burt et al., 1995; D. J. Hyman & Pavlik, 2000; D. M. LloydJones et al., 2000). Rates of blood pressure above treatment goal among US adults taking
antihypertensive medications range from 53-56% (D. Lloyd-Jones et al., 2010; Muntner et
al., 2018). A separate study reported that 14% of patients diagnosed with hypertension had
resistance to common antihypertensive treatments (Carey, 2013).
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Currently there are several antihypertensive therapies available and prescribed for
hypertension treatment. These include diuretics, beta blockers, calcium channel blockers,
angiotensin converting enzyme (ACE) inhibitors, alpha-1 antagonists, and angiotensin
receptor blockers (Aronow, 2018). However, while these drugs do lower blood pressure
significantly, they do not significantly lower sympathetic nerve activity (Q. Fu et al., 2005).
Elevated sympathetic activity is an important factor in the development of most cases of
primary hypertension (Oparil, 1986; Rahn, Barenbrock, & Hausberg, 1999; Schlaich,
2004; Wyss, 1993), and thus developing treatments that target sympathetic nerve activity
could offer more effective hypertensive therapeutic options. One of the main drugs
currently available that can lower sympathetic activity is the alpha-2 blocker, Clonidine,
but the need for a greater number of pharmaceuticals that lower sympathetic activity longterm are still needed (Foote, Bloom, & Aston-Jones, 1983). Surgical interventions that
lower sympathetic nerve activity include renal denervation, which has shown limited
effectiveness in lowering blood pressure in clinical trials (Fengler et al., 2019; Kuhl, Frey,
& Frank, 2016). Another is a catheter-based renal endovascular approach used to disrupt
renal nerve activity by using radiofrequency, ultrasound or chemical agents which has
shown some success in several clinical trials (Azizi et al., 2018; Desch et al., 2015;
Mahfoud et al., 2017). Baroreflex activation therapy is a third option, which involves
electrically stimulating the carotid baroreceptors, which help regulate blood pressure
(Gordin et al., 2016; Kuhl et al., 2016). This method has been shown to reduce blood
pressure in treatment resistant hypertensive patients in particular (de Leeuw et al., 2017;
Wustmann et al., 2009). Both pharmacological and surgical interventions remain crucial
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for the treatment of hypertension, but better understanding of the central control of blood
pressure could lead to the development of novel, more targeted therapies.
1.1.2. Sympathetic and Neural Control of Blood Pressure Regulation
Increased sympathetic activity is a significant factor in the development of
hypertension (Carmichael & Wainford, 2015; Mancia & Grassi, 2014), which can be
exacerbated by pro-hypertensive stimuli such as high stress, high-caloric and high-salt diets
(Chida & Steptoe, 2010; Lambert & Lambert, 2011; Steptoe & Kivimaki, 2012; Whelton,
1994). This increase in sympathetic activity has been observed in young, middle-aged, and
elderly adults with hypertension, as well pregnant and obese individuals (Hart &
Charkoudian, 2014; Mancia & Grassi, 2014). Sympathetic activation is thought to be
mainly driven by the paraventricular nucleus of the hypothalamus (PVN), contributing to
various disease conditions such as hypertension, heart failure and post myocardial
infarction (Floras, 2009). Both increases in excitation and decreases in inhibitory
mechanisms have been suggested to enhance sympathetic output from the PVN (D.-P. Li
& H.-L. Pan, 2007; D. P. Li & Pan, 2006; K. Zhang, Mayhan, & Patel, 1997; Z. H. Zhang,
Yu, Kang, Wei, & Felder, 2008). Presympathetic neurons within the PVN stimulate spinal
sympathetic preganglionic neurons in the intermediolateral (IML) cell column directly or
via the rostral ventrolateral medulla (RVLM) (R. A. Dampney, 1994; Stornetta, 2009).
Sympathetic preganglionic neurons innervate the heart, blood vessels, kidneys, adrenal
medulla and peripheral vasculature to elevate blood pressure, heart rate and sympathetic
nervous system activity which in turn activates baroreceptors (Guyenet, 2006). These are
mechanoreceptors located in the aortic arch and carotid sinus, capable of sensing blood
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pressure changes via distention of the arterial wall. The baroreceptors activate sensory
afferents via the vagus and glossopharyngeal nerves that project to the nucleus of the
solitary tract (NTS), where they excite the caudal ventrolateral medulla (CVLM), which in
turn inhibits the RVLM from increasing sympathetic output. This negative feedback loop
between the NTS, CVLM and RVLM, is known as the baroreflex (Fig. 1.). This pathway
serves an important role in processing sensory information, responding to blood pressure
changes and regulating sympathetic nervous system activity (Agarwal, Gelsema, &
Calaresu, 1990; Andresen & Kunze, 1994; Benarroch, 2008; Coote, 2005; R. A. Dampney,
1994; Thrasher, 2005). Alterations in excitatory and inhibitory signaling within this neural
circuitry, particularly within the PVN, has been shown to contribute to elevated blood
pressure and sympathetic activity (Fisher, Young, & Fadel, 2009; Guyenet, 2006; J. He &
Whelton, 1997; D.-P. Li & H.-L. Pan, 2007; D. P. Li & Pan, 2006; Mark, 1996). However,
our understanding of the complex neuroanatomical interactions governing the central
regulation of sympathetic nervous system overactivity and its role in the pathophysiology
of hypertension remains unclear.
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Figure 1. Presympathetic neurons within the PVN stimulate spinal sympathetic
preganglionic neurons in the intermediolateral (IML) cell column directly or via the
rostral ventrolateral medulla (RVLM). Sympathetic preganglionic neurons innervate the
heart, blood vessels and kidneys to elevate blood pressure, heart rate and sympathetic
nervous system activity which in turn activates baroreceptors. The baroreceptors activate
sensory afferents via the vagus and glossopharyngeal nerves that project to the nucleus of
the solitary tract (NTS), where they excite the caudal ventrolateral medulla (CVLM),
which in turn inhibits the RVLM from increasing sympathetic output. This negative
feedback loop between the NTS, CVLM and RVLM, is known as the baroreflex. The
NTS also sends inhibitory catecholaminergic projections to the PVN to inhibit PVN
neuron activity.
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1.2. Brain Regions Involved in Sympathetic and Cardiovascular Regulation
1.2.1. Paraventricular Nucleus of the Hypothalamus (PVN)
The PVN is an important integration center involved in autonomic, neuroendocrine,
behavioral and cardiovascular regulation (R. A. Dampney, 1994, 2005). The PVN
integrates a variety of information from the cortex, brainstem, and hypothalamic areas. It
receives

interoceptive

information

from

nociceptors,

visceral

receptors,

and

thermoreceptors carried by spinal afferents synapsing onto PVN neurons via the dorsal
horn, the NTS, parabrachial nucleus, and the ventrolateral medulla (VLM) (Sawchenko,
Li, & Ericsson, 2000). The PVN receives information related to blood osmolality levels,
circulating steroids, and glucose levels from the circumventricular organs, mainly the
median preoptic nucleus (MnPO), organum vasculosum lamina terminalis (OVLT) and the
subfornical organ (SFO) (R. A. Dampney, Michelini, Li, & Pan, 2018; McKinley et al.,
2001; Sawchenko et al., 2000). The PVN also receives limbic information from the
amygdala and orbitomedial prefrontal cortex, related to emotional responses to stressors,
relayed by the bed nucleus of the stria terminalis (BNST) and the dorsomedial nucleus of
the hypothalamus (DMH) (R. A. Dampney et al., 2018; Sawchenko et al., 2000). The PVN
receives information from the suprachiasmatic nucleus (SCN) about circadian control of
endocrine and autonomic function. Finally, the PVN receives metabolism and food intake
information from the arcuate nucleus and perifornical area (R. A. Dampney et al., 2018; A.
V. Ferguson & Samson, 2003; Mastorakos & Zapanti, 2004).
The PVN sends efferent projections primarily to neuroendocrine and
cardiovascular areas. The PVN sends neuroendocrine projections to the median eminence
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and the posterior pituitary to activate the hypothalamic pituitary adrenal (HPA) axis via
corticotrophin releasing hormone (CRH) neurons, and the hypothalamic pituitary thyroid
(HPT) axis via thyroid releasing hormone (TRH) neurons. The PVN also regulates body
fluid balance via arginine vasopressin (AVP) and oxytocin (OXT) neurons, regulates
growth and development via somatostatin neurons, and transmits gastrointestinal and
cardiovascular information via the NTS, RVLM, dorsal motor nucleus of the vagus
(DMV), nucleus ambiguous, parabrachial region and midbrain periaqueductal grey (PAG)
(Biag et al., 2012; R. A. Dampney et al., 2018; Alastair V. Ferguson, Latchford, & Samson,
2008; Pyner & Coote, 1999).
The functional and structural architecture of the PVN has been extensively studied
via neuroanatomical tracing and immunohistochemistry, mostly in rats (Cechetto & Saper,
1988; Hallbeck, Larhammar, & Blomqvist, 2001; Jansen, Wessendorf, & Loewy, 1995;
Sawchenko et al., 1996; Swanson, 1991). The PVN borders the third ventricle bilaterally
and is broadly divided into a magnocellular and a parvocellular area. The parvocellular
area is further subdivided into three sub-nuclei: dorsal, medial and ventrolateral
parvocellular nuclei (Stocker, Cunningham, & Toney, 2004; Swanson & Kuypers, 1980).
The magnocellular subdivision contains large neurons involved in the synthesis of AVP
and OXT. These neurons project to the posterior pituitary and are involved in
neuroendocrine regulation and the release of AVP and OXT into the blood stream
(Benarroch, 2005; Engelmann, Landgraf, & Wotjak, 2004; Renaud & Bourque, 1991).
Magnocellular PVN neurons also play a role in osmotically related sympathoexcitation and
blood pressure elevation (Ribeiro, Panizza Hdo, Santos, Ferreira-Neto, & Antunes, 2015;
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Son et al., 2013), whereby AVP is released from magnocellular neurons which increases
PVN and RVLM neuronal activity, which can then be blocked by an AVP receptor
antagonist in the PVN (Ribeiro et al., 2015; Son et al., 2013).
The medial parvocellular subdivision contains small neurons that synthesize CRH,
somatostatin and other regulatory hormones. These neurons project to the median
eminence to regulate hormonal secretion from the anterior pituitary (Benarroch, 2005;
Sawchenko et al., 1996). Parvocellular CRH neurons also stimulate the production of
adrenocorticotrophic hormone (ACTH) which activates the HPA axis (Sawchenko et al.,
2000). The dorsal and ventrolateral parvocellular subdivisions of the PVN project to
autonomic areas of the brainstem and spinal cord (Badoer, 2001; Coote, Yang, Pyner, &
Deering, 1998). These neurons can be immunoreactive for a variety of neurotransmitters
such as AVP, OXT, CRH, dopamine, tyrosine hydroxylase (TH), somatostatin, enkephalin,
angiotensin and neurotensin (Cechetto & Saper, 1988; Hallbeck et al., 2001; Jansen et al.,
1995). PVN neurons can also be divided up into three different categories based on their
electrophysiological and neuroendocrine properties. Type I neurons are the magnocellular
neurons involved in AVP and OXT secretion (Hoffman, Tasker, & Dudek, 1991), they also
express a pronounced transient A-type K+ current and project to the posterior pituitary.
Type II neurons are neurosecretory parvocellular neurons that synthesize and secrete CRH
or TRH, and project to the median eminence to control hormone release from the anterior
pituitary and initiate the HPA and HPT axes (Hoffman et al., 1991; Lechan & Fekete, 2006;
Luther & Tasker, 2000; Tasker & Dudek, 1991; Vale, Spiess, Rivier, & Rivier, 1981).
Finally, type III neurons, also known as pre-autonomic, presympathetic or non9

neurosecretory parvocellular neurons, express a Ca2+- dependent low-threshold spike
(LTS) current. They project to the brainstem and spinal cord and are involved in the
regulation of sympathetic activity (S. Lee et al., 2008; Luther et al., 2002; Stern, 2001).
Type III neurons project mainly to autonomic centers in the central nervous system
(CNS), such as the spinal cord, NTS, DMV and the RVLM, where they play a critical role
in the regulation of blood pressure and sympathetic activity (R. A. Dampney et al., 2018;
Guyenet, 2006). This is supported by studies showing that bilateral inhibition of the PVN
significantly decreases mean arterial pressure (MAP) and sympathetic nerve activity
(Allen, 2002a; Zahner & Pan, 2005). Approximately 30% of spinally-projecting PVN
neurons also project to the RVLM. PVN neurons can thus influence sympathetic activity
via a PVN-IML pathway directly or indirectly via a PVN-RVLM-IML pathway (Badoer,
2001; Card et al., 2006; Coote et al., 1998; Cruz, Bonagamba, Machado, Biancardi, &
Stern, 2008; Moon, Goodchild, & Pilowsky, 2002; Pyner & Coote, 1999; Ross, 1984; Z.
Yang & Coote, 1998). Neuropeptide expression within the PVN is also known to be very
plastic and can change in response to alterations in the hormonal environment (Benarroch,
2005; Swanson, 1991). PVN neurons are sensitive to both glutamate and γ-aminobutyric
acid (GABA) and numerous studies have examined the functional roles of these
transmitters within the PVN. There are several glutamate interneurons within the PVN, and
extensive glutamate inputs to the PVN, mostly from other hypothalamic nuclei and
forebrain nuclei (Alastair V. Ferguson et al., 2008; Ulrich-Lai, Jones, Ziegler, Cullinan, &
Herman, 2011). GABA interneurons are extensively distributed around the PVN in an area
sometimes referred to as the peri-PVN area, specifically known as the anterior
10

hypothalamic area and the perifornical regions. Within the PVN, there is also sparse GABA
neuron expression (Alastair V. Ferguson et al., 2008). Finally, human studies examining
the role of the PVN in hypertension have shown increased activity of neurosecretory cells
within the PVN in patients with hypertension (Postnov Yu, Strakhov, Glukhovets, &
Gorkova, 1974). However, the implication of this observation for specific PVN
subpopulations remains to be determined.
1.2.2. Rostral Ventrolateral Medulla (RVLM)
The rostral ventrolateral medulla (RVLM) is a critical autonomic brainstem region
involved in elevating sympathetic activity, associated with several cardiovascular diseases
such as hypertension. The RVLM receives excitatory glutamatergic input from the PVN
and inhibitory, largely GABAergic inputs, from the CVLM, NTS, the midbrain PAG,
pontine reticular formation and the caudal pressor area (CPA) (Campos et al., 2008;
Campos & McAllen, 1999; R. A. Dampney, 1994). Excitation of RVLM neurons via the
application of glutamate, GABA antagonists or electrical stimulation, in both anesthetized
and awake animals leads to an increase in sympathetic activity and blood pressure (de Paula
& Machado, 2000; Moraes, Bonagamba, Zoccal, & Machado, 2011; Reis, Ross, Ruggiero,
Granata, & Joh, 1984; Ross, Ruggiero, Joh, Park, & Reis, 1984; Sakima, Yamazato,
Sesoko, Muratani, & Fukiyama, 2000; Willette, Barcas, Krieger, & Sapru, 1983).
Meanwhile, microinjections of GABA agonists, tetrodotoxin application, or electrolytic
lesions of the RVLM, lead to decreases in blood pressure (Benarroch, Granata, Ruggiero,
Park, & Reis, 1986; R. A. Dampney & Moon, 1980; Reis et al., 1984; Willette et al., 1983)
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RVLM glutamatergic neurons project directly to sympathetic preganglionic
neurons in the IML in the thoracic spinal cord and provide tonic excitation (Amendt,
Czachurski, Dembowsky, & Seller, 1979; Ross et al., 1984). These sympathetic
preganglionic neurons provide inputs to sympathetic postganglionic neurons, in the
paravertebral sympathetic ganglia near the spinal cord or prevertebral sympathetic ganglia
near the viscera. Postganglionic sympathetic neurons then provide inputs to glands and
smooth muscle (Sugiyama, Suzuki, & Yates, 2011). Glutamatergic neurons are the largest
neuronal population present in the RVLM, some of them also contain phenylethanolamineN-methyl transferase (PNMT), which categorizes them as C1 epinephrine-synthesizing
neurons (Ross, 1984; Ross et al., 1984). Photostimulation of these C1 neurons in the
RVLM using a lentivirus that expresses channelrhodopsin-2 has been shown to increase
blood pressure and sympathetic nerve activity in rats in vivo which further emphasizes
their involvement in cardiovascular regulation (Abbott, Stornetta, Socolovsky, West, &
Guyenet, 2009).
1.2.3. Caudal Ventrolateral Medulla (CVLM)
The CVLM is an important vasodepressor area in the brainstem, containing many
cell populations involved in different aspects of cardiovascular regulation (Feldberg &
Guertzenstein, 1976). Stimulation of the CVLM produces hypotension and bradycardia due
to a decrease in sympathetic nerve activity, while inactivating or lesioning CVLM neurons
leads to hypertension due to increases in sympathetic activity (Blessing & Reis, 1982,
1983; Cravo, Morrison, & Reis, 1991). CVLM neurons tonically inhibit RVLM
sympathoexcitatory neurons by forming mostly inhibitory GABAergic synapses via the
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baroreflex, contacting both adrenergic and non-adrenergic neurons in the RVLM (Aicher
et al., 1996). The majority of CVLM projections contacting the RVLM are GABAergic but
there is also some evidence of sparse catecholaminergic projections to the RVLM
(Colombari et al., 2001; Granata, Numao, Kumada, & Reis, 1986; Milner, Pickel,
Morrison, & Reis, 1989; Suzuki, Takayama, & Miura, 1997). The CVLM can be divided
into a rostral portion, involved in control of sympathetic outflow and the baroreceptor
reflex, and a caudal portion, involved in sympathetic outflow but importantly not involved
in mediating the baroreceptor reflex (Cravo et al., 1991).
A1 noradrenergic neurons in the CVLM have been implicated in the regulation of
cardiovascular homeostasis (Pedrino, Rosa, Korim, & Cravo, 2008). Neuroanatomical
studies have shown that A1 neurons in the CVLM are mostly reciprocally connected to
hypothalamic structures, involved in cardiovascular and neuroendocrine functions
(Blessing & Reis, 1982). Approximately, 80% of the A1 noradrenergic neurons in the
CVLM have been suggested to project to the PVN and the MnPO (D. C. Tucker, Saper,
Ruggiero, & Reis, 1987). A recent study injecting dopamine-beta-hydroxylase (DBH)
conjugated to saporin (DSAP) to lesion A1 neurons in the CVLM, showed an 81% decrease
in A1 neurons in the CVLM and a 10% decrease in the number of C1 neurons in the RVLM
(da Silva et al., 2013). However, these A1 noradrenergic projections may prove significant
in blood pressure regulation and have not been fully examined yet.
1.2.4. Nucleus of the Solitary Tract (NTS)
The NTS is an important brainstem area involved in the integration of sensory
afferent information from sensory afferents such as the arterial baroreceptors (Kline, King,
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Austgen, Heesch, & Hasser, 2010). Projections from the NTS relay this information to
various brain regions involved in autonomic regulation such as the PVN, CVLM and
RVLM (Andresen & Kunze, 1994; Spyer, 1994). Ablating the NTS in normotensive rats
by electrolytic lesioning elevates blood pressure (Doba & Reis, 1974; Duale et al., 2007;
Talman, Snyder, & Reis, 1980), while electrically stimulating the NTS results in
baroreceptor-like responses such as hypotension and bradycardia (Crill & Reis, 1968).
Specifically, A2 noradrenergic neurons in the NTS have been broadly implicated in the
chronic regulation of blood pressure (Affleck, Coote, & Pyner, 2012; Duale et al., 2007;
McKellar & Loewy, 1981; Ricardo & Koh, 1978; Ter Horst, de Boer, Luiten, & van
Willigen, 1989). Lesioning NTS catecholaminergic neurons in rats has led to contradictory
results, either increasing (Daubert, McCowan, Erdos, & Scheuer, 2012; Duale et al., 2007;
Itoh & Bunag, 1993) or having no effect on blood pressure (Itoh, Alper, & Bunag, 1992;
Itoh & Bunag, 1992; Talman et al., 1980). Destruction of A2 noradrenergic neurons within
the NTS using the neurotoxin 6-hydroxydopamine (6-OHDA), increases lability of blood
pressure (Reis, Doba, Snyder, & Nathan, 1977; Talman et al., 1980) and decreases the
baroreceptor reflex (Talman et al., 1980). A2 noradrenergic neurons are believed to
tonically inhibit brain regions that generally increase blood pressure, such as the PVN
(Cunningham & Sawchenko, 1988; R. A. Dampney, 1994; Loewy & McKellar, 1980;
Sawchenko & Swanson, 1982b). The possible inhibitory role of NTS-PVN noradrenergic
projections in blood pressure regulation has been shown but the mechanism behind the
apparent reduction in inhibitory function under hypertensive conditions remains to be
explored.
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1.2.5. Baroreflex
The arterial baroreflex acts as a negative feedback system that senses and responds
to blood pressure changes that occur during changes in behavior, emotion, posture,
exercise, and other conditions (Benarroch, 2008; R. A. Dampney et al., 2018; R. A. L.
Dampney, 2017; Veerman, Imholz, Wieling, Wesseling, & van Montfrans, 1995). The
baroreflex depends on a feedforward mechanism that serves as a general adaptive response
to stress and exercise, and a second feedback mechanism which allows for moment-tomoment regulation of blood pressure in response to peripheral cardiovascular, respiratory,
and vestibular receptor information (Benarroch, 2008; Gordan, Gwathmey, & Xie, 2015).
Activation of baroreceptors due to an increase in blood pressure results in a decrease of
sympathetic nerve activity innervating the heart, arterioles, and veins, while also increasing
the vagal output of the heart. This results in a decrease of total peripheral resistance, venous
return, heart rate and cardiac output. However, in response to a decrease in blood pressure,
reduced baroreceptor activity leads to sympathoexcitation and inhibition of cardiovagal
output, leading to an increase in total peripheral resistance and tachycardia (Benarroch,
2008; Gordan et al., 2015).
Blood pressure changes are sensed by changes in blood vessel stretch by
mechanosensitive arterial baroreceptors located in the carotid sinus, innervated by the
glossopharyngeal nerve, and aortic arch, innervated by the vagus nerve. Information is then
conveyed via glutamatergic afferents which synapse onto excitatory glutmatergic neurons
in the NTS. The NTS then sends excitatory glutamatergic neurons to the CVLM to synapse
with GABAergic inhibitory neurons which then proceed to inhibit sympathetic premotor
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neurons in the RVLM. These sympathetic premotor neurons in the RVLM then project to
sympathetic preganglionic neurons within the IML of the spinal cord where they synapse
onto sympathetic preganglionic neurons which then contact organs in the periphery
(Benarroch, 2008; Guyenet, 2006; Swenne, 2013). Both baroreceptor sensitivity and
function can be dysregulated by chronic increases in blood pressure, as seen in
hypertension (Chapleau, Li, Meyrelles, Ma, & Abboud, 2001).
1.3. Neurotransmitter and Neuromodulator Signaling Mechanisms Involved in the
Regulation of Sympathetic, Cardiovascular and Neural activity in the PVN
1.3.1. Glutamatergic signaling in the PVN
Glutamate and GABA are the main excitatory and inhibitory neurotransmitters in
the brain, and the firing activity of PVN neurons is known to be affected by the signaling
of these two transmitters (D. P. Li, Yang, Pan, & Pan, 2008a, 2008b). The PVN has a dense
concentration of excitatory glutamatergic nerve terminals and receptors (Boudaba,
Schrader, & Tasker, 1997; Herman, Eyigor, Ziegler, & Jennes, 2000; van den Pol, 1991).
Glutamate receptors in the PVN include N-methyl-D-aspartate (NMDA) receptors, αamino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPA) receptors, and
kainite receptors which are ionotropic receptors, and the PVN also expresses metabotropic
glutamate receptors (mGluRs) (R. A. Dampney et al., 2018). The PVN receives
glutamatergic inputs mainly from the DMH and the perifornical region (Boudaba et al.,
1997), as well as glutamatergic interneurons within the PVN and from telencephalic
regions (D.-P. Li & H.-L. Pan, 2007). The PVN sends glutamatergic projections, mainly to
the RVLM and the IML of the spinal cord (Xu, Zheng, & Patel, 2012).
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Glutamate can alter neuronal signaling and plasticity by acting at both ionotropic
and metabotropic glutamate receptors (Evanson & Herman, 2015). In terms of blood
pressure regulation, the NMDA receptor is particularly important since the PVN is
populated by neurons that express NMDA receptor subunit genes and proteins (Eyigor,
Centers, & Jennes, 2001; Herman et al., 2000; Petralia, Yokotani, & Wenthold, 1994), and
the expression of NMDA receptor subunits in the PVN can be modified by changes in
blood pressure (D.-P. Li & H.-L. Pan, 2007; Y. F. Li, Cornish, & Patel, 2003). A
microinjection of glutamate or NMDA into the PVN has been found to increase blood
pressure, and sympathetic nerve activity in both anesthetized and conscious rats (Busnardo,
Crestani, Tavares, Resstel, & Correa, 2010; Kannan, Hayashida, & Yamashita, 1989; D. P.
Li et al., 2008b). Meanwhile, microinjections of glutamate receptor antagonists, such as
the NMDA receptor antagonist AP5, has little effect on sympathetic activity and blood
pressure in normotensive animals (Q. H. Chen, Haywood, & Toney, 2003; D.-P. Li & H.L. Pan, 2007; D. P. Li et al., 2008b; Zahner & Pan, 2005). This suggests that under
normotensive conditions, glutamatergic input in the PVN is not crucially involved in tonic
control of sympathetic tone.
In contrast, when the NMDA receptor antagonist AP5 is injected into a
spontaneously hypertensive rat (SHR), sympathetic nervous system activity and blood
pressure is significantly decreased (D.-P. Li & H.-L. Pan, 2007; D. P. Li et al., 2008b).
Microinjections of NMDA receptor agonists in the PVN also increases neuronal activity in
the RVLM, which is reduced by the application of glutamate receptor inhibitors in the
RVLM (Z. Yang & Coote, 1998). This suggests that sympathoexcitatory glutamatergic
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PVN-RVLM projections are crucially involved in the cardiovascular response to increased
glutamate release in the PVN. SHRs also have a higher excitability of PVN presympathetic
neurons, which contributes to increased sympathetic outflow (Allen, 2002b; D. P. Li et al.,
2008b; Ye, Li, Li, & Pan, 2011), while also showing elevated glutamatergic inputs to PVN
presympathetic neurons. This is believed to be maintained by an upregulation of
postsynaptic NMDA receptors and an increase in presynaptic glutamate release (D.-P. Li
& H.-L. Pan, 2007; D. P. Li et al., 2008b).
1.3.2. GABAergic signaling in the PVN
GABAergic inhibition plays a major role in regulating the activity of the PVN.
GABA, acting mostly on ionotropic GABAA receptors but also partly on metabotropic
GABAB receptors, tonically restrains PVN neuronal activity and autonomic outflow
(Biancardi, Campos, & Stern, 2010; Q. H. Chen et al., 2003; Decavel & Van den Pol, 1990;
D. P. Li & Pan, 2006; Y. F. Li & Patel, 2003; Tasker & Dudek, 1993; K. Zhang, Li, &
Patel, 2002). Tonic inhibition is largely believed to be controlled by delta-containing
GABAA receptors, due to their high sensitivity for GABA (Zheleznova, Sedelnikova, &
Weiss, 2009). The immediate surround of the PVN, also referred to as the peri-PVN area,
appears to consist of intermixed populations of glutamate and GABA neurons that send
local excitatory and inhibitory projections to PVN neurons, including PVN parvocellular
neurons (Cullinan, 2000). GABAA receptor subunit mRNAs for alpha1–2, beta1–3 and
gamma1–2 and delta are expressed within CRH neurons and in parvocellular PVN neurons
broadly (Kiss, 1988). In addition to GABAA receptors, recent studies have also revealed
that GABAB receptors are expressed in the parvocellular PVN (Margeta-Mitrovic,
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Mitrovic, Riley, Jan, & Basbaum, 1999). The role of these receptors in stress regulation
has yet to be extensively investigated.
Altered PVN GABAergic function has been associated with increased sympathetic
activity during hypertension (D. P. Li & Pan, 2006; D. S. Martin & Haywood, 1998) and
heart failure (K. Zhang et al., 2002). PVN-RVLM neurons and sympathetic outflow are
also tonically inhibited by GABA (Q. H. Chen et al., 2003; R. A. Dampney et al., 2018; D.
P. Li & Pan, 2005; Y. F. Li & Patel, 2003; K. Zhang & Patel, 1998). In the SHR,
GABAergic activity is altered, resulting in a decrease in GABAA receptor function and an
increase in GABAB receptor function. This alteration may contribute to the elevated
sympathetic outflow, as seen in hypertension (Cork, Chazot, & Pyner, 2016; Y. F. Li,
Jackson, Stern, Rabeler, & Patel, 2006). Microinjection of the GABAA antagonist
bicuculline into the PVN attenuate increases in sympathetic nerve activity, blood pressure
and heart rate in renal-wrapped hypertensive rats (D. S. Martin & Haywood, 1998).
Microinjections of the GABAA antagonist, gabazine, into the PVN of both WKY and SHR
rats has also been found to increase sympathetic activity and blood pressure. However, this
effect was found to be significantly reduced in SHRs compared to WKY rats (D. P. Li &
Pan, 2005; D. P. Li & H. L. Pan, 2007). The GABAA receptor agonist isoguvacine and
muscimol have also been tested in the PVN and been found to reduce blood pressure
significantly more in normotensive rats compared to SHRs (Ding et al., 2015; D. P. Li &
H. L. Pan, 2007). Finally, a microinjection of baclofen, a GABAB receptor agonist, into
the PVN produces a greater inhibitory effect on sympathetic outflow in SHR than in
normotensive WKY rats (D. P. Li & H. L. Pan, 2007).
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Another mediator of GABAergic signaling are GABA transporters (GATs). GATs
have been shown to play a critical role in modulating tonic GABAA inhibition (Dalby,
2003). GAT1 is the most abundantly expressed form of GAT, it is mainly expressed in
presynaptic neuronal terminals (Gadea & López-Colomé, 2001; Schousboe, 2000). Other
notable GATs include GAT3 and GAT4 transporters, which are mostly expressed in glial
cells (Minelli, Alonso-Nanclares, Edwards, DeFelipe, & Conti, 2003; Minelli, DeBiasi,
Brecha, Zuccarello, & Conti, 1996; Ribak, Tong, & Brecha, 1996). PVN injections of the
GAT inhibitor, nipecotic acid, has been shown to decrease renal sympathetic nervous
system activity and heart rate but have no effect on blood pressure in normotensive rats.
The study also found greater immunoreactivity of GAT3 over GAT1 in the PVN of these
rats, which tended to display glial like staining and partially colocalize with glial fibrillary
acidic protein (J. B. Park, Jo, Zheng, Patel, & Stern, 2009). Thus, GATs may play a
significant role in modulating GABAergic signaling, especially under hypertensive
conditions considering that GABAA activity in the PVN is diminished in SHRs. Finally,
glutamic acid decarboxylase 65 (GAD65) and 67 (GAD67) are enzymes that catalyze the
conversion of glutamate to GABA and CO2. They are also often used as markers of
GABAergic activity and the expression of GAD67 has been shown to be elevated in
renovascular hypertensive rats compared to normotensive control animals (Biancardi et al.,
2010). This may suggest that alterations in the level of expression of GAD67 in the PVN
reflect changes in GABAergic signaling in hypertension.
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1.3.3. Catecholaminergic signaling in the PVN
A few key brain regions in the brainstem are known to synthesize catecholamines,
all of which help regulate sympathetic activity. These include the A2 noradrenergic and C2
adrenergic neurons in the NTS, A5 noradrenergic neurons in the ventrolateral pons, and
A1 noradrenergic and C1 adrenergic neurons in the VLM (Cunningham & Sawchenko,
1988; Sawchenko & Swanson, 1982a). The majority of catecholaminergic projections into
the PVN come from A2 noradrenergic neurons in the NTS, which tonically inhibit PVN
presympathetic neurons (Cunningham & Sawchenko, 1988; R. A. Dampney, 1994; Loewy
& McKellar, 1980; Sawchenko & Swanson, 1982b). Ablating the NTS in normotensive
rats by electrolytic lesioning results in hypertension (Doba & Reis, 1974; Duale et al., 2007;
Talman et al., 1980), while electrically stimulating the NTS results in hypotension and
lower heart rate (Crill & Reis, 1968). Specifically, lesioning NTS A2 noradrenergic
neurons in rats has led to contradictory results, either increasing (Daubert et al., 2012;
Duale et al., 2007) or having no effect on blood pressure (Itoh et al., 1992; Itoh & Bunag,
1992; Talman et al., 1980). Studies that claim that NTS noradrenergic projections are
excitatory are mostly stress studies, which may indicate that these neurons inhibit PVN
neurons under baseline conditions but exert the opposite effect under stress conditions.
Additionally, the baroreceptor reflex has been reported to decrease after noradrenergic and
dopaminergic neuron destruction using the neurotoxin 6-Hydroxydopamine (Talman et al.,
1980).
In terms of receptor expression, adrenergic alpha-1a, alpha-1b, alpha-2, and beta
adrenergic receptors have all been identified in parvocellular neurons within the PVN
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(Cummings & Seybold, 1988; Little, Duncan, Breese, & Stumpf, 1992). Alpha 1a and
alpha-1b adrenergic receptors are highly expressed in both the PVN and NTS (Day,
Campeau, Watson, & Akil, 1997). Stimulation of alpha1 adrenergic receptors in the PVN
leads to increased blood pressure and sympathetic outflow (Boudaba et al., 1997; Q. Chen,
Li, & Pan, 2006; Daftary, Boudaba, Szabó, & Tasker, 1998; Daftary, Boudaba, & Tasker,
2000). Meanwhile, alpha-2 adrenergic receptors have been shown to exert a hypotensive
effect throughout the CNS, reducing sympathetic nerve activity and blood pressure, mostly
in the forebrain (Wyss & Carlson, 1999). The role of alpha-2 adrenergic receptors in the
PVN is unclear, with one study showing limited effect on blood pressure regulation when
the alpha-2 adrenergic receptor antagonist yohimbine is administered to the PVN, which
does not significantly reduce the increased MAP response to histamine administration
(Bealer & Abell, 1995). Another publication has implicated alpha-2 receptors in the PVN
in the modulation of synaptic GABA release and regulation of sympathetic outflow,
suggesting a hypotensive effect of alpha-2 activation (D. P. Li & Pan, 2005).
Beta 1 and beta 2 adrenergic receptors in the PVN have been shown to exert an
inhibitory action on AVP secretion (Veltmar, Culman, Qadri, Rascher, & Unger, 1992),
suggesting that they may inhibit AVP-mediated increases in blood pressure. Further,
microinjections of the beta-adrenergic receptor antagonist propranolol into the PVN have
been found to increase spontaneous electrical activity of catecholaminergic neurons,
preventing the inhibitory actions of NTS noradrenergic projections to the PVN (Saphier &
Feldman, 1991). Propranolol is also known to significantly decrease the gain of reflex
bradycardia, while isoprenaline, a general beta-adrenergic agonist, significantly increases
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the gain of reflex bradycardia and increases baroreflex sensitivity (D. Wang et al., 2013).
Finally, the beta-2 adrenergic agonist fenoterol has been shown to reduce blood pressure
in rats, when injected into the PVN (Tsushima, Fujimoto, & Matsuda, 1994). This suggests
that beta-adrenergic signaling in the PVN may play a part in cardiovascular and baroreflex
regulation.
1.3.4. Angiotensinergic signaling in the PVN
Several cardiovascular nuclei in the hypothalamus and brainstem contain
angiotensin type I and II (Ang I and II) cell bodies and nerve terminals, as well as their
respective receptors angiotensin type I and type 2 receptors (AT1R and AT2R). These
nuclei include the RVLM, SFO, SON and the PVN (Lind, Swanson, & Ganten, 1985; J.
M. Wang, Veerasingham, Tan, & Leenen, 2003). Ang II stimulates a G-protein signaling
pathway associated with protein kinase activation which leads to an increase in reactive
oxygen species (ROS) (G. Wang et al., 2006; Zimmerman, Lazartigues, Sharma, &
Davisson, 2004), which can inhibit voltage-gated potassium channels to increase neuronal
activity (Zimmerman et al., 2004). Ang II has been shown to activate presympathetic
neurons in the PVN either directly or via their presynaptic terminals (Cato & Toney, 2005),
and can also affect the release of neurotransmitters such as glutamate and GABA (Tsuda,
2012). In the PVN, activation of AT1R on GABAergic interneurons stimulates G-protein
coupled signaling, activating nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase subunit Nox2, which increases ROS and inhibits GABA release onto
presympathetic neurons projecting to the RVLM or IML (Q. Chen & Pan, 2007; D. P. Li
& Pan, 2005). Ang II can also increase the release of glutamate from glutamate
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interneurons in the PVN to activate magnocellular neurons (Latchford & Ferguson, 2004),
similar to what occurs in the RVLM (Nishihara, Hirooka, Matsukawa, Kishi, & Sunagawa,
2012; Zhu, Moriguchi, Mikami, Higaki, & Ogihara, 1998).
Studies have found consistent evidence for a sympathoexcitatory role for the
angiotensinergic system in the PVN, RVLM and IML of the spinal cord. Regions of the
SFO, OVLT and MnPO that express high levels of Ang II, are known to project to the
parvocellular region of the PVN (Lind et al., 1985; McKinley, Allen, Burns, Colvill, &
Oldfield, 1998; Oldfield, Ganten, & McKinley, 1989; Sunn, McKinley, & Oldfield, 2001;
Westerhaus & Loewy, 1999). Projections between the SFO and the PVN use Ang II as a
neurotransmitter, since activating SFO neurons by applying either Ang II or glutamic acid
increases the release of Ang II in the PVN (Wright, Roberts, Stubley, Hanesworth, &
Harding, 1993). SFO microinjections of Ang II also increase blood pressure, which is
prevented by applying an AT1R blocker in the PVN (Ku, Jia, & Chang, 1999).
Additionally, in vitro application of Ang II on PVN neurons excites PVN-RVLM neurons
(Cato & Toney, 2005). Applying the GABAA receptor antagonist bicuculline in the PVN
increases renal sympathetic nerve activity and blood pressure, but these effects are
attenuated by 40-50% by using an AT1R blocker in the RVLM (Tagawa & Dampney,
1999). Finally, microinjecting Ang II into the PVN increases blood pressure which can be
blocked by using an AT1R blocker in the RVLM (Ku et al., 1999). Additionally, Ang II in
the RVLM increases local glutamate release, blood pressure and heart rate (Zhu et al.,
1998). A decrease in GABAA inhibition of the PVN and an increase in Ang II signaling in
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the PVN-RVLM pathway leads to activation of the AT1R in the RVLM, thereby increasing
blood pressure, sympathetic activity and glutamate release (Gabor & Leenen, 2012b).
Angiotensinergic signaling in the CNS is also broadly known to contribute to
elevated sympathetic activity and blood pressure in cold exposure (Sun, Cade, & Morales,
2002), DOCA-salt models (C. G. Park & Leenen, 2001), during increased plasma
aldosterone (Xue et al., 2011), and in high salt diets in Dahl S rats and SHRs (B. S. Huang
& Leenen, 1996, 1998). Elevated AT1R activity may be explained by elevated synthesis
of Ang II or an increased responsiveness to Ang II, but both may act in combination since
ACE and AT1R are increased in the PVN of Dahl S rats on a high salt diet (J. M. Wang et
al., 2003). These studies underline the importance of the role of the angiotensinergic system
in the PVN and RVLM in central cardiovascular regulation.
1.3.5. Vasopressinergic, Oxytocinergic and Corticotrophin Signaling in the PVN
The neuropeptides AVP and OXT are synthesized, transported and secreted by
magnocellular neurons in both the PVN and the SON (Burbach, Luckman, Murphy, &
Gainer, 2001; Hatton, 1990; Japundžić-Žigon, 2013), and also partly by parvocellular
neurons in the PVN and the SCN (DeVries, Buijs, Van Leeuwen, Caffe, & Swaab, 1985).
The magnocellular PVN and SON neurons project to the neurohypophysis where AVP and
OXT are released into the general circulation as hormones affecting distant organs and
participating in the regulation of osmotic homeostasis and reproduction (Stoop, 2012). The
parvocellular PVN projects to the median eminence to release AVP and OXT into the
portal circulation, modulating the release of ACTH during the stress response. AVP and
OXT are also known to act in a paracrine or autocrine manner to reduce or enhance
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neuronal activity throughout the CNS (Geerling, Shin, Chimenti, & Loewy, 2010; M.
Ludwig & Leng, 2006). AVP and OXT are both cyclic nonapeptides and differ only in two
amino acids (De Bree et al., 2003). They both bind to V1a, V1b, V2 and one OXT receptor,
which are all a part of a family of heptahelical guanine nucleotide-binding protein-coupled
receptors (GPCRs), which are located widely in the brain and periphery (Kimura,
Tanizawa, Mori, Brownstein, & Okayama, 1992; Koshimizu et al., 2012).
Application of selective antagonists, peripherally and centrally, has shown that
physiological concentrations of AVP and OXT do not modulate or maintain blood pressure
under baseline physiological conditions (Japundzic-Zigon, 2001; Milutinovic, Murphy, &
Japundzic-Zigon, 2006). However, V1a receptor knockout (KO) mice show a lower
baseline blood pressure compared to wildtype control animals (Koshimizu et al., 2012),
and microinjections of AVP into the PVN of euhydrated rats has been shown to increase
blood pressures and sympathetic nerve activity. Meanwhile, pretreatment with a V1a
receptor antagonist in the PVN decreases sympathetic nerve activity and blood pressure in
dehydrated rats compared with euhydrated rats. Thus, AVP in the PVN seems to modulate
salt-intake related blood pressure elevations, via activation of V1a receptors (Ribeiro et al.,
2015). On the other hand, OXT KO mice show a greater baseline blood pressure and heart
rate compared to control animals (Bernatova, Rigatto, Key, & Morris, 2004), and further
chronic PVN OXT neuron activation in vivo has been shown to prevent hypertension that
occurs in rats exposed to three weeks of chronic intermittent hypoxia-hypercapnia
(Jameson et al., 2016). These findings indicate that both AVP and OXT signaling play a
vital role within the PVN in regulating blood pressure in hypertension.
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Another important signaling mechanism in the PVN involved in blood pressure
regulation and the initiation of the HPA axis is CRH which binds to CRH type 1 (CRHR1)
and CRH type 2 (CRHR2) receptors (Dautzenberg, Dietrich, Palchaudhuri, & Spiess,
1997). The release of CRH from the PVN leads to the release of ACTH (Vale et al., 1981),
which then in turn acts on adrenal cortical cells to elevate corticosteroid production, the
primary effector hormone of the HPA axis. Elevated corticosteroids activate glucocorticoid
receptors (GR) and mineralocorticoid receptors (MR). Activation of these receptors can
modify gene expression via binding to specific DNA sequences and recruitment of
transcriptional complexes (Arriza et al., 1987; de Kloet, 2000; Joels & de Kloet, 1992;
Weinberger et al., 1985; Whirledge & DeFranco, 2018), and they further activate cognitive
and metabolic resources to respond to current and future stressors and threats (Dallman &
Yates, 1967; McEwen & Sapolsky, 1995; Swanson, Sawchenko, Rivier, & Vale, 1983;
Ulrich-Lai & Herman, 2009; Vale et al., 1981).
Dysregulation of the HPA axis is widely associated with stress and hypertension
(Burford, Webster, & Cruz-Topete, 2017; Whitworth, Mangos, & Kelly, 2000). CRH
neurons in the PVN are known to project to the RVLM (Coldren, Li, Kline, Hasser, &
Heesch, 2017; Milner, Reis, Pickel, Aicher, & Giuliano, 1993) and the NTS (Sawchenko,
1987), where they regulate sympathetic activity and blood pressure (Bardgett, Sharpe, &
Toney, 2014; Milner et al., 1993; T. Nakamura, Kawabe, & Sapru, 2009; T. Nakamura &
Sapru, 2009; Yamazaki et al., 2008). In an unstressed SHR, CRH mRNA was found to be
elevated in the PVN compared with normotensive WKY rats. In addition, stress-induced
increase in CRH mRNA levels was found to be much higher in the PVN of the SHR
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(Krukoff, MacTavish, & Jhamandas, 1999). ICV injection of CRH, which increases the
CRH gene in the PVN (Mansi, Rivest, & Drolet, 1996; Parkes, Rivest, Lee, Rivier, & Vale,
1993), also activates the HPA axis, and leads to an increase in blood pressure and heart rate
(Brown, Hauger, & Fisher, 1988; Kalin, Shelton, Kraemer, & McKinney, 1983; Saunders
& Thornhill, 1986). ICV administration of CRH additionally enhances activity of neurons
in brain regions involved in cardiovascular regulation (Cummings, Elde, Ells, & Lindall,
1983; De Souza et al., 1985; Swanson, Sawchenko, & Lind, 1986; Swanson, Sawchenko,
Lind, & Rho, 1987; Valentino & Foote, 1988; Valentino, Foote, & Aston-Jones, 1983).
These findings suggest that CRH signaling in the PVN plays an important role in activation
of the HPA axis, and regulation of cardiovascular responses in the hypothalamus and
brainstem.
1.4. BDNF Signaling in the Central Nervous System
1.4.1. BDNF Synthesis, Transport and Secretion
Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family
of growth factors which also includes nerve growth factor (NGF), neurotrophin (NT) 3,
and NT4/5 (Barbacid, 1995; Berkemeier et al., 1991; Ernfors, Ibanez, Ebendal, Olson, &
Persson, 1990; Gotz et al., 1994; Leibrock et al., 1989; Levi-Montalcini, 1987;
Maisonpierre et al., 1990). BDNF is encoded by the BDNF gene, and is first synthesized
as the precursor molecule pro-BDNF (32 kDa), which is later cleaved by the extracellular
protease plasmin into the mature and biologically active form of BDNF (~13 kDa) or a
BDNF pro-peptide (~17 kDa) (Z. Y. Chen et al., 2004; Negro, Tavella, Grandi, & Skaper,
1994; Pang et al., 2004; Timmusk et al., 1993; B. Yang, Ren, Zhang, Chen, & Hashimoto,
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2017). NGF binds to the tyrosine kinase A (TrkA) receptor, NT-3 binds to the tyrosine
kinase C (TrkC) receptor, and NT-4/5 binds to the tyrosine kinase B (TrkB) receptor. The
mature form of BDNF also binds with high affinity to the TrkB receptor (Dawbarn & Allen,
2003; R. Klein et al., 1991) and binds with low affinity to the pan neurotrophin receptor 75
(p75NTR) (Chao et al., 1986; Teng et al., 2005), while pro-BDNF binds to p75NTR
(Goodman et al., 1996; B. Yang et al., 2017). Binding of BDNF to TrkB receptors activates
intracellular signaling cascades involving Ras and extracellular signal-related kinase (Erk)
1 and 2, phospholipase C-γ (PLC-γ), phosphatidylinositol 3-kinase (PI3K), and protein
kinase C (PKC) (Nakagawara, Azar, Scavarda, & Brodeur, 1994; Zirrgiebel et al., 1995).
Induction of several transcription factors follows this, including c-Jun, c-Fos, and early
growth response 1 (Egr-1). Finally, activation of cyclic adenosine 3′,5′-monophosphate
(cAMP) response element binding protein occurs (Finkbeiner et al., 1997; Gaiddon,
Loeffler, & Larmet, 1996; Nakagawara et al., 1994).
BDNF and the TrkB receptor are present in postsynaptic dendrites and presynaptic
axon terminals, where they are capable of bidirectional release and activity (Tyler, Alonso,
Bramham, & Pozzo-Miller, 2002). BDNF signaling stimulates neuron differentiation and
development (Alderson, Alterman, Barde, & Lindsay, 1990; Knusel & Hefti, 1991),
promotes neuron survival (Grothe & Unsicker, 1987; Hofer & Barde, 1988; Kalcheim &
Gendreau, 1988) and long-term potentiation (LTP) (Korte et al., 1995; Korte, Staiger,
Griesbeck, Thoenen, & Bonhoeffer, 1996; Patterson et al., 1996). BDNF is expressed
throughout the developing and mature CNS (Bishop, Mueller, & Mouradian, 1994;
Leibrock et al., 1989; Timmusk et al., 1993) and in peripheral tissues such as muscle, liver,
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kidney, lung and adipose tissue (Cassiman, Denef, Desmet, & Roskams, 2001;
Lommatzsch et al., 1999; Mousavi & Jasmin, 2006; Ukropec, Ukropcova, Kurdiova,
Gasperikova, & Klimes, 2008). Regional differences have been reported between BDNF
mRNA levels and protein concentrations in the CNS (Altar et al., 1997; Conner,
Lauterborn, Yan, Gall, & Varon, 1997; Narisawa-Saito, Wakabayashi, Tsuji, Takahashi,
& Nawa, 1996; Nawa, Carnahan, & Gall, 1995), which may be due to BDNF anterograde
transport (Altar et al., 1997) and mRNA decay (Malter, 2001). BDNF is synthesized in
several areas of the hypothalamus, such as the PVN, the lateral hypothalamic area (LH),
and the ventromedial hypothalamic nucleus (VMN) (Conner et al., 1997). BDNF is also
expressed in areas of the thalamus and hindbrain, in the arcuate nucleus, hippocampus,
amygdala, ventral tegmental area (VTA), and the dorsal vagal complex (DVC) (Bariohay,
Lebrun, Moyse, & Jean, 2005; Conner et al., 1997).
BDNF is transported to secretion sites by motor protein complexes of neurons, as
has been observed in axons and dendrites of cultured cortical and hippocampal neurons (N.
Adachi, Kohara, & Tsumoto, 2005; Naoki Adachi, Numakawa, Richards, Nakajima, &
Kunugi, 2014; Jakawich et al., 2010; Matsuda et al., 2009), and in knock-in mice
expressing myc-tagged BDNF in the hippocampus at presynaptic terminals of neurons
(Dieni et al., 2012). BDNF is transported both retrogradely and anterogradely in the CNS
(N. Adachi et al., 2005; Altar & DiStefano, 1998; Caleo, Menna, Chierzi, Cenni, & Maffei,
2000; Rind, Butowt, & von Bartheld, 2005; Spalding, Tan, Hendry, & Harvey, 2002).
Retrograde transport has been shown in motor neurons, where BDNF is released from
postsynaptic sites and internalized by afferent presynaptic terminals (Rind et al., 2005).
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Anterograde transport of BDNF involves motor protein kinesin and coordinator dynactin
(Kwinter, Lo, Mafi, & Silverman, 2009), and has been shown to occur in the visual system
(Caleo et al., 2000; Spalding et al., 2002). Activity-dependent local BDNF secretion occurs
in the axon, soma, and dendrites of neurons (Edelmann, Lessmann, & Brigadski, 2014;
Horton & Ehlers, 2003; Horton et al., 2005; Lessmann & Brigadski, 2009), and involves
Ca2+ influx via inotropic glutamate receptors or L-type voltage gated calcium channels.
This is then followed by signal amplification through Ca2+-induced Ca2+ release from the
ryanodine receptors (Lessmann & Brigadski, 2009). Activation of both CaMKII and PKA
is required for BDNF secretion (Edelmann et al., 2014; Kolarow, Brigadski, & Lessmann,
2007).
The human BDNF gene contains 10 exons coding for the 5’ untranslated region and
are alternatively spliced to a common 3’ coding exon, resulting in 34 possible mRNA
transcripts (Pruunsild, Kazantseva, Aid, Palm, & Timmusk, 2007). The rodent BDNF
contains 9 exons, encoding 24 different mRNA transcripts, each of them translating into
an identical mature BDNF (Cunha, Brambilla, & Thomas, 2010). Transcription of the
BDNF gene occurs principally via exons I and IV, with the promoter on exon IV being
particularly sensitive to increases in Ca2+ levels (Tao, West, Chen, Corfas, & Greenberg,
2002; Zheng et al., 2011; Zheng, Zhou, Moon, & Wang, 2012). The BDNF gene has
multiple promoters regulated in specific ways under specific conditions to produce
different mRNAs in certain tissues and in response to certain environmental stimuli
(Pruunsild et al., 2007; Timmusk et al., 1995; Timmusk et al., 1993). Environmental factors
such as stress can alter transcript expression of BDNF (Fuchikami, Morinobu, Kurata,
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Yamamoto, & Yamawaki, 2009; Marmigere, Givalois, Rage, Arancibia, & TapiaArancibia, 2003; Tognoli et al., 2010), which causes alterations in the ratio between proBDNF and total BDNF (Tognoli et al., 2010). Defeat stress significantly decreases BDNF
mRNA by downregulating BDNF transcripts from promoters IV and VI (Tsankova et al.,
2006). Meanwhile chronic stress in rats increases BDNF mRNA expression in the BNST
(Hammack et al., 2009), while acute and repeated immobilization stress in rats increases
BDNF mRNA expression in the parvocellular PVN, the lateral hypothalamus, and the
pituitary gland (Smith, Makino, Kim, & Kvetnansky, 1995). Other pro-hypertensive
stimuli such as high salt intake increase BDNF mRNA expression in the SON (Choe et al.,
2015).
1.4.2. BDNF and Catecholaminergic Signaling
BDNF is a known modulator of catecholaminergic neurotransmission in the CNS
(Castren, Thoenen, & Lindholm, 1995; M. J. Chen, Nguyen, Pike, & Russo-Neustadt,
2007; Scott, Zhang, & Nurse, 2015), and has been shown to effect the survival and
regulation of catecholaminergic neurons. BDNF treatment of cultured neurons has been
shown to lead to a dose-dependent increase in the number of TH-positive neurons,
dopamine content, and dopamine uptake activity (C. Hyman et al., 1994). Further, BDNFTrkB signaling increases the release of dopamine via stimulation of PI3K and mitogenactivated protein kinase (MAPK) in brain striatal slices (Goggi, Pullar, Carney, &
Bradford, 2003). Within the hypothalamus BDNF has been shown to increase
norepinephrine uptake and decrease its stimulated release (Rodriguez Fermepin, Trinchero,
Minetto, Beltran, & Fernandez, 2009), while homozygous BDNF mutations lead to a
32

significant reduction of norepinephrine signaling (Dluzen, Story, Xu, Kucera, & Walro,
1999). The PVN receives substantial catecholaminergic input from NTS A2 and C2
neurons (Cunningham & Sawchenko, 1988; Pacak, Palkovits, Kopin, & Goldstein, 1995;
Saphier & Feldman, 1991; Sawchenko & Swanson, 1982b), and although the role of these
projections is not completely understood, prior studies have indicated that these neurons
exert a hypotensive effect at baseline (Daubert et al., 2012; Duale et al., 2007; Itoh &
Bunag, 1993). In addition, NTS catecholaminergic neurons are thought to be activated
during both acute and chronic stress (Cullinan, Herman, Battaglia, Akil, & Watson, 1995;
Teppema et al., 1997; R. Zhang et al., 2010) and to play a role in the HPA axis response to
systemic stressors (Rinaman & Dzmura, 2007; Ulrich-Lai & Herman, 2009). However, the
effect of BDNF on catecholaminergic signaling in the PVN and its relation to altered
cardiovascular function has not yet been studied
1.4.3. BDNF and Glutamatergic Signaling
BDNF has been shown to increase excitatory synaptic transmission in the CNS
through both pre- and postsynaptic mechanisms (Minichiello, 2009; Waterhouse & Xu,
2009). Post-synaptically, BDNF enhances excitatory synaptic efficacy by modulating
NMDA receptor function (Lin et al., 1998; Suen et al., 1997), Na+ channels (Lesser,
Sherwood, & Lo, 1997), Kv1.3 (K. Tucker & Fadool, 2002) and transient receptor potential
cation subfamily C member 3 (TRPC3) channels (H. S. Li, Xu, & Montell, 1999). BDNF
also promotes the expression of NMDA (Caldeira et al., 2007) and AMPA (Itami et al.,
2003) receptors in postsynaptic sites. However, BDNF has only been shown to selectively
enhance postsynaptic responses to exogenously applied NMDA, but not AMPA (Crozier,
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Black, & Plummer, 1999; Levine, Crozier, Black, & Plummer, 1998), while also increasing
NMDA single-channel open probability (Levine et al., 1998; Levine & Kolb, 2000). The
mechanism behind this may involve BDNF enhancement of the phosphorylation of NMDA
receptor subunits (Lin et al., 1998; Suen et al., 1997). Pre-synaptically, BDNF enhances
glutamate release in synaptosomes (Pascual, Climent, & Guerri, 2001; Sala et al., 1998)
and increases the frequency of miniature excitatory post-synaptic currents (mEPSCs) in the
cultured hippocampal and visual cortex neurons (Carmignoto, Pizzorusso, Tia, & Vicini,
1997; Lessmann & Heumann, 1998; Y. X. Li, Zhang, Lester, Schuman, & Davidson, 1998;
Schinder, Berninger, & Poo, 2000; Tyler & Pozzo-Miller, 2001). BDNF has also been
reported to enhance NMDA signaling by increasing the expression and membrane
trafficking of NMDA receptor 1 (NMDAR1) and 2 subunits via a TrkB and MAPKpathway (Caldeira et al., 2007; Kim et al., 2012). BDNF can also phosphorylate NMDA
receptor subunits to increase the open probability of the NMDA receptor, thereby
enhancing synaptic transmission (Black, 1999). Finally, acute exposure to BDNF enhances
the magnitude of NMDA receptor mediated synaptic currents, increasing the activity of
NMDA receptors containing NMDAR2 (Kolb, Trettel, & Levine, 2005). BDNF has also
been shown to regulate vesicular glutamate transporters (VGLUT), which mediate Lglutamate uptake into synaptic vesicles [332]. BDNF upregulates VGLUT1 and 2 gene and
protein expressions in cultured hippocampal neurons, through activation of the PLCγ
signaling pathway [333].
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1.4.4. BDNF and GABAergic Signaling
BDNF is a crucial regulator of synapse development and function in the CNS
(Cohen-Cory, Kidane, Shirkey, & Marshak, 2010; B. Lu, Pang, & Woo, 2005), and
GABAergic neuronal development is known to rely on BDNF (Gottmann, Mittmann, &
Lessmann, 2009; Hong, McCord, & Greenberg, 2008; Kuzirian & Paradis, 2011; Sakata et
al., 2009). Acute and chronic BDNF administration can suppress presynaptic GABA
transmission in hippocampal slices (Bolton, Pittman, & Lo, 2000; Frerking, Malenka, &
Nicoll, 1998), but alternately potentiate GABA transmission in cultured hippocampal
neurons (Baldelli, Novara, Carabelli, Hernandez-Guijo, & Carbone, 2002). BDNF
potentiation (Jovanovic, Thomas, Kittler, Smart, & Moss, 2004) and suppression (T.
Tanaka, Saito, & Matsuki, 1997) has also been demonstrated in postsynaptic GABAergic
currents. BDNF is known to modulate the efficacy of synaptic responses via TrkB and
p75NTR (B. Lu et al., 2005), and alter the development of neuronal circuits and
construction of inhibitory connections (Gottmann et al., 2009; Gubellini, Ben-Ari, &
Gaïarsa, 2005; Kovalchuk, Holthoff, & Konnerth, 2004). BDNF binds to TrkB, which
couples to the PLC-γ/PKC-δ and ERK/ MAPK pathway. Activated PLC-γ can induce PI3K
activation which increases intracellular Ca2+ concentration (M. Yamada, Mizuguchi, Rhee,
& Kim, 1991) consequently, BDNF disrupts GABAA receptor function through elevated
intracellular Ca2+ concentration (T. Tanaka et al., 1997).
BDNF-TrkB signaling regulates the expression and trafficking of various GABAA
receptor subunits (Bell-Horner, Dohi, Nguyen, Dillon, & Singh, 2006; Y. Nakamura,
Darnieder, Deeb, & Moss, 2015), GAD65 (Hanno-Iijima, Tanaka, & Iijima, 2015;
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Sanchez-Huertas & Rico, 2011), GAD67 (Hanno-Iijima et al., 2015) and GATs (Vaz et al.,
2011), through the recruitment of the ERK-MAP kinase cascade, which activates the
CREB protein (Yoshii & Constantine-Paton, 2010). In primary cultured hippocampal
neurons and cerebellar granule cells, BDNF decreases the plasma membrane expression of
GABAA receptors (Brunig, Penschuck, Berninger, Benson, & Fritschy, 2001; Q. Cheng &
Yeh, 2003) and reduces GABAergic miniature inhibitory postsynaptic currents (mIPSC)
(Brunig et al., 2001). BDNF can also increase the expression of the GABAA-alpha4
subunit and decrease the alpha1 subunit in hippocampal neurons, suggesting that BDNF
has a potential role in differentially regulating the expression of extrasynaptic and synaptic
GABAA receptors (Roberts, Hu, Lund, Brooks-Kayal, & Russek, 2006). Within the
hypothalamus, BDNF has also been shown to alter GABAergic neurotransmission, by
reducing the expression of GABAA receptors, membrane density and function in
hypothalamic neurons (Hewitt & Bains, 2006; Lund et al., 2008).
Indirect modulation of GABAergic neurotransmission by BDNF can occur through
the regulation of Cl− transport (Wardle & Poo, 2003). Previous studies suggest that
downregulation of the K+-Cl− cotransporter 2 (KCC2) may decrease the efficacy of
inhibitory transmission (C. Rivera et al., 1999). In developing neurons, BDNF increases
KCC2 mRNA transcription through activation of the Shc pathway (Aguado et al., 2003;
A. Ludwig et al., 2011; Claudio Rivera et al., 2004), but in adult neurons BDNF decreases
both mRNA and protein KCC2 via activation of both Shc and PLCγ cascades (Boulenguez
et al., 2010; Claudio Rivera et al., 2002; Claudio Rivera et al., 2004; Shulga et al., 2008;
Wake et al., 2007). KCC2 expression is also significantly decreased in TrkB double KO
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mice hippocampi (Carmona et al., 2006). Similarly, neurons in the dorsal horn of the spinal
cord treated with BDNF show a depolarizing shift of the GABA reversal potential (Coull
et al., 2005; Coull et al., 2003).
1.4.5. BDNF-mediated Neuroplasticity
Neurotrophins are important mediators of neuronal plasticity in the developing and
mature CNS. They serve to modulate axonal and dendritic growth, neuronal survival,
neuronal migration, membrane receptor trafficking, neurotransmitter signaling and release,
and synapse formation (B. Lu et al., 2005; Poo, 2001). BDNF is an important mediator of
neuronal plasticity, due to its high expression in brain regions relevant for plasticity and
because of its function as an activity-dependent modulator of neuronal structure, function
and signaling (Bramham & Messaoudi, 2005). BDNF has been shown to perform
excitatory neurotransmitter and neurotrophic functions to facilitate long-term alterations
within the CNS (Blum, Kafitz, & Konnerth, 2002; Matsumoto et al., 2008; H. Park & Poo,
2013). These include increasing axonal growth (Baldelli et al., 2002; P. L. Cheng et al.,
2011; Cohen-Cory & Fraser, 1995; Shelly et al., 2011; Song, Ming, & Poo, 1997;
Yoshimura et al., 2005), altering the structure of synapses and neurons (Gottmann et al.,
2009; H. Park & Poo, 2013; Zagrebelsky & Korte, 2014), and increasing dendritic spine
density, and dendritic arbor of neurons (N. Adachi et al., 2005; Gorski, Zeiler, Tamowski,
& Jones, 2003; Ji et al., 2010; Ji, Pang, Feng, & Lu, 2005; Kellner et al., 2014; Yoshii &
Constantine-Paton, 2007).
In hippocampal neurons, BDNF increases axon-growth via a TrkB-dependent local
elevation and stabilization of cAMP/PKA activity (P. L. Cheng et al., 2011; Shelly et al.,
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2011), and plays a role in microtubule formation during axon growth via activation of TrkB
receptors which phosphorylate Akt and reduce glycogen synthase kinase 3 activation,
leading to a decrease in active collapsing response mediator protein-2 formation (Baldelli
et al., 2002; Song et al., 1997; Yoshimura et al., 2005). Additionally, in cultured xenopus
spinal neurons, BDNF concentration gradients produced by BDNF-containing
micropipettes can cause axonal growth cones to turn towards a higher BDNF concentration
in a cAMP-dependent way (Cohen-Cory & Fraser, 1995; Song et al., 1997)
Dendritic arborization is also affected by BDNF, where it has been shown to
increasing the length and number of apical dendrites of pyramidal cells in rats (Wirth, Brun,
Grabert, Patz, & Wahle, 2003), which is mediated by MAP kinase and PI3 kinase activation
(Dijkhuizen & Ghosh, 2005; Miller & Kaplan, 2003). BDNF also promotes the growth of
cultured striatal and hippocampal neurons and their dendrites (Kwon, Fernández, Zegarek,
Lo, & Firestein, 2011; Moya-Alvarado, Gonzalez, Stuardo, & Bronfman, 2018; Rauskolb
et al., 2010), as well as increasing the dendritic spine density of cortical pyramidal neurons
(Horch & Katz, 2002) and hippocampal neurons (Alonso, Medina, & Pozzo-Miller, 2004).
Finally, BDNF is known to increase the soma size of neurons in the striatum (Yu et al.,
2018), in the hippocampus and cortex (Rutherford, Nelson, & Turrigiano, 1998), as well
as GABAergic neurons in the hippocampus (M. K. Yamada et al., 2002).
BDNF is also a key regulator of synapse formation and stabilization (VicarioAbejon, Owens, McKay, & Segal, 2002), particularly in inhibitory GABAergic neuronal
connections in the visual cortex (Z. J. Huang et al., 1999), cerebellum (Rico, Xu, &
Reichardt, 2002) and hippocampus (Marty, Wehrle, & Sotelo, 2000). Exogenous
38

application of BDNF onto rat hippocampal neurons promotes both excitatory and
inhibitory synapse formation, as well as increasing excitatory synapse numbers (Tyler &
Pozzo-Miller, 2001; Vicario-Abejon, Collin, McKay, & Segal, 1998). Finally, selectively
knocking out TrkB in the cerebellum leads to a reduction in inhibitory synapses, and a
significant decline in synapses in the hippocampus (Martinez et al., 1998).
BDNF is also a key facilitator of LTP at excitatory glutamatergic synapses (Bliss
& Collingridge, 1993; Y. Lu et al., 2011; Panja & Bramham, 2014; Patterson et al., 1996).
LTP is a process of strengthening synaptic connections between neurons with frequent
activation, essential for memory formation and long-term memory consolidation. BDNF
mRNA levels have been shown to increase following LTP in the hippocampal CA1 region
and dentate gyrus (Castrén et al., 1993; Dragunow et al., 1993; Morimoto, Sato, Sato,
Yamada, & Hayabara, 1998; Pang & Lu, 2004; Patterson, Grover, Schwartzkroin, &
Bothwell, 1992). Meanwhile BDNF KO mice show impaired LTP (Minichiello et al.,
1999), which is reversed following BDNF application (Patterson et al., 1996; Pozzo-Miller
et al., 1999). Deficient LTP in BDNF KO mice also leads to behavioral impairments such
as reduced conditioned fear extinction, reduced novel object recognition, and reduced
spatial learning in the Morris water maze. (Heldt, Stanek, Chhatwal, & Ressler, 2007).
Heterozygous BDNF KO mice also show a significant deficit in LTP induced by theta burst
stimulation or forskolin application (Korte et al., 1995; Pang et al., 2004; Patterson et al.,
2001). Further, applying the BDNF scavenger TrkB-Fc or antibodies against BDNF or
TrkB also inhibits LTP in hippocampal slices (Kang, Welcher, Shelton, & Schuman, 1997).

39

The importance of BDNF signaling in learning and memory formation has been
well-demonstrated in the literature (Croll, Ip, Lindsay, & Wiegand, 1998; Tokuyama,
Okuno, Hashimoto, Xin Li, & Miyashita, 2000), particularly in the conversion of shortterm to long-term memories (Alonso et al., 2002; Y. Lu et al., 2011; Radiske et al., 2015).
Disrupting BDNF expression impairs spatial memory and learning, which has been shown
using antisense BDNF KO mice (Linnarsson, Bjorklund, & Ernfors, 1997), anti-BDNF
antibodies (Mu, Li, Yao, & Zhou, 1999), and oligonucleotides (Mizuno, Yamada, Olariu,
Nawa, & Nabeshima, 2000). BDNF could prove important for LTP because of its
promotion of excitatory neurotransmitter activity. To this end, nanomolar concentrations
of BDNF in the hippocampus, cortex, and cerebellum all elevate neuronal excitation
(Kafitz, Rose, Thoenen, & Konnerth, 1999), via promoting glutamate activity through the
NMDA receptor (Blum et al., 2002), and GABA receptors during development when
GABA is excitatory (Brunig et al., 2001; T. Tanaka et al., 1997). Meanwhile pro-BDNF
primarily promotes long-term depression (LTD) following p75NTR activation in the
hippocampus (Rösch, Schweigreiter, Bonhoeffer, Barde, & Korte, 2005; Woo et al., 2005).
This occurs independent of NMDA or AMPA receptors, since p75NTR KO mice have
been shown to have NMDA receptor dependent LTP and LTD which were not affected
(Woo et al., 2005). Pro-BDNF also has the opposite effect on neuronal morphology and
synaptic plasticity compared to BDNF, where it reduces dendrite morphology and spine
density in pyramidal neurons in the hippocampus (Zagrebelsky et al., 2005).
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1.5. BDNF Signaling in the Hypothalamus
1.5.1. BDNF-mediated Cardiovascular and Sympathetic Regulation
In the hypothalamus, BDNF modulates several homeostatic mechanisms, such as
regulation of food intake and body weight (Lebrun, Bariohay, Moyse, & Jean, 2006;
Pelleymounter, Cullen, & Wellman, 1995; Toriya et al., 2010), as well as the activation of
the HPA axis, which is responsible for the neuroendocrine-related aspects of the stress
response (Givalois et al., 2004; Jeanneteau et al., 2012). The importance of BDNF in
cardiovascular regulation is supported by findings that BDNF mRNA and protein
expression is increased in the PVN in response to hypertensive stimuli such as chronic and
acute stress, hyperosmolality, and repeated amphetamine administration (Aliaga,
Arancibia, Givalois, & Tapia-Arancibia, 2002; Hammack et al., 2009; Meredith, Callen, &
Scheuer, 2002; Rage, Givalois, Marmigere, Tapia-Arancibia, & Arancibia, 2002; Smith,
Makino, Kim, et al., 1995). This indicates that BDNF may serve as a stress-responsive
intracellular messenger and could be a key mediator of the stress response (Castren et al.,
1995; Hammack et al., 2009; Rage et al., 2002; Smith, Makino, Kim, et al., 1995). Using
in situ hybridization, BDNF mRNA was shown to be present in the PVN, and acute or
repeated immobilization stress was found to significantly increase its expression there
(Smith, Makino, Kim, et al., 1995). Rats exposed to a 7-day chronic stress procedure have
also showed a significant increase in BDNF levels in the PVN (Hammack et al., 2009).
Finally, hypertonic saline injections also increase BDNF mRNA expression in both the
magnocellular and parvocellular PVN (Castren et al., 1995). The mechanism behind how
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stress and other hypertensive stimuli elevate BDNF expression in the PVN is not fully
understood.
Recent studies have suggested that BDNF may play a critical role in the
development of hypertension. We have recently shown that both long-term overexpression
and acute microinjection of exogenous BDNF into the PVN leads to significant increases
in blood pressure and heart rate under baseline conditions (Erdos, Backes, McCowan,
Hayward, & Scheuer, 2015; Chris L. Schaich, Wellman, Koi, & Erdos, 2016). BDNF has
also been shown to modulate cardiovascular responses to acute water and acute restraint
stress, where increases in blood pressure due to stress were significantly reduced in BDNF
rats compared to control GFP rats, but heart rate responses to acute stress were unaffected
by BDNF (Erdos, Backes, et al., 2015). Additionally, we have shown that inhibiting the
TrkB receptor in the PVN lowers acute stress-induced pressor responses in SD rats, while
resting blood pressure, heart rate, food intake and body weight were unaffected (C. L.
Schaich, Wellman, Einwag, Dutko, & Erdos, 2018).
The elevations in blood pressure and heart rate caused by BDNF overexpression in
the PVN are mediated partly by angiotensin signaling. BDNF promotes angiotensin II
signaling in the PVN and elevates the expression of AT1R in the PVN, which is associated
with increased blood pressure (Becker, Wang, Tian, & Zucker, 2015; Erdos, Backes, et al.,
2015; Erdos, Clifton, et al., 2015; Chris L. Schaich et al., 2016). Inhibiting AT1Rs with
losartan in the PVN has also been shown to cause a significant reduction in MAP and heart
rate (Erdos, Backes, et al., 2015). Furthermore, infusion or pretreatment with the AT1R
antagonist losartan in the PVN of conscious and anesthetized rats has been shown to
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attenuate BDNF-induced increases in MAP (Chris L. Schaich et al., 2016). Additionally,
peripheral blockade using hexamethonium was found to diminish average and peak
elevations in MAP, similar to rats pretreated with losartan while also diminishing the heart
rate response, and decreasing baseline MAP (Chris L. Schaich et al., 2016).
These results suggest that angiotensin signaling is a potential mediator of the acute
blood pressure response to BDNF within the PVN (Chris L. Schaich et al., 2016). Another
potential mediator of BDNFs effects on cardiovascular parameters in the PVN is AVP.
BDNF is known to stimulate the synthesis of AVP in the PVN (Aliaga et al., 2002; Givalois
et al., 2004), which may promote sympathetic activity acting centrally within the PVN (ElWerfali, Toomasian, Maliszewska-Scislo, Li, & Rossi, 2015) or elevate blood pressure
through peripheral mechanisms (Henderson & Byron, 2007). Other mechanisms may be
involved, and further research is needed to elucidate the specific signaling and structural
effects of BDNF within the PVN.
1.5.2. BDNF-mediated Regulation of the Hypothalamic-Pituitary-Adrenal (HPA)
Axis
The HPA axis involves a variety of feedback mechanisms between the
hypothalamus, the pituitary gland, and the adrenal gland. The PVN is a key regulator and
initiator of HPA axis activity which mediates the neuroendocrine stress response and
adaptation to future stressors (Bartanusz, Aubry, Jezova, Baffi, & Kiss, 1993; Bartanusz,
Jezova, et al., 1993; Givalois et al., 2004). The pathway is initiated by the release of CRH
and AVP from neuroendocrine neurons in the medial parvocellular region of the PVN,
which then travel to the median eminence (Antoni, 1993; Herman & Tasker, 2016;
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Whitnall, Mezey, & Gainer, 1985). From there they are released into portal circulation
(Plotsky, 1987), leading to ACTH secretion from the anterior pituitary (Antoni, 1986;
Gillies, Linton, & Lowry, 1982; Herman & Tasker, 2016; Merchenthaler, Vigh, Petrusz, &
Schally, 1982), which triggers the release of glucocorticoids from the adrenal cortex.
Glucocorticoids are important for stress adaptation, and their receptors are involved in the
negative feedback regulation of the HPA axis during stress (Reul & de Kloet, 1985).
Glucocorticoids are also colocalized with CRH and highly expressed in the PVN (Liposits
et al., 1987; Uht, McKelvy, Harrison, & Bohn, 1988). CRH neurons are important for
adaptation to chronic (Herman, 1995; Herman, Adams, & Prewitt, 1995) and acute stress
responses (Whitnall, 1989), and are the main initiators of the HPA axis pathway. However,
AVP is also co-expressed in about 50% of CRH neurons (Aguilera, 1998) and can
significantly potentiate the effect of CRH to stimulate ACTH release (Gillies et al., 1982).
CRH neurons are under excitatory control from catecholaminergic neurons in the
brain stem and glutamatergic interneurons in the periventricular area (Herman, Prewitt, &
Cullinan, 1996). Indirect projections from the forebrain via the BNST and amygdala can
also stimulate CRH neurons by activating glutamatergic or inhibiting GABAergic
interneurons (Herman et al., 1996). Deletion of the CRH gene blocks baseline and stressinduced release of ACTH (Muglia, Bethin, Jacobson, Vogt, & Majzoub, 2000), which
shows the necessity of CRH signaling in HPA axis activation. CRH and AVP both trigger
the secretion of ACTH by binding to their respective receptors, CRH binds to CRHR1
(Aguilera, 1994), and AVP binds to AVP 1B receptors to assist in CRH-mediated ACTH
release (Rabadan-Diehl, Kiss, Camacho, & Aguilera, 1996). In addition to activating the
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HPA axis, binding of CRH to CRHR1 coordinates stress responses and stress-related
behaviors, such as sympathetic activation, central suppression of the immune system, and
arousal (Bale & Vale, 2004). Parvocellular CRH neurons also express a variety of
neuropeptides such as glutamate, Ang II, cholecystokinin, and neurotensin (Hrabovszky,
Wittmann, Turi, Liposits, & Fekete, 2005; Swanson et al., 1987) , which may indicate that
CRH neurons can effect various different cell types. This could lead to stimulatory effects
of not only CRH and AVP on ACTH secretion, but cholecystokinin and angiotensin also
(Mezey, Reisine, Skirboll, Beinfeld, & Kiss, 1986; Swanson et al., 1986).
Inactivation of the HPA axis is important for minimizing the deleterious effects of
excessive CRH production. This involves changes in excitatory and inhibitory
neurocircuitry and negative feedback by glucocorticoids. Glucocorticoids inhibit pituitary
ACTH secretion and POMC transcription (Autelitano, Lundblad, Blum, & Roberts, 1989;
Dallman et al., 1987), while administration of glucocorticoids inhibits CRH transcription
and desensitizes the HPA axis response to stress (Dallman et al., 1994; Lightman & Young,
1989; Ma & Aguilera, 1999). Removal of glucocorticoids results in the opposite effect (Ma
& Aguilera, 1999; Makino et al., 1995). Glucocorticoids also have an indirect inhibitory
effect on CRH neurons, through decreasing alpha-adrenergic receptors in the PVN and
inhibiting stress-induced release of norepinephrine from the PVN (Day, Campeau, Watson,
& Akil, 1999; Pacak, Palkovits, Kvetnansky, et al., 1995). Glucocorticoids can also signal
via the mineralocorticoid receptors (MR) since MR receptors are known to be expressed in
the PVN and occupation of the MR receptor is required during certain kinds of stress
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(Arriza, Simerly, Swanson, & Evans, 1988; Cole et al., 2000). However, the specific role
of MR receptors in regulation of the HPA axis is currently unknown.
BDNF mRNA expression in the PVN is elevated in response to acute and chronic
stress (Givalois et al., 2004; Hammack et al., 2009; Smith & Cizza, 1996; Smith, Makino,
Kim, et al., 1995). Immobilization stress significantly increases BDNF mRNA expression
in both the pituitary and hypothalamus (Givalois et al., 2004; Rage et al., 2002). BDNF is
also involved in the activation of the HPA axis via the regulation of CRH and AVP
(Givalois et al., 2001; Jeanneteau et al., 2012). ICV BDNF injections increase CRH mRNA
and, decrease AVP mRNA expression in the parvocellular and magnocellular PVN
(Givalois et al., 2004). In situ hybridization shows additionally that BDNF co-localizes
with both CRH and AVP in the parvocellular and magnocellular areas of the PVN after
immobilization stress (Aliaga et al., 2002; Givalois et al., 2001; Smith, Makino,
Kvetnansky, & Post, 1995), and CRH co-localizes with AVP (Whitnall, 1993). Deletion of
the glucocorticoid receptor in the PVN also upregulates CRH and BDNF expression while
also disinhibiting the HPA axis (Jeanneteau et al., 2012). Finally, BDNF may play a part
in replenishing neurohormone stock by stimulating the synthesis of neuropeptides in
cultured hypothalamic neurons (Loudes, Petit, Kordon, & Faivre-Bauman, 1999, 2000).
1.5.3. BDNF-mediated AVP Secretion and Osmoregulation
Osmoregulation refers to the process of maintaining water and salt balance
throughout the body and involves various signaling mechanisms that report body fluids
and distribution, as well as integration of that information leading to autonomic, endocrine,
and behavioral effects (Johnson, 2009). Secretion of AVP is known to be influenced by
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changes in both blood osmolality and volume (Robertson & Athar, 1976). AVP is
synthesized and secreted from magnocellular neurons in the PVN (Lechan & Toni, 2000),
where AVP increases plasma volume leading to the induction of cAMP and the
translocation of aquaporin-2 water channels to the plasma membrane of tubular epithelial
cells, allowing for water reabsorption (Shaw & Marples, 2002; Valenti, Procino, Tamma,
Carmosino, & Svelto, 2005). When plasma osmolality increases, thirst is increased shortly
following the release of AVP (Lechan & Toni, 2000).
Osmoregulatory input to the PVN comes from projections from the OVLT and the
MnPO nucleus, both of which promote AVP secretion. Their role in the thirst response to
hyperosmolarity has also been demonstrated in lesion studies (Bourque, Oliet, & Richard,
1994; McKinley, 2001). The PVN itself is also known to be osmosensitive to some extent
(Honda, Negoro, Higuchi, & Tadokoro, 1987; Osaka, Kannan, Kasai, Inenaga, &
Yamashita, 1990). Another important brain region involved in blood volume regulation is
the SFO, which sends projections to the PVN and the OVLT, and contribute to AVP
secretion in response to hyperosmolarity using Ang II as a mediator (Bourque et al., 1994;
A. V. Ferguson & Renaud, 1986; Krause et al., 2008; J. Tanaka, Nojima, Yamamuro, Saito,
& Nomura, 1993). The NTS carries information involved in AVP secretion as well, such
as baroregulatory information (Bourque et al., 1994; Lechan & Toni, 2000), which is
relayed to the NTS from baroreceptors in the aortic arch and carotid sinus via the vagus
and glossopharyngeal nerves. This information then travels to the PVN via
catecholaminergic neurons (Lechan & Toni, 2000).

47

High salt intake is known to upregulate the expression of BDNF (Carreno, Walch,
Dutta, Nedungadi, & Cunningham, 2011; Choe et al., 2015; Choe, Trudel, & Bourque,
2016; Marosi & Mattson, 2015) and BDNF can also stimulate the secretion of AVP in
response to high salt and hyperosmotic stimuli (Aliaga et al., 2002; Castren et al., 1995).
BDNF mRNA expression precedes AVP increases in the SON and PVN following i.p.
injections of hypertonic saline. This may suggest that BDNF can function as an autocrine
or paracrine regulator of AVP secretion (Aliaga et al., 2002). Increases in BDNF
expression also reverse the GABAA mediated inhibition of AVP neurons by increasing
intracellular chloride. This is mediated by BDNF-TrkB signaling and the downregulation
of KCC2, leading to a sustained release of AVP and an increase in blood pressure (Choe
et al., 2015; Choe et al., 2016; Marosi & Mattson, 2015). Acute immobilization stress also
significantly increases both AVP mRNA and hypothalamic BDNF mRNA (Givalois et al.,
2004). BDNF additionally positively modulates AVP release in studies of isolated
hypothalamic cell cultures (Moreno, Piermaria, Gaillard, & Spinedi, 2011). Finally,
osmotic stress can lead to morphological changes in the PVN and SON (Hatton, 1997),
which could indicate that elevations in BDNF mRNA expression may prepare neurons for
osmolarity associated alterations in metabolic demand (McAllister, Katz, & Lo, 1999).
1.5.4. BDNF-mediated Regulation of Metabolism and Food Intake
The hypothalamus has been shown to play a significant role in metabolism and food
intake since lesioning the hypothalamus results in obesity (Brobeck, 1946). Conversely,
lesioning the lateral hypothalamus has been shown to lead to anorexia and weight loss (D.
J. Lee, Elias, & Lozano, 2018). Leptin serves as a critical regulator of metabolism and food
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intake, broadly acting as a satiety signal, responsible for inhibiting hunger. Plasma
concentrations of leptin can also serve as an important indicator of body fat stores (Ahima,
Saper, Flier, & Elmquist, 2000; Barsh & Schwartz, 2002; Gautron & Elmquist, 2011; Kalra
et al., 1999; Ollmann et al., 1997; Schwartz, Woods, Porte, Seeley, & Baskin, 2000). An
increase in nutrient consumption increases leptin secretion thereby decreasing appetite,
while nutrient insufficiency decreases leptin secretion thereby increasing appetite and
consumption. Leptin acts primarily in the arcuate nucleus and exerts its effects depending
on its concentration level.
High levels of leptin are associated with increased expression of weight loss
promoting genes such as elevated POMC neuron activity and the production of several
hormones involved in feeding behavior, including alpha melanocyte-stimulating hormone
(alpha-MSH), ACTH, and b-endorphins (Millington, 2007). Mutations interfering with the
functioning of type 4 melanocortin receptor (MC4r) or MC43 KO in animals leads to the
development of severe obesity syndrome (Farooqi et al., 2000; Huszar et al., 1997; Jackson
et al., 1997; Krude et al., 1998). Additionally, weight gain associated with aging can be
attributed to the reduction of melanocortin signaling (Gruenewald & Matsumoto, 1991;
Mobbs et al., 2001). Melanocortin signaling may be a critical regulatory system involved
in appetite and satiety (Lechan & Toni, 2000). Similarly, there is also evidence that cancer
cachexia, a wasting syndrome characterized by weight loss, may be prevented by the
melanocortin receptor antagonist administration (Marks, Ling, & Cone, 2001; Wisse,
Frayo, Schwartz, & Cummings, 2001).
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Low levels of leptin lead to increased expression of genes that promote weight gain
and reduce energy expenditure such as agouti-related protein (AGRP) and neuropeptide Y
(NPY) (Decourt, Tillet, Caraty, Franceschini, & Briant, 2008). These neurons act via the
PI3K signaling pathway and by phosphorylating signal transducer and activator of
transcription 3 (STAT3) (Bates et al., 2003; Lechan & Toni, 2000; Zhao, Huan, Gupta, Pal,
& Sahu, 2002). NPY and AGRP neurons send projections to similar regions in the
hypothalamus as POMC neurons, before being relayed to other brain regions associated
with feeding behavior and energy expenditure (Ahima et al., 2000; Barsh & Schwartz,
2002; Kalra et al., 1999; Schwartz et al., 2000). Reciprocal connections also exist between
the arcuate nucleus NPY/AGRP neurons and the alpha-MSH neurons (Cowley et al., 2001).
Injecting AGRP or NPY into the brain causes an increase in food intake (Aponte, Atasoy,
& Sternson, 2011), and AGRP also antagonizes melanocortin receptors, leading to lowered
melanocortin and leptin due to a rise in AGRP (Nijenhuis, Oosterom, & Adan, 2001;
Ollmann et al., 1997).
TRH neurons in the medial parvocellular PVN receive direct projections from
NPY/AGRP and alpha-MSH/CART neurons, which serve to alter the range at which
circulating thyroid hormone inhibits TRH (Fekete et al., 2001; Fekete, Legradi, et al., 2000;
Fekete, Mihaly, et al., 2000; Fekete et al., 2002). The anterior and ventral parvocellular
PVN also receive a significant amount of input from alpha-MSH and AGRP axons which
are thought to regulate various feeding behaviors (Hahn, Breininger, Baskin, & Schwartz,
1998; Spiegelman & Flier, 2001). The anterior parvocellular PVN sends projections to the
limbic system which may regulate behavioral aspects of feeding (Luiten, ter Horst, Karst,
50

& Steffens, 1985; Roeling, Veening, Peters, Vermelis, & Nieuwenhuys, 1993). Meanwhile,
ventral parvocellular PVN neurons send projections to the brainstem and spinal cord which
may regulate energy disposal (Roeling et al., 1993; Sawchenko & Swanson, 1982a;
Swanson & Kuypers, 1980).
BDNF signaling has been linked to body weight and food intake regulation (Lebrun
et al., 2006). Central and peripheral administration of BDNF induce appetite suppression
and weight loss (Pelleymounter et al., 1995; C. Wang, Bomberg, Billington, Levine, &
Kotz, 2007b; C. Wang, Bomberg, Levine, Billington, & Kotz, 2007; C. Wang, Godar,
Billington, & Kotz, 2010), increases locomotor activity (Naert, Ixart, Tapia-Arancibia, &
Givalois, 2006), lowers resting metabolic rate (C. Wang, Bomberg, Billington, Levine, &
Kotz, 2007a; C. Wang, Bomberg, Levine, et al., 2007), lowers blood glucose and increases
energy expenditure in type 2 diabetes animal models (Nakagawa et al., 2000). Chronic ICV
administration of BDNF also prevents weight gain (Lapchak & Hefti, 1992), whereas an
obese phenotype is observed in BDNF conditional KO mice (Rios et al., 2001). BDNF is
also known to have peripheral actions that affect glucose metabolism (Yamanaka, Itakura,
Ono-Kishino, et al., 2008; Yamanaka, Itakura, Tsuchida, Nakagawa, & Taiji, 2008;
Yamanaka, Tsuchida, et al., 2007), energy expenditure (Yamanaka, Itakura, et al., 2007;
Yamanaka, Tsuchida, et al., 2007), and food intake (Yamanaka, Itakura, Ono-Kishino, et
al., 2008). These effects of BDNF are also clear from conditions where BDNF is globally
reduced, such as in rodents and humans with haploinsufficiency for the BDNF gene, which
results in obesity and hyperphagia (Gray et al., 2006; Han et al., 2008; Kernie, Liebl, &
Parada, 2000). BDNF also interacts with leptin signaling since leptin injections into the
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VMN of the hypothalamus increase BDNF mRNA expression, which is also regulated by
nutritional state and MC4r signaling (Komori, Morikawa, Nanjo, & Senba, 2006; Baoji Xu
et al., 2003). Finally, BDNF also interacts with CRH signaling to decrease body weight
and food intake through upregulating CRH and activating CRHR2 in the PVN (Toriya et
al., 2010).
We have previously shown that increased BDNF expression in the PVN
significantly increases nighttime physical activity and significantly reduces body weight
compared to pre-injection body weight and compared to control GFP treated rats (Erdos,
Backes, et al., 2015). Losartan treatment prevents BDNF-induced weight loss, however in
a combined treatment of BDNF and losartan, body weight was still significantly lower
compared to control animals (Erdos, Backes, et al., 2015). These results suggest that
angiotensin signaling mediates some of the BDNF-induced reductions in body weight
(Erdos, Backes, et al., 2015; Chris L. Schaich et al., 2016). Mutations in the TrkB receptor
which affect its ability to autophosphorylate have also been associated with obesity and
hyperphagia (Yeo et al., 2004). Wild type mice that express the truncated form of the TrkB
receptor, which inhibits the activity of BDNF, are obese (Xu et al., 2000; B. Xu et al.,
2003). However, when the TrkB ligand NT4 and a TrkB-specific antibody are administered
to the hypothalamus of mice, a reduction in food intake and resistance to diet-induced
obesity is seen (Tsao et al., 2008).
Finally, BDNF signaling can be altered through the Val66Met, single nucleotide
polymorphism (SNP), which substitutes a valine for methionine residue at position 66. This
substitution alters the intracellular packaging of pro-BDNF and may affect the signaling
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activity of mature BDNF (Z. Y. Chen et al., 2004; M. F. Egan et al., 2003). This SNP
strongly correlates with anorexia nervosa in humans and is further associated with a low
body mass index (Ribases et al., 2003). However, there are conflicting studies regarding
this gene variant, some studies indicate that the Val66Met polymorphism is associated with
an increased risk of eating disorders (Gratacos et al., 2007), while others have found no
association between eating disorders and Val66Met (Arija, Ferrer-Barcala, Aranda, &
Canals, 2010; Dardennes et al., 2007), and still others report a link between Val66Met and
obesity in females (Beckers et al., 2008). This dissertation will attempt to show how BDNF
might be altering catecholaminergic, glutamatergic and GABAergic signaling mechanisms
in the PVN to elevate blood pressure by looking at the effect of BDNF overexpression in
the PVN on the expression of catecholaminergic, glutamatergic and GABAergic signaling
components within the PVN and the NTS.
CHAPTER 2: BDNF Downregulates Beta-Adrenergic Receptor-Mediated
Hypotensive Mechanisms in the Paraventricular Nucleus of the Hypothalamus
2.1. Introduction
Increased sympathetic activity is a significant factor in the development of
hypertension and a major contributor to cardiovascular risk factors such as stress, high fat
and high salt diets (Chida & Steptoe, 2010; Guyenet & Stornetta, 2004; Lambert &
Lambert, 2011; Steptoe & Kivimaki, 2012; Whelton, 1994). Neural control of blood
pressure is mediated by a core network of hypothalamic and brainstem nuclei.
Presympathetic neurons within the PVN stimulate spinal sympathetic preganglionic
neurons directly or via the RVLM (R. A. Dampney, 1994; Stornetta, 2009), while the
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nucleus of the NTS plays an important role in processing sensory information, responding
to blood pressure changes and regulating sympathetic nervous system activity through the
baroreflex (Andresen & Kunze, 1994; R. A. Dampney, 1994). The PVN plays a critical
role in integrating autonomic, neuroendocrine and cardiovascular responses to stressful
stimuli (Busnardo, Tavares, & Correa, 2014; R. A. Dampney, 2005; Wamsteeker & Bains,
2010), and our recent findings indicate that BDNF, acting in the PVN through its highaffinity TrkB receptor, may be a novel regulator of stress-induced elevations in sympathetic
activity and blood pressure (Erdos, Backes, et al., 2015; C. L. Schaich et al., 2018; Chris
L. Schaich et al., 2016).
BDNF is a member of the neurotrophin family, capable of excitatory
neurotransmitter and neurotrophic functions to induce both short- and long-term adaptive
alterations throughout the CNS (Blum et al., 2002; Matsumoto et al., 2008; H. Park & Poo,
2013). In the hypothalamus, BDNF modulates several homeostatic mechanisms such as
regulation of food intake and body weight (Lebrun et al., 2006; Pelleymounter et al., 1995;
Toriya et al., 2010) and activation of the hypothalamic pituitary adrenal (HPA) axis, which
is responsible for the neuroendocrine aspects of the stress response (Givalois et al., 2004;
Jeanneteau et al., 2012). In addition, BDNF mRNA and protein levels in the PVN are
elevated in response to several hypertensive stimuli such as chronic and acute stress,
hyperosmolality and repeated amphetamine administration (Aliaga et al., 2002; Hammack
et al., 2009; Meredith et al., 2002; Rage et al., 2002; Smith, Makino, Kim, et al., 1995),
and we have recently shown that both long-term overexpression and acute microinjection
of exogenous BDNF into the PVN lead to significant increases in sympathetic nervous
54

system activity, blood pressure and heart rate (Erdos, Backes, et al., 2015; Chris L. Schaich
et al., 2016). Furthermore, we have found that inhibition of BDNF signaling by blocking
its high affinity receptor TrkB in the PVN reduces acute stress-induced blood pressure
elevations without affecting baseline cardiovascular function (C. L. Schaich et al., 2018).
BDNF has been shown to promote angiotensin II signaling and elevate the
expression of AT1R in the PVN which is associated with elevated blood pressure (Becker
et al., 2015; Erdos, Backes, et al., 2015; Erdos, Clifton, et al., 2015; Chris L. Schaich et al.,
2016), and BDNF is also known to stimulate the synthesis of arginine vasopressin (AVP)
in the PVN (Aliaga et al., 2002; Givalois et al., 2004) which may promote sympathetic
activity acting centrally within the PVN (El-Werfali et al., 2015) or elevate blood pressure
through peripheral actions (Henderson & Byron, 2007). However, BDNF is also a known
modulator of catecholaminergic neurotransmission (Castren et al., 1995; M. J. Chen et al.,
2007; Scott et al., 2015), and within the hypothalamus, BDNF has been shown to increase
norepinephrine uptake and decrease its evoked release (Rodriguez Fermepin et al., 2009).
The PVN receives substantial catecholaminergic input from NTS A2 and C2 neurons
(Cunningham & Sawchenko, 1988; Pacak & Palkovits, 2001; Saphier & Feldman, 1991;
Sawchenko & Swanson, 1982b), and while the role of these projections is not completely
understood, several studies have indicated that these neurons exert a hypotensive action at
baseline (Daubert et al., 2012; Duale et al., 2007; Itoh & Bunag, 1993). In addition, NTS
catecholaminergic neurons are thought to be activated during both acute and chronic stress
(Cullinan et al., 1995; Teppema et al., 1997; R. Zhang et al., 2010) and to play a role in the
HPA axis response to systemic stressors (Rinaman & Dzmura, 2007; Ulrich-Lai &
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Herman, 2009). Thus, an increase in BDNF expression in the PVN in response to
hypertensive stimuli may have a significant impact on cardiovascular regulation by
interfering with catecholaminergic signaling.
Here, we set out to test the hypothesis that upregulation of BDNF in the PVN
elevates blood pressure either by diminishing catecholaminergic β receptor-mediated
inhibitory input from the NTS or by augmenting α receptor-mediated excitatory
mechanisms. We used our previously published model (Erdos, Backes, et al., 2015) of
vector-mediated upregulation of BDNF in the PVN to induce hypertension and investigated
the interaction of BDNF and catecholaminergic signaling by selectively lesioning NTS
catecholaminergic neurons using the neurotoxin anti-dopamine-β-hydroxylase-conjugated
saporin (DSAP) (Madden, Ito, Rinaman, Wiley, & Sved, 1999). In addition, cardiovascular
responses to PVN microinjections of adrenergic receptor agonists and mRNA expression
of adrenergic receptors were analyzed following overexpression of BDNF in the PVN.
Better understanding of BDNF-mediated cardiovascular regulatory mechanisms within the
PVN is crucial for elucidating the central circuitry involved in the development of
hypertension and could eventually lead to the identification of novel therapeutic targets.
2.2. Methods
All animal housing, handling, surgical and experimental procedures were
conducted within an Association for the Assessment and Accreditation of Laboratory Care
International-accredited animal care facility at the University of Vermont, in accordance
with the U.S. Public Health Service Policy on Humane Care and Use of Laboratory
Animals and the National Institutes of Health Guide for the Care and Use of Laboratory
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Animals. Experiments were performed in male Sprague-Dawley (SD) rats obtained from
Charles River (Saint-Constant, QC, Canada). Rats were housed individually with a 12:12h light-dark cycle (lights on at 6:00 AM), with free access to food (standard chow) and
water. All experimental procedures were approved by the Institutional Animal Care and
Use Committee at the University of Vermont.
2.2.1. Experimental Design
Experiment 1. The aim of this experiment was to determine how increased BDNF
expression in the PVN affects catecholaminergic input from the NTS. Radiotelemetric
transmitters were implanted for blood pressure measurement in 8-week-old male SD rats,
and animals were allowed to recover for two weeks. Baseline cardiovascular parameters
were recorded for 6 days, then, adeno-associated viral vectors (AAV2, 1012 vps/mL; 200
nL/side) expressing GFP or myc epitope-tagged BDNF fusion protein (BDNFmyc) were
injected bilaterally into the PVN. In addition, PBS (100 nL) or DSAP (22 ng in 100 nL
PBS), was injected bilaterally into the NTS as described previously (Daubert et al., 2012).
After a week of recovery, cardiovascular parameters were recorded for 3 weeks. During
this period, rats were subjected to an acute restraint stress procedure 3 weeks after brain
injections and to an acute water stress procedure 4 weeks after brain injections (Fig. 2A).
At the end of the experiment, animals were deeply anesthetized with isoflurane and
perfused transcardially with ice-cold PBS and 4% paraformaldehyde. PVN expressions of
GFP and BDNFmyc as well as effects of DSAP lesioning in the NTS were verified with
immunofluorescence (Fig. 2B – H). In addition, percent volumetric density of DβH-
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positive vesicles, an indicator of catecholaminergic projections into the PVN, was
determined within the PVN using immunofluorescence and confocal microscopy.
Experiment 2. The goal of this experiment was to determine the effect of BDNF on
adrenergic receptor signaling in the PVN. 7-week-old male SD rats received bilateral PVN
injections of AAV2 viral vectors (1012 vps/mL; 200 nL/side) expressing GFP or
BDNFmyc. Three weeks later, blood pressure and heart rate responses were recorded
following unilateral PVN injections of isoprenaline (125 µM or 250 µM, 200 nL/side) a βadrenergic agonist under α-chloralose-urethane anesthesia. In addition, responses to
unilateral PVN injections of phenylephrine (200 µM, 200 nL), an α1 agonist or vehicle
(aCSF, 200 nL/side) were also recorded. At the end of the experiment, animals were deeply
anesthetized and perfused transcardially with PBS and 4% paraformaldehyde. PVN
expressions of GFP, BDNFmyc and drug injection sites of isoprenaline, phenylephrine and
aCSF indicated by a red fluorescent microbead solution were verified with
immunofluorescence and fluorescent microscopy in coronal sections of the PVN (Fig. 3A
– C).
Experiment 3. The goal of this experiment was to determine the effect of BDNF on
adrenergic receptor expression in the PVN. 7-week-old male SD rats received bilateral
PVN injections of AAV2 viral vectors (1012 vps/mL; 200 nL/side) expressing GFP or
BDNFmyc. Three weeks later, animals were euthanized, and the brains were quickly
removed and snap frozen. PVN and NTS tissue samples were isolated and mRNA levels
of BDNF, corticotrophin releasing hormone (CRH), α1a, α1b, α2a, β1and β2 were
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determined in the PVN and mRNA levels of tyrosine hydroxylase (TH) and DβH were
determined in the NTS with quantitative real-time RT-PCR.
2.2.2. Surgical Procedures
Surgeries were performed using aseptic techniques under continuous isoflurane
anesthesia (5% induction, 2-3% maintenance) delivered in oxygen. Depth of anesthesia
was assured by lack of a reflex response to pinch of the hind paw. Carprofen (5
mg·kg−1·day−1 sc) was used for postsurgical analgesia administered at the beginning of
surgery and for 2 days after surgery.
2.2.2.1. Telemetry Transmitter Implantation
In the first experiment, radiotelemetric transducers (model HD-S10; Data Sciences
International, St. Paul, MN) were implanted into the descending aorta via a midline
abdominal incision. The aorta was isolated and briefly occluded, and the tip of the catheter
was inserted using a 21-gauge needle. Surgical glue (3M Vetbond Tissue Adhesive) and a
nitrocellulose patch were applied to secure the catheter in place. The transducer was
sutured to the abdominal muscle, and the incision closed in layers.
2.2.2.2. Stereotaxic Viral Vector and DSAP Injections
Rats were put under isoflurane anesthesia and placed in a stereotaxic frame,
BDNFmyc and GFP viral vectors (1012 viral particles/ml; 200 nL/side) were injected
bilaterally into the PVN using pipettes pulled from thin walled borosilicate glass capillary
tubes (OD, 1 mm; ID, 0.58 mm; tip diameter: ∼25 μm; World Precision Instruments Inc.,
Sarasota, FL, USA) at the following stereotactic coordinates: 1.80 mm posterior to bregma;
1.70 mm lateral to the midline; and 7.65 mm ventral from the dorsal surface of the brain,
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with the micropipette tilted 10º laterally toward the midline. Virus stocks were injected
over 5 min using a pneumatic pico pump (World Precision Instruments, Sarasota, FL). The
pipette was left in place for an additional 3 min before being withdrawn.
In experiment 1, PVN injections were combined with bilateral NTS injections of sterile
PBS (for control) or DSAP (Advanced Targeting Systems, San Diego, CA, USA), an
immunotoxin that selectively lesions catecholaminergic neurons (Madden et al., 1999).
The head was ventro-flexed at an angle of approximately 30o to allow for surgical exposure
of the dorsal surface of the hindbrain. The micropipette tip was lowered at the calamus
scriptorius (rostral–caudal), 0.3 mm lateral from midline and 0.5 mm ventral to the surface
of the medulla and 100 nL of PBS or DSAP diluted to a concentration of 0.22 mg·ml −1 in
sterile PBS was injected over 5 min using a pneumatic pico pump. This concentration of
DSAP was chosen since it has been used previously to lesion NTS catecholaminergic
neurons without any significant impact on other catecholaminergic nuclei (Daubert et al.,
2012). The pipette was left in place for an additional 3 min before being withdrawn.
2.2.2.3. Assessment of Cardiovascular Responses to Adrenergic Receptor Agonists
In experiment 2, the left femoral artery and vein were catheterized under isoflurane
anesthesia 3 weeks after bilateral PVN injections of AAV2-GFP or AAV2-BDNFmyc.
Rats were then placed in a stereotaxic frame, and isoflurane anesthesia was gradually
switched to intravenous α‐chloralose (60 mg kg−1 hr-1) and urethane (800 mg kg−1 hr-1)
anesthesia, administered through the femoral vein catheter over a 30-min period, during
which, isoflurane was gradually reduced from 2.5% to 0%. Blood pressure, heart rate, toepinch and eye-blink reflexes were monitored closely to ensure the animal remained
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anesthetized. After complete withdrawal of isoflurane, anesthesia was maintained by
intravenous α-chloralose (15 mg kg−1 hr−1) and urethane (200 mg kg−1 hr−1) infusion for
the remainder of the experiment. After establishing steady baseline blood pressure and
heart rate for a minimum of 30 min, rats received unilateral PVN injections of isoprenaline
hydrochloride (125 µM or 250 µM, 200 nL/side; Acros Organics, AC437210050),
phenylephrine (200 µM, 200 nL/side; Fisher Scientific, AC207240100) or aCSF (200
nL/side). Blood pressure was monitored via the catheter placed in the left femoral artery,
and heart rate was extracted from the pulsatile pressure wave using Lab Chart Pro 8
(ADInstruments). To verify locations of the isoprenaline, phenylephrine and aCSF
injections in the PVN with fluorescent microscopy, 10% rhodamine‐labelled fluorescent
microspheres (0.04 μm; Molecular Probes) were mixed into the injection solution.
2.2.3. Viral Vector-mediated Gene Transfer into the PVN and DSAP Lesioning of
NTS Neurons
AAV2 viral vectors were used to elicit the expression of enhanced GFP and
BDNFmyc, derived from rat bdnf, constructed and packaged by Vector Biolabs
(Philadelphia, PA). The expression of GFP and BDNFmyc was driven by a chicken-β-actin
promoter with human cytomegalovirus enhancer, and a woodchuck post-transcriptional
regulatory element, which enhanced the expression of transgenes, present downstream of
GFP and BDNFmyc. The BDNFmyc plasmid was a generous gift from Dr. Ronald Klein
(LSU Health Sciences Center Shreveport) and was used previously to protect retinal
ganglion cells in a rat glaucoma model (K. R. Martin et al., 2003), and to study
cardiovascular effects of BDNF in the PVN (Erdos, Backes, et al., 2015). In addition, full
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efficacy of BDNFmyc expression driven by the rat neuron-specific enolase promoter was
confirmed previously both in vitro and in vivo (R. L. Klein et al., 1999). PVN injections of
AAV2-GFP and AAV2-BDNFmyc resulted in marked expressions of GFP and BDNFmyc
in the PVN as confirmed by fluorescent imaging and an antibody against the myc tag (Fig.
2B – C). Only animals with bilateral GFP or BDNF expression in the PVN were included
in the study, and analysis of the number of GFP or myc positive cells in the subnuclei of
the PVN indicated that DSAP treatment in the NTS had no effect on GFP or BDNFmyc
expression in the PVN (Fig. 2F – G). In addition, analysis of DβH-positive neurons in the
NTS indicated a significant DSAP-mediated reduction of catecholaminergic neurons in the
NTS in both the GFP and BDNF group, and vector treatment had no effect on the efficacy
of DSAP lesioning (Fig. 2H).
2.2.4. Analysis of Resting Radiotelemetric Cardiovascular Data
Blood pressure, heart rate, and physical activity of the animals were analyzed with
Dataquest A.R.T. Analysis software (Data Sciences International). Data were recorded
every 10 min for 15 seconds and averaged between 8:00 AM and 4:00 PM to calculate
daytime values and between 8:00 PM and 4:00 AM to calculate nighttime values for each
animal. Spontaneous baroreflex sensitivity was calculated with the sequence technique
with

the

freely

available

HemoLab

software

(http://www.haraldstauss.com/HaraldStaussScientific/hemolab/), as previously described
(Bhatia, Rarick, & Stauss, 2010). Blood pressure was recorded continuously at a sampling
rate of 500 Hz for a minimum of 2 hours between 8:00 AM and 10:00 PM before water
stress experiments (3 weeks after vector injections). Sampling rate of the data sets was first
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increased to 1,500 Hz with spline interpolation. Then, sequences defined as a minimum of
three consecutive (beat by beat) increases or decreases in systolic blood pressure
accompanied by likewise increases or decreases in the pulse interval, were identified.
Sequences with increases in systolic blood pressure (“up sequences”) and decreases in
systolic blood pressure (“down sequences”) were pooled. No time delay and no thresholds
for changes in systolic blood pressure or pulse interval were used. However, only
sequences with a correlation coefficient (R) for the linear correlation between systolic
blood pressure and pulse interval of >0.8 were included in the analysis, and the slope of
the linear correlation was taken as the gain of the baroreceptor-pulse interval reflex (Bhatia
et al., 2010; Laude, Baudrie, & Elghozi, 2008).
2.2.5. Acute Stress Procedures
Acute stress procedures were performed between 10:00 AM and 12:00 PM and
were started after obtaining baseline blood pressure and heart rate recordings for a
minimum of 30 min. For water stress, rats were placed in standard rat cages filled with 1
cm deep water (room temperature, ∼25°C) for 15 min. Restraint stress was performed by
placing animals in cylindrical plastic restrainers for 60 min. After animals were returned
to their home cages, blood pressure and heart rate were recorded for an additional 60-min
recovery period. Blood pressure and heart rate data were exported with 3-minute moving
average from continuously recorded blood pressure data, and baseline values were
calculated by averaging the baseline period after physical activity-related peaks from blood
pressure and heart rate datasets were removed. Average blood pressure and heart rate
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changes from baseline (during stress and recovery periods), as well as amplitude and time
delay of peak responses, were calculated.
2.2.6. Analysis of Cardiovascular Data from Anesthetized Animals
Blood pressure and heart rate were recorded using LabChart software version 8.0.7
(ADInstruments, Dunedin, New Zealand) at a 1000 Hz sampling rate and condensed to 10second moving averages for data analysis and presentation. Maximum and average changes
in MAP and heart rate following aCSF, isoprenaline and phenylephrine microinjections
were evaluated.
2.2.7. Immunofluorescence
Following experiment 1 and 2, animals were perfused with 400 mL of ice-cold PBS
followed by 400 mL of ice-cold 4% paraformaldehyde in PBS. Brains were removed and
post-fixed for 2 hours in 4% paraformaldehyde and then equilibrated in 30% sucrose
solution at 4°C. Coronal sections (40 µm) were cut on a microtome (Leica SM2000R) and
mounted on Fisher Superfrost Plus slides. BDNFmyc and DβH were detected using the
following primary antibodies: anti-c-Myc (Santa Cruz-9E10, 1:200, overnight incubation
at 4°C) and anti-DβH primary antibody (Millipore, Billerica, MA, USA, 1:1000, overnight
incubation at 4°C). Secondary antibodies were donkey anti-mouse AF546 (Invitrogen,
1:200, 2-h incubation at room temperature) and donkey anti-rabbit A555 (Invitrogen,
1:200,

2-h

incubation

at

room

temperature).

GFP,

BDNFmyc

and

DβH

immunofluorescence in the PVN and NTS were detected with a fluorescent microscope
(Nikon Eclipse 50i).
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Figure 2. A: Timeline
of experiment 1. B
and C: representative
fluorescent images of
coronal brain sections
~1.8 mm posterior
from bregma showing
PVN expression of
GFP and BDNFmyc,
respectively.
BDNFmyc expression
was detected with an
anti-myc tag antibody
and
immunofluorescence;
scale bars = 100 µm.
D and E:
representative
fluorescence images
showing DβH
expression in the NTS
in coronal brain
sections at the level of
the calamus
scriptorius following
PBS and DSAP
injections,
respectively; scale
bars, 100 µm. F and
G: number of GFPand myc-positive
cells was assessed in
subnuclei of the PVN;
dorsal parvocellular
nuclei (dp), medial parvocellular nuclei (mp), ventrolateral parvocellular nuclei (vlp), and
posterior magnocellular nuclei (pm) following AAV2-GFP or AAV2-BDNFmyc
injections in the PVN and PBS or DSAP injections in the NTS. DSAP had no significant
effect on vector mediated gene transduction in GFP or BDNF rats. GFP+PBS (n = 12),
GFP+DSAP (n = 14), BDNF+PBS (n = 12), BDNF+DSAP (n = 14); n refers to number
of PVN sides. H: number of DβH-positive neurons in the NTS following AAV2-GFP or
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AAV2-BDNFmyc injections in the PVN and PBS or DSAP injections in the NTS. DSAP
significantly reduced the number of DβH-positive neurons in both the GFP and BDNF
groups. 3V, third ventricle; PVN, paraventricular nucleus; NTS, nucleus of the solitary
tract; GFP, green fluorescent protein; PBS, phosphate-buffered saline; BDNF, brainderived neurotrophic factor; BDNFmyc, myc epitope-tagged BDNF; DβH, dopamine βhydroxylase; DSAP, anti-dopamine-β-hydroxylase-conjugated saporin; AAV2, adenoassociated viral vector 2. ***P < 0.001 for DSAP (1-way ANOVA).
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Figure 3. A: Representative fluorescent image
of a coronal brain section ~1.8 mm posterior to
bregma showing PVN expression of GFP and
the red fluorescent microbead solution that was
mixed with injected drug solution to verify
injection sites; scale bars, 250 µm. B and C:
diagrams of the PVN ~1.8 mm and ~1.9 mm
posterior to bregma showing locations of
isoprenaline injections in rats previously
injected with AAV2-GFP (gray circles) or
AAV2-BDNFmyc (filled circles), and
phenylephrine (open circles) and aCSF (open
triangles) injections in untreated rats. 3V, third
ventricle; lm, lateral magnocellular nuclei; dp,
dorsal parvocellular nuclei; mp, medial
parvocellular nuclei; vlp, ventrolateral
parvocellular nuclei; PVN, paraventricular
nucleus; GFP, green fluorescent protein; BDNF,
brain-derived neurotrophic factor; BDNFmyc,
myc epitope-tagged BDNF; AAV2, adenoassociated viral vector 2; aCSF, artificial
cerebrospinal fluid.
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2.2.8. Confocal Microscopy and Image Analysis
PVN brain sections from experiment 1 were used to determine the effect of BDNF
overexpression on volumetric density of DβH-positive vesicles located on axon terminals
in the PVN. Z-stack images of PVN brain slices labeled with immunofluorescence as
described above were taken using a Zeiss LSM 510 Meta confocal laser scanning imaging
system. The z-stacks were then deconvoluted using the deconvolution software AutoQuant
X3 (Media Cybernetics, Inc.). Volumetric density of DβH-positive vesicles within the PVN
was then calculated with the custom-written software Volumetry G7 (Grant Hennig; Dept.
of Pharmacology UVM). DβH immunoreactivity is limited to vesicles in the PVN, which
appear as distinct points in the image. To precisely capture those points in the PVN, each
image was thresholded such that all vesicles were captured, and any background
fluorescence was removed. DβH percent density was quantified in each slice of the z-stack
of each side of the PVN. Then, the z-stack slice with the highest percent density was
selected on each side of the PVN in each group and the mean percent density calculated
for each experimental group.
2.2.9. Real-Time RT-PCR
Frozen forebrains and hindbrains were mounted on a cryostat, and rostral coronal
sections were cut until reaching the level ~1.5 mm posterior of the bregma for the PVN
and ~14.1 mm posterior of the bregma for the NTS. Then, tissue samples 0.75 mm in
diameter and 0.5 mm deep were punched bilaterally from the region of the PVN or NTS
under microscope with the third ventricle used as reference for the PVN and the midline
and dorsal brainstem surface for the NTS. The depth of the punches was limited by a spacer
68

glued on the outside of the punch tool. Total RNA was extracted from brain punches with
Qiashredder columns (Qiagen, Valencia, CA) and the RNeasy Micro Kit (Qiagen).
Samples were treated with an RNase-free DNase Set (Qiagen) on column to remove
genomic DNA. RNA was quantified with a Qubit Fluorometer, and cDNA was synthesized
with a high-capacity cDNA reverse transcription kit (Applied Biosystems) according to
manufacturer’s instructions and stored at −20°C. All quantitative RT-PCR reactions were
run in duplicate in eight-well optical-grade strips in a Prism 7000 Sequence Detection
System (Applied Biosystems) and quantified with the cycle threshold (CT) method. The
mRNA levels of BDNF and CRH, which is known to be elevated by BDNF (Jeanneteau et
al., 2012), adrenergic receptors and the reference genes beta actin (ActB) and 18S were
analyzed with quantitative real-time RT-PCR using specific oligonucleotide primers and
TaqMan probes (Applied Biosystems, Foster City, CA; BDNF: Rn02531967_s1; CRH:
Rn01462137_m1;

ActB:

Rn00667869_m1;

α1a:

RN00567876_m1;

α1b:

RN01471343_m1; α2a: RN00562488_s1; β1: RN008244536_s1 and β2: RN00560650_s1;
18S: Hs03003631_g1; DβH: Rn00565819_m1; TH: Rn00562500_m1). Control reactions
containing no template were run for each plate, and results were analyzed with the 2−ΔΔCT
method.
2.2.10. Statistics
Baseline (day/night) telemetry data was analyzed using two-way repeated measures
ANOVA with Tukey's post-hoc test. Peak and average changes in MAP and heart rate
during acute stress and microinjection experiments, as well as mean DβH percent
volumetric density were analyzed by one-way ANOVA with Bonferroni’s multiple
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comparisons test. RT-PCR data was analyzed by unpaired t-test. Statistical tests were
performed using Prism 7.0 software (GraphPad, San Diego, CA). Results are expressed as
means ± SE, and the criterion for statistical significance was P < 0.05.
2.3. Results
2.3.1. Effects of BDNF and DSAP Treatments
Results from our first experiment confirmed our previous findings (Erdos, Backes,
et al., 2015) and showed that BDNF overexpression in the PVN without DSAP lesioning
in the NTS significantly increased MAP and heart rate during both day- and nighttime
compared with the GFP group (Fig. 4 and Table 1). In addition, we found that in GFP
animals, DSAP lesioning of NTS catecholaminergic neurons significantly increased MAP
both during day- and nighttime, whereas DSAP lesioning in BDNF animals had no further
effect on blood pressure (Fig. 4 and Table 1). Heart rate was significantly elevated by
DSAP treatment in the GFP group during week 3 and 4 both day- and nighttime, and while
it tended to increase heart rate in the BDNF animals, the difference between BDNF+PBS
and BDNF+DSAP groups was not statistically significant (Fig. 4 and Table 1).
Furthermore, BDNF overexpression reduced spontaneous baroreflex sensitivity in rats
receiving PBS injections into the NTS (p<0.05), and DSAP reduced baroreflex sensitivity
in GFP rats (p<0.05). However, DSAP failed to have an effect in the BDNF group (p=0.99,
Table 1).
In addition to its effects on cardiovascular function, BDNF overexpression also
significantly reduced body weight gain in agreement with our previous study (Erdos,
Backes, et al., 2015). At baseline, the body weight of the GFP+PBS group was 428±18 g,
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and the BDNF+PBS group was 414±11 g. At the end of the experiment the GFP+PBS
group was 554±26 g and the BDNF+PBS group was 445±17 g (p<0.05). In contrast, DSAP
lesioning of NTS catecholaminergic neurons had no effect on body weight gain in either
GFP or BDNF rats. At baseline, the body weight of the GFP+DSAP group was 420±12 g,
and final body weight was 566±12 g, compared to the BDNF+DSAP group whose body
weight at baseline was 411±10 g, and final body weight was 448±15 g. BDNF
overexpression was also found to increase daytime locomotor activity compared to the GFP
group (p<0.01), at the end of week 3 (Table 1).
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Figure 4. Radiotelemetric
recordings of daytime mean
arterial pressure (MAP) and
heart rate [HR, in beats/min
(bpm)]. Radiotelemetric
parameters were recorded
for 6 days before brain
injections and during weeks
2–4 after brain injections.
Recording was turned off
during the postsurgical
recovery phase (between
days 6 and 14), and data
from day 28 are omitted
because animals were
subjected to water stress on
that day. Since viral vector
and DSAP treatments had
similar effects on daytime
and nighttime parameters,
only daytime parameters are
shown (nighttime data are
summarized in Table 1). A:
daytime MAP (top) and HR
(bottom) in GFP+PBS (n = 6), GFP+DSAP (n = 7), BDNF+PBS (n = 6), and
BDNF+DSAP (n = 7) rats. B: average changes in daytime MAP (top) and HR (bottom)
during weeks 2, 3, and 4 from pretreatment baseline period. PVN, paraventricular
nucleus; NTS, nucleus of the solitary tract; GFP, green fluorescent protein; PBS,
phosphate-buffered saline; BDNF, brain-derived neurotrophic factor; DSAP, antidopamine-β-hydroxylase-conjugated saporin. Results represent means ± SE. Two-way
repeated-measures ANOVA on weekly averages indicated significant treatment effect for
MAP and HR (P < 0.001), significant time effect for HR (P < 0.05), and significant
treatment × time interaction for both MAP and HR (P < 0.01). Post hoc analysis indicated
*P < 0.05 for GFP+PBS vs. BDNF+PBS, **P < 0.01 for GFP+DSAP vs. BDNF+DSAP,
***P < 0.001 for GFP+PBS vs. BDNF+PBS, ****P < 0.0001 for GFP+PBS vs.
BDNF+PBS; #P < 0.05 for GFP+PBS vs. GFP+DSAP, ##P < 0.01 for GFP+PBS vs.
GFP+DSAP.
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Table 1. Radiotelemetric parameters. Values are
means ± SE. HR, heart rate; DIA, diastolic pressure;
SYS, systolic pressure; ACT, activity; sBRS,
spontaneous baroreflex sensitivity; AU, arbitrary
units; BDNF, brain-derived neurotrophic factor;
DSAP, anti-dopamine-β-hydroxylase-conjugated
saporin; GFP, green fluorescent protein; PBS,
phosphate-buffered saline; D, daytime; N, nighttime;
week 0 values represent average of parameters
measured during the week preceding vector injections;
week 3 values represent average of parameters
measured during week 3 after vector injections.
GFP+PBS, n = 6; GFP+DSAP, n = 7; BDNF+PBS, n
= 6; BDNF+DSAP, n = 7. †P < 0.05 GFP+PBS vs.
GFP+DSAP; *P < 0.05 GFP+PBS vs. BDNF+PBS;
**P < 0.01 GFP+PBS vs. BDNF+PBS; ***P < 0.001
GFP+PBS vs. BDNF+PBS (2-way repeated-measures
ANOVA for MAP and HR, and 1-way ANOVA for
sBRS).
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Relative volumetric density of DβH-positive vesicles was quantified in PVN brain
sections as an indicator of catecholaminergic projections to the PVN. DSAP treatment in
GFP rats tended to reduce DβH-positive vesicle density in the PVN compared to the
GFP+PBS group (p=0.06), and significantly reduced DβH-positive vesicle density
compared to the BDNF+DSAP group (p<0.05). No significant difference was seen in the
BDNF+DSAP group compared to the BDNF+PBS group. Additionally, BDNF alone did
not significantly alter DβH-positive vesicle density in the PVN compared to the GFP+PBS
group (Fig. 5).
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Figure 5. DβH-positive vesicles
in the PVN of rats previously
injected with AAV2-GFP or
AAV2-BDNFmyc in the PVN
and with PBS or DSAP in the
NTS. Top: representative
confocal images of DβH
expression within the PVN in all
experimental groups as detected
with an anti-DβH antibody and
immunofluorescence; scale bars,
100 µm. Bottom: maximum
percent volumetric density of
DβH-positive vesicles within the
PVN, averaged for each
experimental group; n refers to
number of PVN sides
[GFP+PBS (n = 6), GFP+DSAP
(n = 12), BDNF+PBS (n = 8),
BDNF+DSAP (n = 8)]. 3V, third
ventricle; PVN, paraventricular
nucleus; NTS, nucleus of the
solitary tract; GFP, green
fluorescent protein; PBS,
phosphate-buffered saline;
BDNF, brain-derived
neurotrophic factor; DBH,
dopamine β-hydroxylase;
DSAP, anti-dopamine-βhydroxylase-conjugated saporin;
AAV2, adeno-associated viral
vector 2. Results represent
means ± SE. P = 0.06 for
GFP+PBS vs. GFP+DSAP; &P
< 0.05 for GFP+DSAP vs.
BDNF+DSAP (1-way ANOVA)
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2.3.2. Acute Water and Restraint Stress
Water stress-induced peak pressor responses and average MAP increase during
stress were significantly reduced in the BDNF+PBS group compared to the GFP+PBS
group (p<0.01), while amplitude of heart rate increases to water stress were unaffected by
BDNF overexpression. DSAP treatment did not significantly alter the amplitude of pressor
and tachycardic responses in either GFP or BDNF rats, and timing of peak MAP and heart
rate responses were also similar in all four experimental groups (Fig. 6).
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Figure 6. Radiotelemetric recordings of
mean arterial pressure (MAP) and heart
rate (HR) during acute water stress and
poststress recovery in GFP+PBS (n =
6), GFP+DSAP (n = 7), BDNF+PBS (n
= 6) and BDNF+DSAP (n = 7) rats. A:
MAP (top) and HR (bottom) traces with
3-min moving average during stress (15
min, indicated by arrow) and during
poststress recovery (60 min). B:
amplitude and delay of peak MAP and
HR responses. C: MAP and HR
increases averaged during stress and
poststress recovery. Prestress MAP and
HR were 94 ± 3 mmHg and 308 ± 11
beats/min (bpm) in the GFP+PBS
group, 101 ± 4 mmHg and 327 ± 9
beats/min in the GFP+DSAP group,
121 ± 4 mmHg and 366 ± 19 beats/min
in the BDNF+PBS group, and 113 ± 5
mmHg and 378 ± 11 beats/min in the
BDNF+DSAP group. GFP, green
fluorescent protein; PBS, phosphatebuffered saline; BDNF, brain-derived
neurotrophic factor; DSAP, antidopamine-β-hydroxylase-conjugated
saporin. Results represent means ± SE.
**P < 0.01 for GFP+PBS vs.
BDNF+PBS (1-way ANOVA).
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Restraint stress-induced peak pressor responses were significantly reduced in the
BDNF+PBS group compared to the GFP+PBS group (p<0.05), while amplitude of heart
rate increases to restraint stress were unaffected by BDNF overexpression. In contrast,
DSAP treatment significantly reduced maximum heart rate increase in the GFP group
(p<0.01), but not in the BDNF group. DSAP treatment did not alter the amplitude of pressor
responses in either GFP or BDNF rats, and timing of peak MAP and heart rate responses
was also similar in all four experimental groups (Fig. 7).
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Figure 7. Radiotelemetric
recordings of mean arterial
pressure (MAP) and heart rate
(HR) during acute restraint
stress and poststress recovery in
GFP+PBS (n = 6), GFP+DSAP
(n = 7), BDNF+PBS (n = 6),
and BDNF+DSAP (n = 7) rats.
A: MAP (top) and HR (bottom)
traces with 3-min moving
average during stress (60 min,
indicated by arrow) and during
poststress recovery (60 min). B:
amplitude and delay of peak
MAP and HR responses. C:
MAP and HR increases
averaged during stress and
poststress recovery. Prestress
MAP and HR were 92 ± 3
mmHg and 311 ± 11 beats/min
(bpm) in the GFP+PBS group,
101 ± 4 mmHg and 351 ± 14
beats/min in the GFP+DSAP
group, 120 ± 2 mmHg and
372 ± 18 beats/min in the
BDNF+PBS group, and 114 ± 3
mmHg and 380 ± 13 beats/min
in the BDNF+DSAP group.
GFP, green fluorescent protein;
PBS, phosphate-buffered saline;
BDNF, brain-derived
neurotrophic factor; DSAP, antidopamine-β-hydroxylaseconjugated saporin. Results are
represented as means ± SE. *P <
0.05, for GFP+PBS vs.
BDNF+PBS, ##P < 0.01,
GFP+PBS vs. GFP+DSAP (1way ANOVA).
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2.3.3. Effect of BDNF on Adrenergic Receptor Signaling in the PVN
In our second experiment, we tested whether BDNF affects PVN adrenergic
receptor mediated cardiovascular responses. We found that stimulation of β-adrenergic
receptors with isoprenaline dose-dependently lowered MAP in GFP rats and that BDNF
overexpression in the PVN almost completely abolished these hypotensive responses to βadrenergic receptor stimulation (p<0.05, Fig. 8). Heart rate tended to decline in the GFP
group in response to isoprenaline, but its effects were not statistically significant in any of
the experimental groups (GFP+ISO high dose vs aCSF, p=0.24; GFP+ISO low dose vs
aCSF, p=0.32). In contrast with isoprenaline, activation of adrenergic α-receptors in the
PVN by phenylephrine injections did not significantly alter either MAP (p=0.99) or heart
rate (p=0.99) and injection of aCSF had no effect on cardiovascular parameters either (Fig.
8).
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Figure 8. Changes in mean arterial pressure (MAP; top) and heart rate (HR; bottom) in
response to PVN injections of adrenergic receptor agonists and vehicle in anesthetized
rats previously treated with AAV2-GFP (n = 6) or AAV2-BDNFmyc (n = 7). A: MAP
and HR obtained with 10-s moving average over 120 s following isoprenaline (ISO)
injection in GFP and BDNFmyc treated rats, and phenylephrine (PE; n = 3) or aCSF,
artificial cerebrospinal fluid (aCSF; n = 3) injections in untreated rats. B: average peak
MAP and HR responses to ISO, PE, and aCSF injections. Baseline MAP and HR were
89 ± 6 mmHg and 351 ± 15 beats/min (bpm) in GFP and 108 ± 4 mmHg and 398 ± 15
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beats/min in BDNF rats, and 105 ± 3 mmHg and 353 ± 7 beats/min in untreated rats.
PVN, paraventricular nucleus; GFP, green fluorescent protein; BDNF, brain-derived
neurotrophic factor; BDNFmyc, myc epitope-tagged BDNF; AAV2, adeno-associated
viral vector 2. Results represent means ± SE. Statistical analysis was done on peak
changes in MAP and HR. #P < 0.05 for 250 µM ISO vs. aCSF, *P < 0.05, for GFP vs.
BDNF (1-way ANOVA)
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2.3.4. Expression of Components of Catecholaminergic Signaling
In our third experiment we tested the effect of BDNF upregulation in the PVN on
expressions of catecholamine biosynthesizing enzymes in the NTS and adrenergic
receptors in the PVN. To verify vector mediated BDNF transduction and activation of
BDNF signaling pathways in the PVN, BDNF and CRH mRNA expressions were
determined, and both were found to be significantly elevated in BDNF rats compared with
GFP rats (p<0.01, Fig. 9A). Analysis of adrenergic receptor expression showed that β1
adrenergic receptor mRNA was significantly downregulated in the PVN of BDNF rats
compared with GFP (p<0.01), whereas expressions of α1a, α1b, α2a and β2 adrenergic
receptors were unaffected by BDNF (Fig. 9B). Additionally, BDNF overexpression in the
PVN also significantly upregulated TH (p<0.01) and DβH (p<0.01) mRNA expression in
the NTS (Fig. 9C).
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Figure 9. Expression of BDNF, CRH,
and adrenergic receptor mRNA in the
PVN, and TH and DβH mRNA in the
NTS of rats previously injected with
AAV2-GFP (n = 6) or AAV2BDNFmyc (n = 6) in the PVN. A:
significant increases in BDNF and CRH
mRNA expressions verify successful
vector mediated BDNF transduction
and activation of BDNF-mediated
signaling mechanisms. B: expressions
of α1a-, α1b-, and α2a- and β1- and β2adrenergic receptor mRNAs in GFP and
BDNF rats. C: expressions of TH and
DβH mRNAs in the NTS of AAV2GFP (n = 7) and AAV2-BDNFmyc (n =
7) rats. PVN, paraventricular nucleus;
NTS, nucleus of the solitary tract; GFP,
green fluorescent protein; BDNF, brainderived neurotrophic factor;
BDNFmyc, myc epitope-tagged BDNF;
TH, tyrosine hydroxylase; DBH,
dopamine β-hydroxylase; AAV2,
adeno-associated viral vector 2; CRH,
corticotropin-releasing hormone.
Results are expressed as 2−ΔΔCT
(where CT is threshold cycle)
normalized to the control group and
presented as means ± SE. **P < 0.01
GFP vs. BDNF (unpaired t test).
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2.4. Discussion
Mounting evidence suggest that BDNF, acting in the PVN, is a key regulator of
blood pressure and plays a major role in eliciting cardiovascular responses to stress and
other hypertensive stimuli (Aliaga et al., 2002; Erdos, Backes, et al., 2015; Hammack et
al., 2009; Rage et al., 2002; C. L. Schaich et al., 2018; Chris L. Schaich et al., 2016; Smith,
Makino, Kim, et al., 1995). Results from this study further emphasize the hypertensive
actions of BDNF within the PVN and demonstrate that a potential mechanism mediating
these effects is a downregulation of inhibitory/hypotensive input from NTS
catecholaminergic neurons via adrenergic β-receptor signaling. This is supported by our
findings that selective lesioning of NTS catecholaminergic neurons increased blood
pressure in control (AAV2-GFP-treated) animals but failed to exert a hypertensive effect
in animals that were subject to BDNF overexpression in the PVN. Additionally, activating
β-adrenergic receptors in the PVN markedly decreased blood pressure in control, AAV2GFP treated rats, whereas β-adrenergic receptor stimulation had a significantly reduced
hypotensive effect after BDNF overexpression in the PVN. Diminished β-adrenergic
receptor signaling was at least partially due to a downregulation of adrenergic β1 receptor
mRNA expression in the PVN, whereas expression of other adrenergic receptors was
unaffected by BDNF. Interestingly, we observed a BDNF-induced upregulation of
catecholamine biosynthetic enzymes in the NTS and recruitment of catecholaminergic
projections to the PVN in DSAP-treated animals, but it seems these compensatory
mechanisms were unable to overcome reduced responsiveness of the PVN to these inputs.
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BDNF, a member of the neurotrophin family, is a widely recognized regulator of
neuronal function throughout the CNS (E. J. Huang & Reichardt, 2001; Matsuda et al.,
2009; H. Park & Poo, 2013), and previous reports have indicated that BDNF is involved in
blood pressure control in several cardiovascular regulatory nuclei. Our previous studies
have shown that both acute injection and chronic overexpression of BDNF in the PVN
elevates blood pressure, heart rate and sympathetic activity (Erdos, Backes, et al., 2015;
Chris L. Schaich et al., 2016), and BDNF expression has been found to be significantly
elevated in the PVN in response to several hypertensive stimuli such as acute and chronic
stress (Givalois et al., 2004; Hammack et al., 2009; Rage et al., 2002; Smith, Makino, Kim,
et al., 1995), hyperosmolality (Aliaga et al., 2002) and repeated amphetamine
administration (Meredith et al., 2002). In addition, BDNF is an important modulator of
stress-related neuroendocrine mechanisms such as CRH synthesis and activation of the
HPA axis (Givalois et al., 2004; Jeanneteau et al., 2012). BDNF signaling within the
supraoptic nucleus has also been shown to reduce GABAA-mediated inhibition of AVP
neurons and increase blood pressure in response to high salt-intake in rats (Choe et al.,
2015). In addition, BDNF microinjections into the RVLM and the medial NTS have also
been found to elevate blood pressure (Clark, Hasser, Kunze, Katz, & Kline, 2011; H. Wang
& Zhou, 2002), and BDNF modulates baroreflex sensitivity in the NTS (Becker, Tian,
Zucker, & Wang, 2016). Thus, BDNF seems to be a key regulator of many different aspects
of cardiovascular regulation both within the hypothalamus and brainstem. However, the
downstream mechanisms mediating these cardiovascular actions of BDNF are not fully
understood.
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In this study, we investigated the potential modulatory role of BDNF on NTS –
PVN catecholaminergic projections since these neurons play a significant role in blood
pressure regulation (Daubert et al., 2012; Duale et al., 2007; Itoh & Bunag, 1993) and
because BDNF is known to influence catecholaminergic signaling throughout the CNS (M.
J. Chen et al., 2007; Rodriguez Fermepin et al., 2009; Scott et al., 2015). NTS A2 and C2
neurons provide the primary catecholaminergic input to the PVN (Cunningham &
Sawchenko, 1988; Sawchenko & Swanson, 1982b). However, the role of these NTS – PVN
projections in cardiovascular regulation is not clear. For example, selective lesioning of
NTS catecholaminergic neurons in rats led to an increase in blood pressure in some cases
(Daubert et al., 2012; Duale et al., 2007; Itoh & Bunag, 1993) indicating that these neurons
exert an inhibitory / hypotensive role, but other studies indicated no effect on baseline
blood pressure (Itoh et al., 1992; Itoh & Bunag, 1992; Talman et al., 1980). Stimulation of
adrenergic receptors in the PVN has also led to conflicting results. For example, PVN
microinjections of the β-adrenergic receptor agonist fenoterol were shown to reduce blood
pressure in WKY rats and SHRs but had no effect in Wistar rats (Tsushima et al., 1994).
However, other studies found that microinjections of the β-adrenergic receptor agonist
isoprenaline in Wistar and SD rats had no effect on blood pressure (Mendonça et al., 2018;
D. Wang et al., 2013), but did increase baroreflex sensitivity in SD rats (D. Wang et al.,
2013). On the other hand, PVN injections of the α1-adrenergic agonist phenylephrine or
the non-selective α-adrenergic receptor antagonist phentolamine significantly increased
renal sympathetic nerve activity and heart rate without an effect on blood pressure (Q. Chen
et al., 2006; Mendonça et al., 2018). Our experiments demonstrated that in control GFP
animals, selective catecholaminergic lesioning in the NTS induced a marked increase in
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blood pressure, whereas stimulation of β-adrenergic receptors in the PVN resulted in
significant hypotensive responses. These findings support the idea that under baseline
conditions in normotensive animals, these catecholaminergic neurons exert an inhibitory
role on hypertensive mechanisms and these actions are mediated at least in part by βreceptor signaling in the PVN. However, in contrast with control GFP rats, DSAP lesioning
in the NTS of BDNF rats did not significantly affect blood pressure. This finding is
especially surprising since catecholamine biosynthesizing enzymes, TH and DβH, were
markedly upregulated in the NTS of BDNF rats indicating an elevated activity of these
catecholaminergic neurons. We propose that a plausible explanation for these results is that
elevated BDNF levels in the PVN diminished sensitivity of PVN neurons to β-adrenergic
receptor-mediated hypotensive input from the NTS. Thus, despite a compensatory increase
in catecholamine biosynthesis in NTS neurons, DSAP lesioning had no further effect on
the already elevated baseline blood pressure. This hypothesis is also supported by our
findings that hypotensive responses to PVN injections of isoprenaline were significantly
diminished in BDNF rats compared to GFP controls.
Reduced β-adrenergic signaling following overexpression of BDNF in the PVN can
be partially explained by downregulation of adrenergic β1 receptor mRNA expression in
the PVN as indicated by our results, but other mechanisms may also be involved. For
example, BDNF increases the expression and release of AVP in the hypothalamus (Aliaga
et al., 2002; Choe et al., 2015; Veltmar et al., 1992), and AVP can stimulate the recruitment
of β-arrestins, which can inhibit adrenergic β-receptor signaling and enhance endocytosis
of β-receptors (U. Klein, Muller, Chu, Birnbaumer, & von Zastrow, 2001; Oakley, Laporte,
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Holt, Barak, & Caron, 1999). Another potential mechanism of BDNF-mediated
downregulation of β-receptor signaling may involve inhibition of G-protein-coupled
inwardly rectifying potassium (GIRK) channels. GIRK1-4 have been shown to be
expressed in the PVN (Karschin, Dissmann, Stuhmer, & Karschin, 1996; Saenz del Burgo
et al., 2008), and a subset of PVN parvocellular neurons respond to β-adrenergic activation
by GIRK channel-mediated hyperpolarization and inhibition (Daftary et al., 2000). BDNF,
on the other hand, has been shown to strongly inhibit the activity of GIRK1 and GIRK4
via activation of TrkB receptors (Rogalski, Appleyard, Pattillo, Terman, & Chavkin, 2000),
thus, BDNF may oppose β-adrenergic inhibition of PVN neurons by blocking β-receptormediated stimulation of GIRK channels. However, future studies are needed to address
specifically how elevated BDNF expression alters β-receptor signaling in the PVN.
In addition to diminishing β-adrenergic signaling in the PVN, BDNF
overexpression also increased the expression of catecholamine biosynthetic enzymes in the
NTS and prevented DSAP-induced reductions in the density of DβH-positive vesicles in
the PVN. The upregulation of TH and DβH in the NTS of BDNF animals may be an indirect
response caused by increased blood pressure and baroreflex-mediated activation of NTS
neurons, but it could also be caused by retrograde actions of BDNF on NTS – PVN neurons.
Retrograde actions of BDNF are well documented in the CNS (Sasi, Vignoli, Canossa, &
Blum, 2017; Sobreviela, Pagcatipunan, Kroin, & Mufson, 1996), and BDNF is known to
localize to noradrenergic nerve fibers and terminals (Fawcett et al., 1998), regulate the
development of noradrenergic neurons (Holm et al., 2003) and stimulate TH gene
expression (Fukuchi et al., 2010; Zhou, Bradford, & Stern, 1994). Thus, BDNF released
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from PVN neurons could retrogradely enhance catecholamine biosynthesis in NTS
neurons. Retrograde BDNF-mediated signaling may also be responsible for recruiting
catecholaminergic projections from other nuclei after lesioning NTS A2 / C2 neurons with
DSAP. Such a mechanism could explain why DβH vesicle density in the PVN remained
unaffected by DSAP lesioning of the NTS in BDNF rats but decreased in the GFP group
despite similar reductions in NTS DβH-positive neuron number in both groups. However,
the current study only demonstrated an increase in TH and DβH mRNA in the NTS and
DβH percent volumetric vesicle density in the PVN, but changes in NTS neuronal activity
or NTS TH, DβH protein expression were not measured. Future studies will be needed to
determine the existence and function of these compensatory mechanisms.
BDNF and catecholaminergic signaling both contribute to neuroendocrine stress
responses and baroreflex regulation (Becker et al., 2016; Givalois et al., 2004; Jeanneteau
et al., 2012; D. Wang et al., 2013). Here, in correlation with our previous study (Erdos,
Backes, et al., 2015), we found that BDNF overexpression in the PVN reduced MAP
increases to both acute water and restraint stress without an effect on heart rate responses.
We have also shown previously that selective inhibition of TrkB signaling in the PVN
reduces MAP elevations to acute stressors (C. L. Schaich et al., 2018). These findings
combined clearly demonstrate that upregulation of BDNF expression in the PVN (Erdos,
Backes, et al., 2015; C. L. Schaich et al., 2018; Chris L. Schaich et al., 2016) and
subsequent activation of TrkB signaling cascades are required for eliciting blood pressure
elevations to stress. Thus, both inhibition of TrkB receptors (C. L. Schaich et al., 2018) and
masking the stress-induced BDNF upregulation in the PVN by vector-mediated
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constitutive BDNF overexpression diminish stress-induced hypertensive responses.
However, while TrkB inhibition fails to affect baseline blood pressure (C. L. Schaich et
al., 2018), vector-mediated BDNF overexpression increases it. One important mechanism
mediating these actions of BDNF could be its ability to interact with angiotensin II
signaling. Angiotensin II is known to play a role in mediating cardiovascular stress
responses (Busnardo et al., 2014), and overexpression of BDNF in the PVN has been
shown to upregulate the expression of AT1R (Erdos, Backes, et al., 2015). In addition,
BDNF-mediated blood pressure increases can be partially attenuated by AT1R antagonists
or by an angiotensin converting enzyme inhibitor (Erdos, Backes, et al., 2015; Chris L.
Schaich et al., 2016). On the other hand, angiotensin II can also upregulate BDNF and
TrkB receptor expression in cultured catecholaminergic cells leading to a reduction in
voltage-gated potassium currents and increases in neuronal excitability (Becker et al.,
2015). Similarly, in chronic heart failure, elevated angiotensin II contributes to increased
sympathoexcitation (I. H. Zucker, Schultz, Patel, Wang, & Gao, 2009) and can increase
neuronal excitability in part by reducing voltage-gated potassium currents via BDNF
signaling (Sumners & Gelband, 1998; Sumners, Zhu, Gelband, & Posner, 1996; Irving H.
Zucker, Xiao, & Haack, 2014).
NTS catecholaminergic neurons are also involved in the regulation of acute and
chronic stress responses. They can be activated in response to physiological and
psychological stressors (Dayas, Buller, Crane, Xu, & Day, 2001; Pacak, Palkovits, Kopin,
et al., 1995), and may play a role in altering cardiovascular responses to stress via
projections to the PVN or other forebrain regions (Cunningham & Sawchenko, 1988;
91

Riche, De Pommery, & Menetrey, 1990). In the current study, DSAP lesioning of the NTS
in the GFP group was found to reduce heart rate responses to restraint stress but not to
water stress and failed to affect blood pressure responses to either stressor. Furthermore,
DSAP treatment had no effect on heart rate and blood pressure in the BDNF group during
either stress paradigm. Thus, our results suggest a limited role of catecholaminergic NTS
neurons in the regulation of acute cardiovascular stress responses regardless of the level of
BDNF expression in the PVN.
The PVN is known to modulate baroreflex-regulated sympathetic outflow (Patel &
Schmid, 1988; Z. Yang & Coote, 1999), and neurons in the PVN have been shown to be
activated by baroreflex challenges (Q. H. Chen & Toney, 2003; Polson, Mrljak, Potts, &
Dampney, 2002). However, while BDNF has been shown to have a significant impact on
baroreflex sensitivity in the NTS (Becker et al., 2016; Clark et al., 2011), its actions on the
baroreflex within the PVN have never been examined. Interestingly, our studies
demonstrated that both inhibition of TrkB signaling (C. L. Schaich et al., 2018) and
upregulation of BDNF expression in the PVN (Table 1) reduced spontaneous baroreflex
sensitivity. Further studies are needed to determine the underlying mechanisms, but trophic
retrograde actions of BDNF on PVN-projecting NTS neurons could potentially be
involved. Additionally, β-receptor signaling has been shown to modulate baroreflex
sensitivity in the PVN (D. Wang et al., 2013); thus, BDNF may also alter baroreflex
sensitivity by diminishing β-receptor signaling in PVN neurons.
Within the NTS, both catecholaminergic neurons and BDNF have been implicated
in the regulation of baroreflex sensitivity. Baroreflex sensitivity was diminished both by
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lesioning NTS catecholaminergic neurons (Itoh et al., 1992; Talman et al., 1980) and by
antagonizing TrkB receptors in the NTS (Becker et al., 2016). Further, microinjections of
function-blocking BDNF antibodies in the NTS have led to depressor responses and
sympathoinhibition (Clark et al., 2011). Similarly, in this study, DSAP lesioning in the
NTS was found to significantly reduce spontaneous baroreflex sensitivity in the GFP group
but the same treatment had no further effect on the already reduced baroreceptor reflex
response seen in the BDNF group. Therefore, the effect of DSAP lesioning on baroreflex
sensitivity was similar to its effects on MAP with significant differences in the GFP, but
not in the BDNF group.
2.5. Conclusion
In summary, our studies demonstrate that disruption of catecholaminergic signaling
between the NTS and PVN contributes to the hypertensive effects of BDNF in the PVN.
Lesioning NTS catecholaminergic neurons was found to increase blood pressure in GFP
control rats but did not further elevate blood pressure following BDNF overexpression in
the PVN. In addition, activating β-adrenergic receptors in the PVN significantly decreased
blood pressure in the GFP control group but did not lower blood pressure in the BDNF
group, and BDNF overexpression in the PVN also significantly reduced mRNA levels of
adrenergic β1 receptors in the PVN. These BDNF-mediated mechanisms may significantly
contribute to stress-induced elevations in blood pressure and the development of stressrelated cardiovascular diseases.
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CHAPTER 3: BDNF Augments NMDA-signaling and Reduces GABAA-signaling in
the Paraventricular Nucleus of the Hypothalamus (PVN) to Elevate Blood Pressure
3.1. Introduction
The paraventricular nucleus (PVN) of the hypothalamus is an important area
involved in the regulation of autonomic, neuroendocrine, and cardiovascular responses
(Martins-Pinge, Mueller, Foley, Heesch, & Hasser, 2013; Swanson & Sawchenko, 1983).
The PVN plays a specific role in cardiovascular regulation via presympathetic neurons
projecting to the rostral ventrolateral medulla (RVLM) or directly to spinal sympathetic
preganglionic neurons in the intermediolateral (IML) cell column of the spinal cord
(Badoer, 2001; R. A. Dampney, 1994; Hardy, 2001; Pyner & Coote, 2000). Increased
activity of PVN presympathetic neurons contributes to elevated sympathetic activity and
blood pressure in hypertension (R. A. Dampney et al., 2018; Guyenet, 2006; Ye, Li, &
Pan, 2013), which can increase the risk of developing other cardiovascular, renal, and
cerebrovascular disorders. (Floras, 2009; Judy et al., 1976). Glutamate and γaminobutyric acid (GABA) are the main excitatory and inhibitory neurotransmitters
within the PVN and have been shown to alter the firing activity of PVN neurons (D. P. Li
et al., 2008a, 2008b). Increases in excitatory and decreases in inhibitory mechanisms
within the PVN are thought to contribute in part to enhanced sympathetic output in
hypertension (Boudaba et al., 1997; Q. H. Chen et al., 2003; Y. F. Li et al., 2006).
Glutamate or NMDA PVN microinjections have been found to increase blood
pressure, and sympathetic nerve activity in both anesthetized and conscious normotensive
rats (Busnardo et al., 2010; Kannan et al., 1989; Y. F. Li et al., 2006; Y. F. Li, Mayhan,
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& Patel, 2001). Meanwhile, NMDA receptor antagonist, AP5, PVN microinjections have
been shown to have a larger inhibitory effect on cardiovascular parameters in the
spontaneously hypertensive rat (SHR) compared to the normotensive Wistar Kyoto
(WKY) rats (D.-P. Li & H.-L. Pan, 2007; Y. F. Li et al., 2006). The PVN is also known
to be under immense tonic GABAA receptor-mediated inhibition under normotensive
conditions (Decavel & Van den Pol, 1990; Tasker & Dudek, 1993), which is reduced
during elevated sympathetic activity in hypertension and heart failure (D. P. Li & Pan,
2006; D. S. Martin & Haywood, 1998; K. Zhang et al., 2002). GABAA receptor agonists
isoguvacine or muscimol PVN microinjections have been found to reduce blood pressure
more significantly in WKY and Sprague Dawley (SD) rats compared to SHRs (Ding et
al., 2015; D. P. Li & H. L. Pan, 2007). Meanwhile GABAA antagonist, gabazine or
bicuculline, PVN microinjections have been found to increase sympathetic activity and
blood pressure more significantly in WKY and Sprague Dawley (SD) rats compared to
SHRs (Ding et al., 2015; D. P. Li & Pan, 2006; D. P. Li & H. L. Pan, 2007; Y. F. Li et
al., 2006).
We have recently identified a key modulator of blood pressure, brain derived
neurotrophic factor (BDNF), which has been shown to be elevated in the PVN in
response to various hypertensive stimuli, such as chronic and acute stress,
hyperosmolality, and repeated amphetamine administration (Aliaga et al., 2002;
Hammack et al., 2009; Meredith et al., 2002; Rage et al., 2002; Smith, Makino, Kim, et
al., 1995). We have also shown that long-term overexpression and acute microinjection
of exogenous BDNF into the PVN leads to significant increases in blood pressure and
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heart rate (Erdos, Backes, et al., 2015; Chris L. Schaich et al., 2016), and we have
recently shown that BDNF can modulate catecholaminergic signaling in the PVN to
elevate blood pressure (Thorsdottir, Cruickshank, Einwag, Hennig, & Erdos, 2019).
BDNF is also a known modulator of glutamatergic and GABAergic signaling
mechanisms in the central nervous system (CNS). BDNF can enhance NMDA-mediated
signaling by activating the expression and membrane trafficking of NMDA receptors
(Caldeira et al., 2007; Kim et al., 2012; Kolb et al., 2005), while also reducing the
expression of GABAA receptors, membrane density and function in hypothalamic
neurons (Carreno et al., 2011; Hewitt & Bains, 2006; Lund et al., 2008). Thus, BDNF
may represent a novel mediator of glutamatergic and GABAergic signaling in
cardiovascular regulation in the PVN.
BDNF can also alter the expression of other excitatory and inhibitory signaling
components in the CNS, such as glutamic acid decarboxylase (GAD) 67, K+- Cl−
cotransporter 2 (KCC2), and synapsin 1a/b. GAD67 has been found to be elevated in
renovascular hypertensive rats compared to normotensive control animals (Biancardi et
al., 2010), while BDNF release has been shown to upregulate GAD67 (Hanno-Iijima et
al., 2015). Further, GAD expression is reduced by application of the TrkB inhibitor,
K252a (Hanno-Iijima et al., 2015). BDNF is also known to alter the expression and
signaling of KCC2, which serves to establish the chloride ion gradient in neurons via the
maintenance of low intracellular chloride concentration (Tang, 2020). The expression of
KCC2 is significantly decreased in TrkB double KO mice hippocampi (Carmona et al.,
2006), and in adult neurons BDNF has been found to decrease both mRNA and protein
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KCC2 (Boulenguez et al., 2010; Claudio Rivera et al., 2002; Claudio Rivera et al., 2004;
Shulga et al., 2008; Wake et al., 2007), while increasing KCC2 expression in immature
neurons (Aguado et al., 2003; Boulenguez et al., 2010; A. Ludwig et al., 2011; Claudio
Rivera et al., 2002; Claudio Rivera et al., 2004; Shulga et al., 2008; Wake et al., 2007).
BDNF-TrkB-KCC2-mediated signaling is also implicated in salt-sensitive hypertension
whereby this mechanism weakens baroreceptor inhibition of vasopressin magnocellular
cells in the SON through a downregulation of KCC2 by BDNF (Choe et al., 2015).
Finally, another important component of neurotransmitter signaling in the CNS involves
synapsins which are phosphoproteins found at most synaptic terminals. They regulate the
maintenance of the reserve vesicle pool, while also recruiting to the vesicle pool and
increasing the release probability of synaptic vesicles to the readily releasable pool
(Khvotchev & Sun, 2009). Deletion of synapsin genes has been shown to reduce the
presynaptic response to BDNF, which may indicate that synapsins play a role in BDNFmediated increase of glutamate release (Jovanovic, Czernik, Fienberg, Greengard, &
Sihra, 2000; Kao et al., 2017). A link between chronic salt loading and increases in
synapsin IIa and IIb transcripts in the magnocellular division of the PVN compared to
control animals (Nomura et al., 2000) has also been observed.
Here, we set out to test the hypothesis that upregulation of BDNF in the PVN
elevates blood pressure by altering the excitatory/inhibitory balance in the PVN by
diminishing GABAA-mediated inhibitory mechanisms and augmenting NMDA-mediated
excitatory mechanisms. We used our previously published model (Erdos, Backes, et al.,
2015) of vector-mediated upregulation of BDNF in the PVN to induce hypertension and
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investigated the interaction of BDNF with glutamatergic and GABAergic signaling by
microinjecting NMDA and GABAA receptor agonists and antagonists into the PVN and
measuring changes in cardiovascular responses, while also analyzing protein and mRNA
expression of excitatory and inhibitory signaling components in the PVN. Understanding
the mechanism behind BDNF-mediated alteration of excitatory and inhibitory signaling
in the PVN will be important for a better understanding of the central blood pressure
neurocircuitry which could aid in the development of novel therapies for the treatment of
hypertension.
3.2. Methods
All animal housing, handling, and surgical and experimental procedures were
conducted within an Association for the Assessment and Accreditation of Laboratory Care
International-accredited animal care facility at the University of Vermont, in accordance
with the National Institutes of Health (NIH) Policy on Humane Care and Use of Laboratory
Animals and the NIH Guide for the Care and Use of Laboratory Animals. Experiments
were performed in male Sprague-Dawley (SD) rats obtained from Charles River (SaintConstant, QC, Canada). Rats were housed individually with a 12:12-h light-dark cycle
(lights on at 6:00 AM), with free access to food (standard chow) and water. All
experimental procedures were approved by the Institutional Animal Care and Use
Committee at the University of Vermont.
3.2.1. Experimental Design
Experiment 1. The aim of the first experiment was to determine the effect of BDNF on
NMDA-mediated glutamatergic and GABAA-mediated GABAergic receptor signaling in
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the PVN. Seven-week-old male SD rats received bilateral injections of adeno-associated
viral vectors (AAV2, 1012 vps/mL, 200 nL/side) expressing GFP or myc epitope-tagged
BDNF fusion protein (BDNFmyc) into the PVN. Three weeks later, blood pressure and
heart rate responses were recorded following PVN injections of the NMDA agonist NMDA
(100 µM) (Y. F. Li et al., 2001), the NMDA antagonist AP5 (10 mM) (Q. H. Chen et al.,
2003; D.-P. Li & H.-L. Pan, 2007), the GABAA agonist muscimol (10 mM) (D. P. Li &
H. L. Pan, 2007), and the GABAA antagonist gabazine (2 mM) (D.-P. Li & H.-L. Pan,
2007) under alpha-chloralose-urethane anesthesia. At the end of the experiment, animals
were deeply anesthetized and perfused transcardially with phosphate buffered saline (PBS)
and 4% paraformaldehyde. GFP, BDNFmyc and drug injection sites of glutamatergic and
GABAergic agonists and antagonists into the PVN were indicated by a red fluorescent
microbead solution, were verified with immunofluorescence and fluorescent microscopy
in coronal sections of the PVN (Fig. 10, A–C.).
Experiment 2. The goal of the second experiment was to determine the effect of BDNF on
various components of inhibitory and excitatory signaling mechanisms in the PVN. Sevenweek-old male SD rats received AAV2 viral vector (1012 vps/mL, 200 nL/side) expressing
bilateral injections of GFP or BDNFmyc into the PVN. Three weeks later, the animals were
euthanized, and the brains were quickly removed and snap-frozen. PVN tissue samples
were isolated, mRNA levels of NMDAR1 and GABAA-delta subunit were determined in
the PVN with quantitative real-time RT-PCR. A second group of animals also received
bilateral PVN injections of AAV2 viral vectors (1012 vps/mL, 200 nL/side) expressing GFP
or BDNFmyc. Three weeks later the animals were deeply anesthetized and perfused
transcardially with PBS and 4% paraformaldehyde. NMDAR1, GABAA-alpha1 subunit,
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GAD67, KCC2 and synapsin 1a/b expression in the PVN were assessed using
immunofluorescence, confocal microscopy, and image analysis. Finally, the average area
of GFP and BDNFmyc cells was also measured in GFP and BDNF groups.
3.2.2. Surgical Procedures
Surgeries were performed using aseptic techniques under continuous isoflurane
anesthesia (5% induction, 2–3% maintenance) delivered in oxygen. Depth of anesthesia
was ensured by lack of a reflex response to pinch of the hindpaw. Carprofen (5 mg·kg – 1
·day– 1 sc) was used for postsurgical analgesia administered at the beginning of surgery and
for 2 days after surgery. Anesthetized rats were placed in a stereotaxic frame, BDNFmyc
and GFP viral vectors (1012 viral particles/mL, 200 nL/side) were injected bilaterally into
the PVN using pipettes pulled from thin walled borosilicate glass capillary tubes (OD, 1
mm; ID, 0.58 mm; tip diameter: ~25 µm; World Precision Instruments Inc., Sarasota, FL)
at the following stereotactic coordinates: 1.80 mm posterior to bregma, 1.70 mm lateral to
the midline, and 7.65 mm ventral from the dorsal surface of the brain, with the micropipette
tilted 10° laterally toward the midline. Virus stocks were injected over 5 min using a
pneumatic pico pump (World Precision Instruments). The pipette was left in place for an
additional 3 min before being withdrawn.
3.2.3. Assessment of cardiovascular responses to NMDA and GABAA agonists and
antagonists
The left femoral artery and vein were catheterized under isoflurane anesthesia 3
weeks after bilateral PVN injections of AAV2-GFP or AAV2-BDNFmyc. Rats were then
placed in a stereotaxic frame, and isoflurane anesthesia was gradually switched to
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intravenous alpha-chloralose (60 mg kg – 1 h – 1 ) and urethane (800 mg kg – 1 h – 1)
anesthesia administered through the femoral vein catheter over a 30-min period, during
which, isoflurane was gradually reduced from 2.5% to 0%. Blood pressure, heart rate, toepinch, and eye blink reflexes were monitored closely to ensure the animal remained
anesthetized. After complete withdrawal of isoflurane, anesthesia was maintained by
intravenous alpha-chloralose (15 mg kg – 1 h – 1) and urethane (200 mg kg – 1 h – 1) infusion
for the remainder of the experiment. After establishment of steady baseline blood pressure
and heart rate for a minimum of 30 min, rats received NMDA (100 µM, 200 nL/side,
Sigma-Aldrich, M3262), AP5 (10 mM, 200 nL/side; Tocris, 0106), muscimol (10 mM, 200
nL/side, Sigma-Aldrich, G019), and gabazine (2 mM, 200 nL/side, Tocris, 1262) injections
into the PVN. Blood pressure was monitored via the catheter placed in the left femoral
artery, and heart rate was extracted from the pulsatile pressure wave by using Laboratory
Chart Pro 8 (ADInstruments). To verify locations of the drug injections in the PVN with
fluorescent microscopy, 10% rhodamine-labeled fluorescent microspheres (0.04 µm;
Molecular Probes) were mixed into the injection solution.
3.2.4. Viral Vector-Mediated Gene Transfer into the PVN
AAV2 viral vectors were used to elicit the expression of enhanced GFP and
BDNFmyc, derived from rat Bdnf, constructed and packaged by Vector Biolabs
(Philadelphia, PA). The expression of GFP and BDNFmyc was driven by a chicken betaactin

promoter

with

human

cytomegalovirus

enhancer

and

a

woodchuck

posttranscriptional regulatory element, which enhanced the expression of transgenes
present downstream of GFP and BDNFmyc. The BDNFmyc plasmid was a generous gift
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from Dr. Ronald Klein (LSU Health Sciences Center Shreveport, LA) and was used
previously to protect retinal ganglion cells in a rat glaucoma model (K. R. Martin et al.,
2003), and to study cardiovascular effects of BDNF in the PVN (Erdos, Backes, et al.,
2015). In addition, full efficacy of BDNFmyc expression driven by the rat neuron-specific
enolase promoter was confirmed previously both in vitro and in vivo (R. L. Klein et al.,
1999).

Figure 10. Representative fluorescent image of a coronal brain section ~1.8 mm posterior
to bregma showing PVN expression of AAV2-GFP (A) or AAV2-BDNFmyc (B) and the
red fluorescent microbead solution that was mixed with injected drug solution to verify
injection sites (C); scale bars, 250 µm. D. diagrams of the PVN ~1.8 mm and ~1.9 mm
posterior to bregma showing locations of drug injections in rats previously injected with
AAV2-GFP (circle, shown aggregated on the left side of the PVN) or AAV2-BDNFmyc
(rectangle, shown aggregated on the right side of the PVN). E. number of GFP- and mycpositive cells was assessed in subnuclei of the PVN; dorsal parvocellular nuclei (DP),
medial parvocellular nuclei (MP), ventrolateral parvocellular nuclei (VLP), and posterior
magnocellular nuclei (PM) following AAV2-GFP or AAV2-BDNFmyc injections in the
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PVN. 3V, third ventricle; PVN, paraventricular nucleus; GFP, green fluorescent protein;
BDNF, brain-derived neurotrophic factor; BDNFmyc, myc epitope-tagged BDNF;
AAV2, adeno-associated viral vector 2.

3.2.5. Analysis of Cardiovascular Data from Anesthetized Animals
Blood pressure and heart rate were recorded using LabChart software version 8.0.7
(ADInstruments, Dunedin, NZ) at a 1,000-Hz sampling rate and condensed to 10 or 20
second moving averages for data analysis and presentation. Maximum and average changes
in mean arterial pressure (MAP) and heart rate following drug microinjections were
evaluated.
3.2.6. Immunofluorescence
After experiments 1 and 2, animals were perfused with 400 mL of ice-cold PBS
followed by 400 mL of ice-cold 4% paraformaldehyde in PBS. Brains were removed and
post-fixed for 2 h in 4% paraformaldehyde and then equilibrated in 30% sucrose solution
at 4°C. Coronal sections (40 µm) were cut on a microtome (Leica SM2000R) and mounted
on Fisher Superfrost Plus slides. BDNFmyc, NMDAR1, GABAA-alpha1, GAD67,
synapsin 1a/b and KCC2 were detected using the following primary antibodies (1:200,
overnight incubation at 4°C): anti-c-Myc (Santa Cruz Biotechnology; 9E10), anti-c-Myc
(Abcam; ab9106) anti-NMDAR1 (Novus Biologicals, R1JHL), anti-GABAA-alpha1
(Abcam, ab33299), anti-GAD67 (Sigma-Aldrich, MAB5406; 1:400), anti-KCC2 (SigmaAldrich, MABN88), and anti-synapsin 1a/b (Santa Cruz Biotechnology, sc-7379).
Secondary antibodies were (1:200, 2-h incubation at room temperature): donkey anti103

mouse A546 (Invitrogen), donkey anti-mouse A555 (A31570), donkey anti-rabbit A555
(Invitrogen), donkey anti-rabbit A488 (A21206), and donkey anti-goat A555 (ab150130).
GFP, BDNFmyc, NMDAR1, GABAA-alpha1, GAD67, KCC2 and synapsin 1a/b
immunofluorescence in the PVN were detected with a fluorescent microscope (Nikon
Eclipse 50i) and a confocal microscope (Nikon A1R).
3.2.7. Confocal Microscopy and Image Analysis
Images of GFP and BDNF PVN brain slices labeled with immunofluorescence as
described above were taken using a Nikon A1R confocal laser-scanning imaging system.
The z-stacks were then deconvoluted using the deconvolution software AutoQuant X3
(Media Cybernetics, Inc.). Then the green channel of the z-stack, expressing GFP or
BDNFmyc, was opened in ImageJ and thresholded using the Phansalkar thresholding
technique which is a modification on the Sauvola method, a variant of Niblack’s method
(Adler & Parmryd, 2014). It uses a combination of local mean, local standard deviation
and normalization to set a threshold below the local mean to select the foreground, reject
the background and boost the threshold at lower intensities (Neerad, Sumit, Ashish, &
Madhuri, 2011). The function Remove Outliers in ImageJ was also used, which replaces a
pixel if it deviates from the median by more than the threshold. The parameters were set
for a 10-pixel radius, which represents the area that is used for calculating the median, at a
50 AU threshold, which determines by how much a pixel must diverge from the median to
be replaced. Pixels that were brighter than the median were replaced. Finally, the Analyze
Particles function was used to measure the area of the cells, set at a size of 50 µm2 – infinity.

104

Following this, region of interest (ROI) mean fluorescence intensity (ROI mean),
and ROI maximum fluorescence intensity (ROI max) were measured in the red channel in
the z-stack, expressing NMDAR1, GABAA-alpha1, GAD67, KCC2 or synapsin 1a/b,
using the ROIs from the green channel representing the cell bodies. This analysis was
conducted separately for each side of the PVN, and the mean calculated for each
experimental group. Additionally, 1 slice from the red channel z-stack was selected to
measure mean fluorescence intensity within the PVN (PVN mean) by drawing a border
along the PVN. This analysis was also conducted separately for each side of the PVN, and
the mean calculated within each experimental group. Finally, for the GABAA-alpha1
subunit expression, mean fluorescence intensity (Area mean) was measured in a defined
area of the peri-PVN (186x186 µM) compared to an area within the medial parvocellular
nucleus of the PVN of the same size.
3.2.8. Real-Time RT-PCR
Frozen forebrains were mounted on a cryostat, and rostral coronal sections were cut
until reaching the level ~1.5 mm posterior of bregma for the PVN. Then, tissue samples
0.75 mm in diameter and 0.5 mm deep were punched bilaterally from the region of the
PVN, with the third ventricle used as reference for the PVN. The depth of the punches was
limited by a spacer glued onto the outside of the punch tool. Total RNA was extracted from
brain punches with Qiashredder columns (Qiagen, Valencia, CA) and the RNeasy Micro
Kit (Qiagen). Samples were treated with an RNase-free DNase Set (Qiagen) on the column
to remove genomic DNA. RNA was quantified with a Qubit Fluorometer, and cDNA was
synthesized with a high-capacity cDNA reverse transcription kit (Applied Biosystems)
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according to manufacturer’s instructions and stored at – 20°C. All quantitative RT-PCR
reactions were run in duplicate in eight-well optical-grade strips in a Prism 7000 Sequence
Detection System (Applied Biosystems) and quantified with the cycle threshold (CT)
method. The mRNA levels of NMDAR1 and GABAA-delta, and the reference gene betaactin (ActB) were analyzed with quantitative real time RT-PCR using specific
oligonucleotide primers and TaqMan probes (Applied Biosystems, Foster City, CA):
NMDAR1, Rn01436034_m1 (reference sequence: NM_001270602.1); GABAA-delta,
Rn01517017_g1 (reference sequence: NM_017289.1). Control reactions containing no
template were run for each plate, and results were analyzed with the 2-ΔΔCT.
3.2.9. Statistics
Maximum decreases or increases in MAP and heart rate during microinjection
experiments were measured using an unpaired t-test. NMDAR1, GABAA-alpha1, GAD67,
KCC2 and synapsin 1a/b ROI max, ROI mean, as well as PVN mean and Area mean in the
peri-PVN and parvocellular PVN were analyzed using an unpaired t-test. RT-PCR data
was also analyzed by unpaired t-test. Statistical tests were performed using Prism 8.2
software (GraphPad, San Diego, CA). Results are expressed as means +/- SE, and the
criterion for statistical significance was P < 0.05.
3.3. Results
3.3.1. Effect of BDNF on NMDA-mediated signaling in the PVN
In our first experiment, we tested whether BDNF affects PVN NMDA-mediated
cardiovascular responses. We found that inhibition of NMDA-receptors with AP5
significantly lowered MAP and heart rate in BDNF rats compared to the control group.
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Specifically, the results from our first experiment showed that in the BDNF group, max
average decreases in blood pressure and heart rate in response to AP5 were -17±5 mmHg
and -61±18 BPM, compared with -2±7 mmHg (p<0.05) and -6±1 BPM (p<0.05) in the
GFP group (Fig. 11. A-B.). We also found that activation of NMDA-receptors did not
have a significant effect on MAP but did significantly lower heart rate responses in the
BDNF group compared to the GFP group (p<0.05). In response to NMDA, max average
increases in blood pressure and max average decreases in heart rate in the BDNF group
were 5±1 mmHg and -94±23 BPM, compared with 8±2 mmHg (p=0.31, n.s.) and -40±13
BPM (p<0.05) in the GFP group. Max average decreases in blood pressure in the BDNF
group was -3.9±2 mmHg and -12.3±4 mmHg in the GFP group (p=0.13, n.s.) (Fig. 11. CD.).
The effect of BDNF overexpression in the PVN on NMDAR1 and synapsin 1a/b
expression were also quantified (Fig. 12-15.). NMDAR1 ROI mean was found to be
significantly elevated in the BDNF group, compared to the GFP group (p<0.001) (Fig.
12C.). NMDAR1 ROI max was also significantly higher in the BDNF group compared to
the GFP group (p<0.05) (Fig. 12D.). Finally, PVN mean was significantly elevated in the
BDNF group compared to the GFP group (p<0.05) (Fig. 12E.). Synapsin 1a/b ROI mean
and ROI max was not significantly different between the GFP and BDNF groups
(p=0.48, n.s., p= 0.29, n.s.) (Fig. 14C-D). PVN mean was also not significantly different
between the GFP and BDNF groups (p=0.79, n.s.) (Fig. 14E.).
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Figure 11. Changes in mean arterial pressure
(MAP; top) and heart rate (HR; bottom) in
response to PVN injections of the NMDA
receptor antagonist AP5 (A, B) and NMDAreceptor agonist NMDA (C, D) in
anesthetized rats previously treated with
AAV2-GFP or AAV2-BDNFmyc. A: MAP
and HR obtained with 10-s moving average
over 180 seconds following AP5 injection in
GFP (n=5) and BDNFmyc (n=7) treated rats.
B: Average max decrease in MAP and heart
rate responses to AP5 injections. C: MAP and
HR obtained with 20-s moving average over
180 seconds following NMDA injection in
GFP (n=5) and BDNFmyc (n=7) treated rats.
D: Average max decrease and increase in
MAP and average max decrease in heart rate
responses to NMDA injections. Statistical
analysis was done on max changes in MAP
and heart rate. PVN, paraventricular nucleus; GFP, green fluorescent protein; BDNF,
brain-derived neurotrophic factor; BDNFmyc, myc epitope-tagged BDNF; AAV2, adenoassociated viral vector 2. Results represent means ± SE. Statistical analysis was done on
peak changes in MAP and HR. *P < 0.05 for GFP vs. BDNF (unpaired t-test).
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Figure 12. NMDAR1
fluorescent expression in
the PVN of rats
previously injected with
AAV2-GFP (A) or
AAV2-BDNFmyc (B) in
the PVN. Representative
confocal images of
NMDAR1 expression
within the PVN in GFP
(A) and BDNFmyc (B)
groups as detected with
an NMDAR1 antibody
and immunofluorescence;
scale bars, 100 µm. C-D.
ROI mean (C) and ROI
max (D) NMDAR1 in the
PVN, averaged for each
experimental group; n
refers to number of PVN
sides [GFP (n = 11) and
BDNFmyc (n = 7)]. E:
PVN mean NMDAR1
expression [GFP (n = 11)
and BDNFmyc (n = 7)].
3V, third ventricle; PVN,
paraventricular nucleus;
GFP, green fluorescent
protein; BDNF, brainderived neurotrophic
factor; AAV2, adenoassociated viral vector 2.
Results represent
means ± SE. *P < 0.05 for
GFP vs. BDNF; ***P <
0.001 for GFP vs. BDNF
(unpaired t test).
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Figure 13. A: NMDAR1
fluorescent expression in the PVN
of rats previously injected with
AAV2-GFP, showing a rectangular
area which is magnified in B-D,
scale bar 100 uM. B-D:
Representative 60X magnification
confocal images showing
NMDAR1 and GFP expression in
the PVN. Arrows show overlap of
NMDAR1 staining with GFP
infected cell bodies and fibers,
scale bar 50 µM. E: NMDAR1
fluorescent expression in the PVN
of rats previously injected with
AAV2-BDNFmyc, showing a
rectangular area which is magnified
in F-H, scale bar 100 uM. F-H:
Representative 60X magnification
confocal images showing
NMDAR1 and BDNFmyc
expression in the PVN. Arrows
show overlap of NMDAR1 staining
with BDNFmyc infected cell bodies
and fibers, scale bar 50 µM.
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Figure 14. Synapsin 1a/b
fluorescent expression in
the PVN of rats previously
injected with AAV2-GFP
or AAV2-BDNFmyc in the
PVN. A-B. Representative
confocal images of
NMDAR1 expression
within the PVN in GFP (A)
and BDNFmyc (B) groups
as detected with a synapsin
1a/b antibody and
immunofluorescence; scale
bars, 100 µm. C-D. ROI
mean (C) and ROI max (D)
synapsin 1a/b expression in
the PVN, averaged for each
experimental group; n
refers to number of PVN
sides [GFP (n = 8) and
BDNFmyc (n = 8)]. E:
PVN mean synapsin 1a/b
expression [GFP (n = 8)
and BDNFmyc (n = 8)].
3V, third ventricle; PVN,
paraventricular nucleus;
GFP, green fluorescent
protein; BDNF, brainderived neurotrophic
factor; AAV2, adenoassociated viral vector 2.
Results represent
means ± SE.
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Figure 15. A: Synapsin 1a/b
fluorescent expression in the
PVN of rats previously
injected with AAV2-GFP,
showing a rectangular area
which is magnified in B-D,
scale bar 100 uM. B-D:
Representative 60X
magnification confocal
images showing synapsin
1a/b and GFP expression in
the PVN. Arrows show
overlap of synapsin 1a/b
staining with GFP infected
cell bodies and fibers, scale
bar 50 µM. E: Synapsin 1a/b
fluorescent expression in the
PVN of rats previously
injected with AAV2BDNFmyc, showing a
rectangular area which is
magnified in F-H, scale bar
100 uM. F-H: Representative
60X magnification confocal
images showing synapsin
1a/b and BDNFmyc
expression in the PVN.
Arrows show overlap of
synapsin 1a/b staining with
BDNFmyc infected cell
bodies and fibers, scale bar
50 µM.
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3.3.2. Effect of BDNF on GABAA-mediated signaling in the PVN
In our first experiment we also tested whether BDNF affects PVN GABAAmediated cardiovascular responses. We found that inhibition of GABAA receptors with
gabazine significantly elevated MAP in the GFP group compared to the BDNF
overexpressed group. In response to gabazine, average max increases in blood pressure
and heart rate in the BDNF group were 34±7 mmHg and 97±26 BPM, compared with
70±12 mmHg (p<0.05) and 155±22 BPM (p=0.12, n.s.) in the GFP group (Fig. 16A-B.).
We also found that activation of GABAA receptors with muscimol significantly
decreased MAP in the GFP group compared to the BDNF overexpressed group. In
response to muscimol, average max decreases in blood pressure and heart rate in the
BDNF group were -15±2 mmHg and -27±8 BPM, compared with -26±5 mmHg (p<0.05)
and -48±9 BPM (p=0.10, n.s.) in the GFP group (Fig. 16C-D..).
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Figure 16. Changes in mean
arterial pressure (MAP; top) and
heart rate (HR; bottom) in response
to PVN injections of the GABAA
receptor antagonist gabazine (A, B)
and GABAA-receptor agonist
muscimol (C, D) in anesthetized
rats previously treated with AAV2GFP or AAV2-BDNFmyc. A:
MAP and HR obtained with 20-s
moving average over 600 seconds
following gabazine injection in
GFP (n=6) and BDNFmyc (n=7)
treated rats. B: Average max
increase in MAP and HR responses
to gabazine injections. C: MAP and
HR obtained with 20-s moving
average over 900 seconds following
muscimol injection in GFP (n=5)
and BDNFmyc (n=7) treated rats.
D: Average max decrease in MAP
and HR responses to muscimol
injections. Statistical analysis was
done on average max changes in
MAP and HR. PVN,
paraventricular nucleus; GFP, green
fluorescent protein; BDNF, brainderived neurotrophic factor;
BDNFmyc, myc epitope-tagged
BDNF; AAV2, adeno-associated
viral vector 2. Results represent
means ± SE. Statistical analysis was
done on peak changes in MAP and
HR. *P < 0.05 for GFP vs. BDNF
(unpaired t test).
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The effect of BDNF overexpression in the PVN on GABAA-alpha1 was also
quantified (Fig. 17-18.) GABAA-alpha1 ROI mean was not significantly different
between the two groups (p=0.56. n.s.), but ROI max was significantly reduced in the
BDNF group compared to GFP (p<0.01) (Fig. 17C-D.). PVN mean was not significantly
different between the GFP and BDNF groups (p=0.053, n.s.) (Fig. 17E.). Area mean
within the PVN in the BDNF group compared to the peri-PVN was significantly lower
(p<0.01), additionally Area mean in the peri-PVN of the BDNF group was significantly
lower compared to the peri-PVN of the GFP group (p<0.05) (Fig. 17F.).
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Figure 17. GABAA-alpha1
fluorescent expression in the
PVN of rats previously injected
with AAV2-GFP or AAV2BDNFmyc in the PVN. A-B.
Representative confocal images
of GABAA-alpha1 expression
within the PVN in GFP (A) and
BDNFmyc (B) groups as
detected with an GABAAalpha1 antibody and
immunofluorescence; scale
bars, 100 µm. C-D. ROI mean
(C) and ROI max (D) GABAAalpha1 expression in the PVN,
averaged for each experimental
group; n refers to number of
PVN sides [GFP (n = 8) and
BDNFmyc (n = 7)]. E: PVN
mean GABAA-alpha1
expression [GFP (n = 8) and
BDNFmyc (n = 7)]. F: Area
mean of GABAA-alpha1 within
the peri-PVN and the
parvocellular PVN [GFP (n = 8)
and BDNFmyc (n = 7)]. 3V,
third ventricle; PVN,
paraventricular nucleus; GFP,
green fluorescent protein;
BDNF, brain-derived
neurotrophic factor; AAV2,
adeno-associated viral vector 2.
Results represent means ± SE.
*P < 0.05 for GFP Peri-PVN vs.
BDNFmyc Peri-PVN; **P <
0.05 for BDNF PVN vs. BDNF
Peri-PVN; **P < 0.01 for GFP
vs. BDNF (unpaired t test).
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Figure 18. A: GABAAalpha1 fluorescent expression
in the PVN of rats previously
injected with AAV2-GFP,
showing a rectangular area
which is magnified in B-D,
scale bar 100 uM. B-D:
Representative 60X
magnification confocal
images showing GABAAalpha1 and GFP expression in
the PVN. Arrows show
overlap of GABAA-alpha1
staining with GFP infected
cell bodies and fibers, scale
bar 50 µM. E: GABAAalpha1 fluorescent expression
in the PVN of rats previously
injected with AAV2BDNFmyc, showing a
rectangular area which is
magnified in F-H, scale bar
100 µM. F-H: Representative
60X magnification confocal
images showing GABAAalpha1 and BDNFmyc
expression in the PVN.
Arrows show overlap of
GABAA-alpha1 staining with
BDNFmyc infected cell
bodies and fibers, scale bar 50
µM.
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GAD67 and KCC2 were also assessed in the PVN (Fig. 19-22.). GAD67 ROI
max and ROI mean was not significantly different between the BDNF and GFP groups
(p=0.96, n.s., p=0.15, n.s.) (Fig. 19C-D.). PVN mean was also not significantly different
between the GFP and BDNF groups (p=0.34, n.s.) (Fig. 19E.). KCC2 ROI max and ROI
mean were significantly elevated in the BDNF group compared with the GFP group
(p<0.001, p<0.05) (Fig. 21C-D.). However, PVN mean was not significantly different
between the two groups (p=0.15, n.s.) (Fig. 21E.). We also tested the effect of BDNF
upregulation in the PVN on expression of NMDAR1 and GABAA-delta subunit mRNA.
BDNF overexpression in the PVN did not significantly alter NMDAR1 (p=0.58, n.s.) or
GABAA-delta subunit (p=0.73, n.s.) mRNA expression in the PVN (Fig. 23.). Finally,
the average area of GFP and BDNFmyc cells was also measured, the average area of a
GFP cell was 225.7±15 µm2 and the average area of a BDNFmyc cell was 253.1±22 µm2
(p=0.30, n.s.) (Fig. 24.).
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Figure 19. GAD67
fluorescent expression in
the PVN of rats previously
injected with AAV2-GFP
or AAV2-BDNFmyc in
the PVN. A-B.
Representative confocal
images of GAD67
expression within the PVN
in GFP (A) and BDNFmyc
(B) groups as detected
with a GAD67 antibody
and immunofluorescence;
scale bars, 100 µm. C-D.
ROI mean (C) and ROI
max (D) GAD67 in the
PVN, averaged for each
experimental group; n
refers to number of PVN
sides [GFP (n = 9) and
BDNFmyc (n = 8)]. E:
PVN mean GAD67
expression [GFP (n = 9)
and BDNFmyc (n = 8)].
3V, third ventricle; PVN,
paraventricular nucleus;
GFP, green fluorescent
protein; BDNF, brainderived neurotrophic
factor; AAV2, adenoassociated viral vector 2.
Results represent
means ± SE.
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Figure 20. A: GAD67 fluorescent
expression in the PVN of rats previously
injected with AAV2-GFP, showing a
rectangular area which is magnified in BD, scale bar 100 uM. B-D: Representative
60X magnification confocal images
showing GAD67 and GFP expression in
the PVN. Arrows show overlap of GAD67
staining with GFP infected cell bodies and
fibers, scale bar 50 µM. E: GAD67
fluorescent expression in the PVN of rats
previously injected with AAV2BDNFmyc, showing a rectangular area
which is magnified in F-H, scale bar 100
uM. F-H: Representative 60X
magnification confocal images showing
GAD67 and BDNFmyc expression in the
PVN. Arrows show overlap of GAD67
staining with BDNFmyc infected cell
bodies and fibers, scale bar 50 uM.
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Figure 21. KCC2 fluorescent
expression in the PVN of rats
previously injected with
AAV2-GFP or AAV2BDNFmyc in the PVN. A-B.
Representative confocal
images of KCC2 expression
within the PVN in GFP (A)
and BDNFmyc (B) groups as
detected with a KCC2
antibody and
immunofluorescence; scale
bars, 100 µm. C-D. ROI
mean (C) and ROI max (D)
KCC2 in the PVN, averaged
for each experimental group;
n refers to number of PVN
sides [GFP (n = 8) and
BDNFmyc (n = 9)]. E: PVN
mean KCC2 expression
[GFP (n = 8) and BDNFmyc
(n = 9)]. 3V, third ventricle;
PVN, paraventricular
nucleus; GFP, green
fluorescent protein; BDNF,
brain-derived neurotrophic
factor; AAV2, adenoassociated viral vector 2.
Results represent
means ± SE. *P < 0.05 for
GFP vs. BDNFmyc; ***P <
0.001 for GFP vs. BDNFmyc
(unpaired t test).
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Figure 22. A: KCC2 fluorescent
expression in the PVN of rats
previously injected with AAV2GFP, showing a rectangular area
which is magnified in B-D, scale
bar 100 µM. B-D: Representative
60X magnification confocal
images showing KCC2 and GFP
expression in the PVN. Arrows
show overlap of KCC2 staining
with GFP infected cell bodies
and fibers, scale bar 50 uM. E:
KCC2 fluorescent expression in
the PVN of rats previously
injected with AAV2-BDNFmyc,
showing a rectangular area which
is magnified in F-H, scale bar
100 uM. F-H: Representative
60X magnification confocal
images showing KCC2 and
BDNFmyc expression in the
PVN. Arrows show overlap of
KCC2 staining with BDNFmyc
infected cell bodies and fibers,
scale bar 50 µM.
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Figure 23. Expression of NMDAR1 and GABAA-delta receptor mRNA in the PVN of
rats previously injected with AAV2-GFP (n = 6) or AAV2-BDNFmyc (n = 7) in the
PVN. A: Expression of NMDAR1 mRNA in the PVN of AAV2-GFP (n = 12 sides of
PVN) and AAV2-BDNFmyc (n = 13 sides of PVN) rats. B: Expression of GABAA-delta
receptor mRNAs in the PVN of AAV2-GFP (n = 13 sides of PVN) and AAV2BDNFmyc (n = 12 sides of PVN) rats. PVN, paraventricular nucleus; GFP, green
fluorescent protein; BDNF, brain-derived neurotrophic factor; BDNFmyc, myc epitopetagged BDNF; AAV2, adeno-associated viral vector 2. Results are expressed as 2−ΔΔCT
(where CT is threshold cycle) normalized to the control group and presented as
means ± SE.
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Figure 24. Mean area of neuronal soma of AAV2-GFP (n=18 sides of PVN) and AAV2BDNFmyc (n=15 sides of PVN) infected cells in the PVN. PVN, paraventricular nucleus;
GFP, green fluorescent protein; BDNF, brain-derived neurotrophic factor; BDNFmyc,
myc epitope-tagged BDNF; AAV2, adeno-associated viral vector 2.
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3.4. Discussion
BDNF is upregulated in the PVN in response to hypertensive stimuli such as
chronic and acute stress, hyperosmolality, and repeated amphetamine administration
(Aliaga et al., 2002; Hammack et al., 2009; Meredith et al., 2002; Rage et al., 2002;
Smith, Makino, Kim, et al., 1995). When acutely injected or overexpressed in the PVN,
BDNF also significantly increases blood pressure and heart rate (Erdos, Backes, et al.,
2015; C. L. Schaich et al., 2018; Chris L. Schaich et al., 2016). BDNF has been shown to
alter both excitatory and inhibitory neurotransmitter signaling in the CNS (Bolton et al.,
2000; Cohen-Cory et al., 2010; Frerking et al., 1998; B. Lu et al., 2005; Minichiello,
2009; Waterhouse & Xu, 2009). Similar cellular mechanisms may contribute to
increasing blood pressure by shifting the balance of excitatory and inhibitory synaptic
balance in the PVN. A shift in PVN excitatory/inhibitory balance towards excitation has
been demonstrated to elevate blood pressure and sympathetic activity in various
hypertensive models including in rats subjected to ICV infusion of Ang II (Sharma et al.,
2021), in SHRs (D.-P. Li & H.-L. Pan, 2007; D. P. Li & Pan, 2006), and in
deoxycorticosterone acetate salt-sensitive hypertension (Basting et al., 2018). Similar
effects have also been observed in salt-sensitive hypertension where PVN microinjections
of kynurenate, an excitatory amino acid antagonist, have been shown to significantly
decrease both MAP and heart rate in hypertensive Dahl S rats on high salt diets compared
to normotensive controls (Gabor & Leenen, 2012a). Additionally, in Ang II-induced
hypertension, a 2 week administration of a sub-pressor dose of Ang II results in an
increase in plasma membrane NMDAR1 in dendrites of PVN neurons in mice, while
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PVN NMDAR1 deletion results in a significant attenuation of Ang II-induced elevations
in blood pressure (Glass et al., 2015).
Previous studies have shown that PVN microinjections of AP5 in WKY and SHRs
result in a larger decrease in blood pressure in SHRs compared to WKY (Q. H. Chen et
al., 2003; D.-P. Li & H.-L. Pan, 2007; Y. F. Li et al., 2006). Meanwhile, a PVN
microinjection of L-glutamate or NMDA have typically been found to increase blood
pressure, and sympathetic nerve activity in both anesthetized and conscious normotensive
rats (Busnardo et al., 2010; Kannan et al., 1989; Y. F. Li et al., 2006; Y. F. Li et al., 2001;
Douglas S. Martin & Haywood, 1992). There is some disagreement in the literature,
where studies have shown that PVN L-glutamate injections in anesthetized SD rats can
lead to no changes in blood pressure and a decrease in heart rate (Darlington, Miyamoto,
Keil, & Dallman, 1989), and in anesthetized Wistar rats a decrease in blood pressure with
no change in heart rate (Katafuchi, Oomura, & Kurosawa, 1988). There is limited
literature on the effect of an NMDA agonist on blood pressure in hypertensive rats.
NMDA PVN injections in sedentary heart failure rats has been shown to produce a larger
increase in blood pressure compared to sham sedentary rats (Kleiber, Zheng, Schultz,
Peuler, & Patel, 2008). There is also a greater increase in renal sympathetic nerve activity
in response to NMDA injected into the PVN in heart failure rats compared to sham rats
(Y. F. Li et al., 2003). We found that inhibition of NMDA-receptors with AP5
significantly lowered MAP and heart rate in BDNF rats compared to the GFP control
group. However, activation of NMDA-receptors did not significantly alter MAP but did
significantly lower heart rate responses in the BDNF group compared to the control GFP
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group. Our AP5 results agree with the broader literature while our NMDA results agree
with parts of the literature that show similar effects on blood pressure and heart rate using
L-glutamate injections (Darlington et al., 1989). These discrepancies could be in part
attributed to the use of different anesthetics and possibly diffusion of the injected
pharmacological agent outside of the PVN or activation of functionally different
subpopulations of neurons both within and outside the PVN (Darlington et al., 1989).
Activation of different subpopulations of the PVN has been demonstrated in studies
where different subregions of the PVN are electrically stimulated leading to opposite
responses in blood pressure (Porter & Brody, 1985). This may suggest that there is a
potential explanation for why different studies report different effects on blood pressure
and heart rate, which may have more to do with the injection site of a pharmacological
agent or site of electrical stimulation.
The results from this experiment indicate that an increase in NMDA-mediated
signaling within the PVN in response to the overexpression of BDNF may be due to an
increase in presynaptic release of glutamate and an increase in glutamatergic innervation
from higher order brain areas. Pre-synaptically, BDNF is known to increase glutamate
release leading to an increase in the frequency of mEPSCs in the hippocampus
(Lessmann & Heumann, 1998; Takei et al., 1998). Post-synpatically, BDNF augments
NMDA receptor single channel opening probability (Levine et al., 1998; Levine & Kolb,
2000; Lin et al., 1998; Suen et al., 1997). In SHRs, the basal frequency of mEPSCs of
PVN presympathetic neurons is significantly increased compared to normotensive
controls (Qiao, Zhou, Li, & Pan, 2017; Ye et al., 2011; Ye, Li, Li, & Pan, 2012).
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Furthermore, inhibiting NMDA receptors eliminates the increased frequency of mEPSCs
of PVN presympathetic neurons in the SHR only, but not in normotensive rats (D. P. Li,
Zhou, Zhang, & Pan, 2017; Shulga et al., 2008). In this study we examined NMDAR1
expression in the PVN by quantifying both protein expression and mRNA expression.
NMDAR1 ROI mean, and ROI max was significantly higher in the BDNF group
compared to the GFP group. PVN mean was also significantly elevated in the BDNF
group compared to the GFP group. However, BDNF overexpression in the PVN did not
significantly upregulate NMDAR1 mRNA expression. This discrepancy between the
protein results and the mRNA results for the NMDAR1 expression may be due to some
key differences between quantifying mRNA and protein expression. Firstly, the RT-PCR
PVN punch we used contains the whole PVN and may contain some hypothalamic tissue
outside of the PVN, whereas the protein analysis used 1 PVN brain slice to quantify
receptor expression where BDNFmyc or GFP expression was also high in the PVN.
Secondly, the PVN is a very heterogenous structure, known to change morphologically
on the caudal-rostral axis and in terms of the different cell types expressed throughout the
extent of the PVN (Stern, 2001). Thirdly, post-transcriptional regulation, and differences
in mRNA and protein turnover rates could explain some of these differences (N. Fu et al.,
2007).
Another important component of neurotransmitter signaling in the CNS involves
synapsins which are phosphoproteins found at most synaptic terminals. They regulate the
maintenance of the reserve vesicle pool, while also recruiting to the vesicle pool and
increasing the release probability of synaptic vesicles to the readily releasable pool
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(Khvotchev & Sun, 2009). Deletion of synapsin genes has been shown to reduce the
presynaptic response to BDNF, which may indicate that synapsins play a role in BDNFmediated increase of glutamate release (Jovanovic et al., 2000; Kao et al., 2017). A link
between chronic salt loading and increases in synapsin IIa and IIb transcripts in the
magnocellular division of the PVN compared to control animals (Nomura et al., 2000)
has also been observed. In this study, synapsin 1a/b ROI mean, ROI max, and PVN mean
were not significantly different between the GFP and BDNF groups. This may indicate
that other synapsins play a greater role in BDNF-mediated hypertensive mechanisms
such as synaptophysin, synaptobrevin and synaptotagmin, all of which have also been
shown to be upregulated in response to BDNF (Tartaglia et al., 2001).
In terms of the effect of BDNF on inhibitory signaling in the PVN, we found that
inhibition of GABAA receptors with gabazine significantly elevated MAP in the GFP
group compared to the BDNF group. Conversely, activation of GABAA receptors with
muscimol significantly decreased MAP in the GFP group compared to the BDNF group.
These results are similar to what has been reported in WKY and SHRs, where PVN
injections of the GABAA receptor agonists isoguvacine or muscimol have been found to
reduce blood pressure more significantly in WKY and SD rats compared to SHRs (Ding
et al., 2015; D. P. Li & H. L. Pan, 2007). Meanwhile PVN microinjections of the
GABAA antagonist, gabazine or bicuculline, have been found to increase blood pressure
significantly more in WKY and SD rats compared to SHR (Ding et al., 2015; D. P. Li &
Pan, 2006; D. P. Li & H. L. Pan, 2007; Y. F. Li et al., 2006), which is also consistent
with our results. The results from this experiment suggest that a decrease in GABAA129

mediated signaling within the PVN in response to the overexpression of BDNF may be
due to a decrease in both presynaptic and postsynaptic GABAA signaling mechanisms,
such as a decrease in GABA release, a decrease in GABAergic innervation of the PVN,
or a decrease in GABAA receptor number.
The effect of BDNF on GABAergic signaling is well-documented. Acute BDNF
application in the hippocampus has been shown to reduce evoked and spontaneous
GABAergic currents via the TrkB receptor (Marty et al., 2000; Rutherford, DeWan,
Lauer, & Turrigiano, 1997), and facilitate the early phase of LTP (Figurov, Pozzo-Miller,
Olafsson, Wang, & Lu, 1996; Kang & Schuman, 1995; Patterson et al., 1996).
Hypertensive conditions are also known to impair normal GABAergic inhibition of PVN
presympathetic neurons. GABAA receptor-binding sites are reduced in the PVN in SHRs
(Kunkler & Hwang, 1995), as is the frequency of GABAergic IPSCs of presympathetic
neurons in the PVN (D. P. Li & Pan, 2006; Ye, Li, Byun, Li, & Pan, 2012). Additionally,
GABAA receptor α5 subunit expression within the PVN is reduced in SHRs compared to
control Wistar rats (Cork et al., 2016). This may be due to reduced presynaptic GABA
release, decreased GABAA receptor number or function, or the loss of GABAergic
neurons in hypertension. There is also a reduction in GABAA-mediated PVN inhibition
in rats with congestive heart failure which contributes to increased sympathetic outflow
(Carillo et al., 2012; K. Zhang et al., 2002).
In this study we quantified GABAA-alpha1 and GABAA-delta subunit expression
in the PVN using protein quantification methods and RT-PCR. GABAA-alpha1 ROI max
was found to be significantly elevated in the GFP compared to the BDNF group, but ROI
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mean was not. The maximum fluorescence measurement is more likely to capture
differences in the higher end of fluorescence intensity, while mean fluorescence provides
an average of the gradient of fluorescence intensity. This elevation of ROI max in the
GFP group compared to the BDNF group could indicate that the difference in
fluorescence intensity is such that the GFP group has a greater distribution of
fluorescence intensity at the higher end of the scale compared to the BDNF group.
GABAA-alpha1 expression was also observed to be consistently lower inside the PVN as
compared to outside the PVN, in the peri-PVN area, as can be seen in the representative
PVN images from both GFP and BDNFmyc injected animals (Fig. 16.). This is consistent
with the literature, which shows that GABA interneurons are highly expressed in the periPVN area, the anterior hypothalamic area and the perifornical regions, while GABA
neurons in the PVN are less common (Alastair V. Ferguson et al., 2008). Thus, the effect
of BDNF overexpression may be more pronounced when comparing the peri-PVN vs the
PVN both within and between the BDNF and GFP groups. We devised a method to
quantify GABAA-alpha1 expression both in the medial parvocellular portion of the PVN
and the peri-PVN. We found that GABAA-alpha1 expression in the PVN in the BDNF
group compared to the peri-PVN in the BDNF group was significantly lower, GABAAalpha1 expression was also lower in the peri-PVN of the BDNF group compared to the
peri-PVN of the GFP group. BDNF may be acting on neighboring neurons outside the
PVN to alter the signaling properties of both PVN and peri-PVN neurons. BDNF
injections into the PVN may affect neurons that project into and out of the PVN, which
could alter GABAA subunit expression and signaling both inside and outside the PVN.
The expression of GABAA-alpha1 subunit has been found to be similar in the PVN of
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renal-wrapped and sham-operated rats (Haywood et al., 2001), but BDNF activation of
TrkB receptors is known to mediate the sequestration of membrane GABAA alpha-1
subunits via differential phosphorylation pathways in the hippocampus and amygdala
(Mou, Heldt, & Ressler, 2011). Additionally, BDNF has been shown to decrease
GABAA-alpha1 expression associated with epilepsy (Lund et al., 2008), and in the
hippocampus (Roberts et al., 2006).
We also quantified the expression of GABAA-delta subunit and found that BDNF
did not significantly alter its expression in the PVN compared to the GFP group. The
GABAA-delta subunit is localized exclusively to extrasynaptic or perisynaptic sites, and
contributes to tonic inhibition in the CNS (Glykys, Mann, & Mody, 2008; Nusser &
Mody, 2002; Nusser, Sieghart, & Somogyi, 1998; Wei, Zhang, Peng, Houser, & Mody,
2003). It is also present in the PVN (Pirker, Schwarzer, Wieselthaler, Sieghart, & Sperk,
2000), where it tonically inhibits PVN presympathetic neurons (J. B. Park et al., 2009; Jin
Bong Park, Skalska, Son, & Stern, 2007). GABAA delta subunit also regulates the
activity of CRH neurons in the PVN (V. Lee, Sarkar, & Maguire, 2014; Sarkar,
Wakefield, MacKenzie, Moss, & Maguire, 2011), and chronic stress has been shown to
significantly reduce the mRNA expression of GABAA delta containing receptors in the
PVN (Verkuyl, Hemby, & Joëls, 2004). BDNFs effect on GABAA delta function or
expression has only been minimally studied. BDNF has been shown to reduce the buildup
of the GABAA delta subunit in the cytoplasmic compartment and increase its surface
expression in hippocampal slices (Joshi & Kapur, 2009). Meanwhile infusion of the
neurosteroid allopregnanolone, a GABAA receptor-positive allosteric modulator, into the
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prefrontal cortex of rats, increased the mRNA expression of the GABAA delta subunit in
the prefrontal cortex, while also elevating the expression of BDNF in the hippocampus
(Almeida, Gomez, Barros, & Nin, 2019)
To further determine the effect of BDNF on GABAergic neurotransmission in the
PVN, we examined the expression of GAD67, which has been found to be elevated in
renovascular hypertensive rats compared to normotensive control animals (Biancardi et
al., 2010). BDNF release has also been shown to be necessary for activity-dependent
upregulation of both GAD65 and GAD67, and further GAD expression is reduced by the
application of the TrkB inhibitor, K252a (Hanno-Iijima et al., 2015). We found that the
expression of GAD67 in the PVN was not significantly different on any of the parameters
measured between the BDNF and GFP groups. This may indicate that GAD65 could play
a more significant role in this mechanism since BDNF-TrkB signaling also regulates
GAD65 expression (Hanno-Iijima et al., 2015; Sanchez-Huertas & Rico, 2011). Another
mechanism might involve GATs, since BDNF is known to elevate presynaptic
concentration of GABA via the activation of GAT-1 (Vaz et al., 2011), which also
increases GABA transport in astrocytes and neurons. GATs are found in both neurons
and astrocytes and are responsible for terminating GABA transmission (Vaz et al., 2011).
BDNF has also been shown to interact with KCC2 expression and signaling.
KCC2 serves to establish the chloride ion gradient in neurons via the maintenance of low
intracellular chloride concentration (Tang, 2020). BDNF signaling has been shown to
increase KCC2 expression in immature neurons and decrease it in adult neurons (Aguado
et al., 2003; Boulenguez et al., 2010; A. Ludwig et al., 2011; Claudio Rivera et al., 2002;
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Claudio Rivera et al., 2004; Shulga et al., 2008; Wake et al., 2007). The expression of
KCC2 is significantly decreased in TrkB double KO mice hippocampi (Carmona et al.,
2006), and in adult neurons BDNF has been found to decrease both mRNA and protein
KCC2 (Boulenguez et al., 2010; Claudio Rivera et al., 2002; Claudio Rivera et al., 2004;
Shulga et al., 2008; Wake et al., 2007). BDNF-TrkB-KCC2-mediated signaling is also
implicated in salt-sensitive hypertension whereby this mechanism weakens baroreceptor
inhibition of vasopressin magnocellular cells in the SON through a downregulation of
KCC2 by BDNF (Choe et al., 2015). KCC2 ROI mean, and ROI max were significantly
higher in the BDNF group compared to the GFP group. This elevation of KCC2 in the
BDNF group could be a compensatory response to the potential downregulation of KCC2
in the SON reported in the literature in response to elevated blood pressure. Another
potential mechanism may involve KCC2 being upregulated in response to elevated
mGluR activity, which has been shown to regulate inhibitory synaptic strength in
pyramidal neurons in the CA3 area of the hippocampus (Banke & Gegelashvili, 2008;
Chorin et al., 2011; H. H. Lee et al., 2007). mGluR activity in the PVN is known to be
elevated in SHRs compared to WKY (D. P. Li & Pan, 2010), and further activation of
mGluRs increases BDNF mRNA and protein expression in C6 glioma cells (Viwatpinyo
& Chongthammakun, 2009).
Finally, BDNF is known to serve as an important mediator of neuronal plasticity,
and functions as an activity-dependent modulator of neuronal structure, function and
signaling broadly in the CNS (Bramham & Messaoudi, 2005). BDNF has been reported
to increase neuronal soma size of striatal neurons (Yu et al., 2018), cortical and
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hippocampal interneurons (Rutherford et al., 1998) and GABAergic neurons in the
hippocampus (M. K. Yamada et al., 2002). Thus, we quantified the mean soma size of
GFP and BDNFmyc infected neurons in previously injected AAV2-GFP and AAV2BDNFmyc rats. However, the average neuronal soma size of GFP and BDNFmyc cells
was not statistically different.
3.5. Conclusion
In summary, our studies demonstrate that BDNF overexpression in the PVN elevates
NMDA-mediated glutamatergic signaling and diminishes GABAA-mediated GABAergic
signaling contributing to the chronic hypertensive effects of BDNF. Specifically, we
found that inhibition of NMDA-receptors significantly lowered MAP in BDNF rats
compared to the control group, while activation of NMDA-receptors did not have a
significant effect on MAP but did significantly reduce heart rate in the BDNF group.
However, BDNF did not significantly alter NMDAR1 mRNA expression in the PVN but
did significantly increase NMDAR1 protein expression in the PVN in the BDNF group.
We also found that inhibition of GABAA receptors significantly elevated MAP in the
GFP group compared to the BDNF group, and activation of GABAA receptors
significantly decreased MAP in the GFP group compared to the BDNF group. BDNF did
not significantly alter GABAA-delta subunit mRNA expression but did significantly
decrease GABAA-alpha1 protein expression in the PVN. However, GAD67 and synapsin
1a/b protein expressions were not significantly different between the two groups while
KCC2 protein expression was found to be significantly elevated in the BDNF group
compared with the GFP group. These BDNF-mediated mechanisms may synergistically
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contribute to elevations in blood pressure and play a significant role in the development
of related cardiovascular diseases such as hypertension.
CHAPTER 4: SIGNIFICANCE OF FINDINGS
4.1. Hypertension and Sympathetic Cardiovascular Regulation
Hypertension is one of the most significant risk factors for the development of
cardiovascular diseases such as heart disease, stroke and heart failure ("Global, regional,
and national comparative risk assessment of 84 behavioural, environmental and
occupational, and metabolic risks or clusters of risks for 195 countries and territories, 19902017: a systematic analysis for the Global Burden of Disease Study 2017," 2018). It is also
a very prevalent medical condition affecting approximately 45.6% of US adults.
Additionally, of those taking antihypertensive medication, 53.4% have reported blood
pressure above treatment goal (Muntner et al., 2018). Lifestyle factors such as high stress
(Hamer et al., 2008; McEwen & Gianaros, 2010), high salt intake (Denton et al., 1995; F.
J. He & MacGregor, 2002; "Intersalt: an international study of electrolyte excretion and
blood pressure. Results for 24 hour urinary sodium and potassium excretion. Intersalt
Cooperative Research Group," 1988) and obesity (Kannel et al., 1967) are known to be
common risk factors for the development of hypertension. The high rate of uncontrolled
hypertension remains a problem, demonstrating the need for more targeted treatments.
Several pharmacological and non-pharmacological treatments available today target the
heart or vasculature (Aronow, 2018). However, only a few treatments target the underlying
mechanisms behind the development of hypertension, most significantly elevated
sympathetic activity (Q. Fu et al., 2005), which is a key contributor to most cases of
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hypertension (Rahn et al., 1999; Schlaich et al., 2004; Wyss, 1993). Several interventions
targeting sympathetic activity have shown limited success in clinical trials, such as
catheter-based renal endovascular approaches (Azizi et al., 2018; Desch et al., 2015;
Mahfoud et al., 2017), and baroreflex activation therapy (de Leeuw et al., 2017; Wustmann
et al., 2009).
Blood pressure regulation can be altered by changes in the neuronal activity in
hypothalamic and brainstem nuclei during baseline and stress conditions. RVLM activation
increases sympathetic activity and blood pressure while inhibition leads to a decrease in
sympathetic activity and blood pressure (R. A. Dampney, 1994). Meanwhile, selective
lesioning of NTS catecholaminergic neurons in rats leads to an increase in blood pressure
in some cases (Daubert et al., 2012; Duale et al., 2007; Itoh & Bunag, 1993), while other
studies have shown no significant effect on baseline blood pressure (Itoh et al., 1992; Itoh
& Bunag, 1992; Talman et al., 1980). Activation of PVN projections to other hypothalamic
areas and other cardiovascular regulatory nuclei tend to increase blood pressure (R. A.
Dampney, 1994; Pyner & Coote, 2000). Specifically lesioning parvocellular PVN neurons
has also been shown to reduce renal sympathetic nerve activity (Haselton, Goering, &
Patel, 1994; Lovick, Malpas, & Mahony, 1993). Further, an elevation of excitatory
signaling and a reduction of inhibitory signaling mechanisms in the PVN are thought to
contribute to enhancing sympathetic output in hypertension (Boudaba et al., 1997; Q. H.
Chen et al., 2003; Y. F. Li et al., 2006). Hypertensive stimuli such as chronic stress
increases the excitability of PVN neurons by elevating the expression of NMDA receptors
(Franco et al., 2016) and reducing the expression of GABAA receptors (Cullinan, 2000;
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Verkuyl et al., 2004). Studies have also shown that the expression of NMDA receptor
subunits can be modified by changes in blood pressure (Coleman et al., 2010; Glass et al.,
2015; D. P. Li, H. S. Byan, & H. L. Pan, 2012; Y. F. Li et al., 2003; Marques-Lopes et al.,
2014), and further that GABAA-mediated inhibition of the PVN is reduced in hypertension
and heart failure (D.-P. Li & H.-L. Pan, 2007; D. S. Martin & Haywood, 1998; K. Zhang
et al., 2002).
In our first study, we showed how BDNF overexpression in the PVN and lesioning
of catecholaminergic NTS neurons with DSAP alters sympathetic cardiovascular
regulation. Similar to what has been seen previously in the literature (Daubert et al., 2012),
blood pressure was elevated following BDNF overexpression in the PVN and DSAP
lesioning of the NTS. Lesioning NTS catecholaminergic neurons was also found to
increase blood pressure in GFP control rats but did not further elevate blood pressure
following BDNF overexpression in the PVN. Additionally, we found that a PVN
microinjection of the general beta-adrenergic agonist isoprenaline decreased blood
pressure more significantly in the GFP control group compared to the BDNF overexpressed
group, and further that beta-1 adrenergic receptor mRNA in the PVN was downregulated
in the BDNF group compared to the GFP group. This indicates that BDNF may be
diminishing the sensitivity of the inhibitory catecholaminergic NTS-PVN projections
through downregulating beta-1 adrenergic receptors in the PVN.
In our second study, we examined the effect of overexpressing BDNF in the PVN
on excitatory NMDA-mediated and inhibitory GABAA-mediated signaling. We found that
BDNF augmented NMDA-receptor signaling and reduced GABAA-receptor signaling in
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the PVN to elevate blood pressure. Specifically, BDNF overexpression reduced the
elevation of blood pressure in response to a PVN injection of the GABAA antagonist
gabazine compared to the control group, while also reducing the decrease of blood pressure
in response to a PVN injection of the GABAA agonist muscimol. BDNF overexpression
in the PVN augmented the reduction in blood pressure in response to the NMDA receptor
antagonist AP5 compared to the GFP group but had no effect on blood pressure when
NMDA was injected into the PVN. The literature shows that AP5 microinjections into the
PVN significantly decrease blood pressure in SHRs compared to WKY rats (D.-P. Li &
H.-L. Pan, 2007; Y. F. Li et al., 2006). GABAA agonist, isoguvacine or muscimol,
microinjections into the PVN also reduce blood pressure more significantly in WKY and
SD rats compared to SHRs (Ding et al., 2015; D. P. Li & H. L. Pan, 2007). Meanwhile
PVN microinjections of the GABAA antagonist, gabazine or bicuculline, have been found
to increase blood pressure significantly more in WKY and SD rats compared to SHRs
(Ding et al., 2015; D. P. Li & Pan, 2006; D. P. Li & H. L. Pan, 2007; Y. F. Li et al., 2006).
In terms of protein and mRNA expression of excitatory and inhibitory signaling
components the results were mixed. NMDAR1 ROI max and ROI mean was higher in the
BDNF group compared to the GFP group. NMDAR1 subunit mRNA expression and
protein level in the PVN have been found to be significantly increased in heart failure
compared with sham rats (Y. F. Li et al., 2003), and further administration of a sub-pressor
dose of Ang II elevates the plasma membrane expression of NMDAR1 in dendrites of PVN
neurons (Glass et al., 2015). Expression of synapsin 1 a/b, a common synaptic marker, was
also assessed and was not found to significantly differ between the GFP and BDNF groups.
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A link between chronic salt loading and elevations in synapsin IIa and IIb transcripts in the
magnocellular division of the PVN compared to control animals has been shown (Nomura
et al., 2000), but the role of synapsin 1 a/b has not been investigated in this context.
In terms of inhibitory signaling in the PVN, GABAA-alpha1 ROI max but not ROI
mean was elevated in the GFP compared to the BDNF group. Additionally, GABAAalpha1 expression in the PVN in the BDNF group compared to the peri-PVN was
significantly lower while GABAA-alpha1 expression in the peri-PVN of the BDNF group
was significantly lower compared to the peri-PVN of the GFP group. In the literature,
GABAA-alpha1 expression has been found to be similar in the PVN of renal-wrapped
hypertension and sham rats (Haywood et al., 2001), while GABAA-alpha5 subunit has
been shown to be significantly decreased in the PVN of SHRs compared to WKY rats
(Cork et al., 2016). Meanwhile protein expression of GAD67, a commonly used marker of
GABAergic activity, was found to be similar between the two groups. In renovascular
hypertensive rats, GAD67 expression has been reported to be elevated in the PVN
compared to normotensive control animals (Biancardi et al., 2010). Finally, the mRNA
expression of NMDAR1 and GABAA-delta subunit were unaffected by BDNF
overexpression.
4.2. The Importance of BDNF Signaling
BDNF is a neurotrophin crucially involved in mediating neuroplasticity
mechanisms such as neuronal growth, differentiation, development and synaptic
strengthening during development and in adult neurons (E. J. Huang & Reichardt, 2001).
BDNF also plays a key role in learning and memory mechanisms (Alonso et al., 2002; Y.
140

Lu et al., 2011; Radiske et al., 2015), and the facilitation of LTP (Y. Lu et al., 2011;
Patterson et al., 1996). BDNFs role in stress and cardiovascular system regulation in the
PVN has also been demonstrated previously. BDNF mRNA and protein levels in the PVN
have been shown to be upregulated following acute and chronic stress, hyperosmolality,
and repeated amphetamine administration (Aliaga et al., 2002; Hammack et al., 2009;
Meredith et al., 2002; Rage et al., 2002; Smith, Makino, Kim, et al., 1995). We (Erdos,
Backes, et al., 2015; Chris L. Schaich et al., 2016) have also shown that both long-term
overexpression and acute microinjection of BDNF into the PVN leads to significant
increases in blood pressure, and heart rate. Furthermore, we (C. L. Schaich et al., 2018)
have found that inhibition of BDNF signaling by blocking the TrkB receptor in the PVN
reduces acute stress-induced blood pressure elevations without altering baseline
cardiovascular parameters.
BDNF may alter central cardiovascular regulation through catecholaminergic
signaling, since BDNF treated rats show a dose-dependent increase in both dopamine
content, uptake activity and TH-72 positive neurons (C. Hyman et al., 1994). BDNF could
also affect central cardiovascular regulation via altering NMDA and GABAA-mediated
signaling. BDNF can enhance NMDA-mediated signaling by activating the membrane
trafficking, expression (Caldeira et al., 2007; Kim et al., 2012; Kolb et al., 2005), and
phosphorylation (Black, 1999) of NMDA receptors to increase excitatory synaptic
transmission. BDNF has also been shown to decrease the expression of GABAA receptors,
both membrane density and function in hypothalamic neurons (Carreno et al., 2011; Hewitt
& Bains, 2006; Lund et al., 2008). In this study, we found that BDNF overexpression in
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the PVN resulted in increased DBH and TH expression in the NTS leading to a reduced
sensitivity to catecholaminergic projections from the NTS in the PVN. We showed that
this occurs at least partly through a downregulation of beta-1 adrenergic receptor mRNA
in the PVN by BDNF, which was also supported by a greater hypotensive response to the
general beta-adrenergic receptor agonist isoprenaline into the PVN, which was seen in the
GFP group but not the BDNF group.
We also found that BDNF upregulated NMDA-mediated signaling and
downregulated GABAA-mediated signaling in the PVN. We found that inhibition of
NMDA-receptors significantly lowered MAP in BDNF rats compared to the control group,
while activation of NMDA-receptors did not have a significant effect on MAP but did
significantly reduce heart rate in the BDNF group. However, BDNF did not significantly
alter NMDAR1 mRNA expression in the PVN but did significantly increase NMDAR1
protein expression in the PVN in the BDNF group. We also found that inhibition of
GABAA receptors significantly elevated MAP in the GFP group compared to the BDNF
group, and activation of GABAA receptors significantly decreased MAP in the GFP group
compared to the BDNF group. BDNF also reduced the protein expression of GABAAalpha1 in the BDNF group compared to the GFP control group but did not alter the
expression of GABAA-delta mRNA in the PVN.
These studies and others suggest that BDNF overexpression in the PVN could be a
potential model for hypertension. Many pro-hypertensive stimuli, which are known risk
factors for the development of hypertension and other cardiovascular disorders, are also
associated with an upregulation of BDNF expression in the PVN. For example, chronic
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stress has been shown to increase BDNF expression in the BNST (Hammack et al., 2009)
and in the PVN (Hammack et al., 2009; Rage et al., 2002; Smith, Makino, Kim, et al.,
1995). Elevated BDNF expression in the PVN has also been shown to decrease body
weight and food intake (C. Wang et al., 2010). Changes in BDNF signaling in the PVN is
also a contributing factor to the development of hypertension. We have shown that chronic
overexpression of BDNF in the PVN leads to increased baseline blood pressure and heart
rate (Erdos, Backes, et al., 2015; Chris L. Schaich et al., 2016), similar to what is seen in
hypertension. BDNF-mediated hypertension could serve as a useful model for
hypertension since it is easy to replicate in rodent models and is associated with a variety
of pro-hypertensive factors. Increased sympathetic activity is a significant contributor to
hypertension, and alterations in CNS neurocircuitry could be explained at least partly by
an increase in BDNF expression and associated BDNF-mediated neuroplasticity effects on
neuronal signaling in the PVN.
4.3. Potential Applications of Findings
BDNF overexpression in the PVN could serve as a useful animal model for BDNFmediated hypertension, which has been demonstrated by the studies discussed here and by
others in the literature (Erdos, Backes, et al., 2015; Chris L. Schaich et al., 2016). BDNF
mRNA and protein expression is elevated in response to various hypertensive stimuli such
as stress (Givalois et al., 2004; Hammack et al., 2009; Smith & Cizza, 1996; Smith,
Makino, Kim, et al., 1995) and hyperosmolality (Aliaga et al., 2002), and thus could mimic
certain cases of hypertension in humans. The mechanism behind BDNFs effect on
cardiovascular regulation within the PVN remains undetermined. It will be important to
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precisely determine this mechanism to better aid in the development of more targeted
pharmaceutical or surgical interventions for the treatment of BDNF-mediated
hypertension. Hypothalamic levels of BDNF can be increased in gene therapy, and has
been shown to be a potential treatment for diabetes, obesity, and metabolic syndrome (Cao
et al., 2009; McMurphy et al., 2019; Nagahara & Tuszynski, 2011). However, as seen in
these studies, increasing hypothalamic BDNF expression will also increase blood pressure
and heart rate, and therefore such a treatment might be associated with harmful
cardiovascular side effects.
Given that BDNF overexpression in the PVN elevates blood pressure and heart rate
chronically, potentially inhibiting the TrkB receptor may lower blood pressure and heart
rate. A few TrkB antagonists have been used to study BDNF signaling in hypertension,
such as the non-specific TrkB antagonist K252a and the highly selective TrkB antagonist
[N2-2-2-oxoazepan-3-yl amino] carbonyl phenyl benzo (b)thiophene-2-carboamide
(ANA-12). NTS injections of K252a lead to a significant decrease in blood pressure and
heart rate in rats (Clark et al., 2011). Meanwhile, injections of BDNF into the NTS of
congestive heart failure rats lead to a depressor effect while ANA-12 injections into the
NTS result in a sympathoexcitatory response in sham rats (Becker et al., 2016). Inhibiting
the TrkB receptors in the PVN by overexpressing the dominant-negative truncated TrkB
receptor (TrkB.T1), which binds to the full-length TrkB receptor and inhibits its activity,
in the PVN reduces acute stress-induced blood pressure elevations but does not affect
resting blood pressure, food intake and body weight in normotensive animals (C. L.
Schaich et al., 2018). Others have found that chemogenetic activation of TrkB-expressing
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PVN neurons suppresses food intake, while inhibition of those same neurons increases
food intake (An et al., 2020). The effect of a TrkB antagonist in the PVN of hypertensive
animals has not been studied.
BDNF does not cross the blood brain barrier (Pardridge, Wu, & Sakane, 1998), but
using a magnetically guided nanocarrier targeting BDNF would allow for blood brain
barrier transmission. Such a drug carrier could deliver systemic BDNF or TrkB antagonists
across the blood brain barrier (Kouhpanji & Stadler, 2020; Pilakka-Kanthikeel, Atluri,
Sagar, Saxena, & Nair, 2013), thereby potentially reducing blood pressure in hypertensive
patients. However, this technology has only been studied in small animal models so far.
Some of the major clinical difficulties associated with moving to a human model would be
reductions in magnetic field strength with greater target depth in the body, the necessity
for driving a significant number of magnetic nanocarriers to get a significant therapeutic
effect (Shapiro et al., 2015), as well as poor retention upon removal of the external
magnetic field, leading to a reduction in drug uptake (D'Agata et al., 2017; Estelrich,
Escribano, Queralt, & Busquets, 2015).
4.4. Experimental Limitations and Future Directions
In these studies, we examined the effects of BDNF on catecholaminergic, NMDA
and GABAA-mediated signaling in the PVN. In agreement with previous papers, we found
that MAP and heart rate were increased in response to BDNF overexpression in the PVN
(Erdos, Backes, et al., 2015). We also found that BDNF diminished catecholaminergic
activity via a downregulation of beta-1 adrenergic receptors in the PVN, which play an
inhibitory role on PVN activity under normal physiological conditions (Saphier &
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Feldman, 1991; Tsushima et al., 1994; D. Wang et al., 2013). We also found that BDNF
overexpression in the PVN elevated NMDA-mediated signaling, while reducing GABAAmediated signaling without altering mRNA expression of NMDAR1 or GABAA-delta
subunit, but with increases in protein expression of NMDAR1 and KCC2 in the PVN and
a reduction in protein expression of GABAA-alpha1 subunit. These results mostly agree
with prior studies that have shown that BDNF enhances NMDA-mediated glutamatergic
transmission (Lessmann, Gottmann, & Heumann, 1994; Lessmann & Heumann, 1998),
and where BDNF reduced GABAergic terminals and GABA (Kohara et al., 2007) and
GABA release in the visual cortex (Abidin, Eysel, Lessmann, & Mittmann, 2008). PVN
overexpression of BDNF as a model for hypertension allows for the investigation of the
role of BDNF mediated neuroplasticity mechanisms. However, this model is limited since
it leads to a continuously high BDNF expression in the PVN, which is unlike what is
thought to occur under acute stress or other pro-hypertensive conditions where BDNF
expression changes are believed to be transient (Bland et al., 2005; Y. Lee, Duman, &
Marek, 2006). It is also unknown if BDNF is upregulated in the PVN in other hypertension
models such as in the SHR. SHRs have been reported to have a higher expression of BDNF
in the motor cortex (Banoujaafar, Van Hoecke, Mossiat, & Marie, 2014) and in the NTS
(Vermehren-Schmaedick et al., 2013) compared to WKY rats. Conversely, in the
hippocampus SHRs exhibit lower levels of BDNF compared to WKY (Pietranera, Lima,
Roig, & De Nicola, 2010). Despite this limitation, the BDNF model reveals important
information on how PVN neuronal activity is altered under hypertensive conditions.
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In these studies, immunofluorescence pixel intensity was used to estimate protein
expression which has limitations in terms of antibody specificity, reliability, and expression
within the PVN. We investigated excitatory signaling, looking at NMDAR1 and synapsin
1a/b expression, which leaves out the potential role of NMDAR2 and the potential role of
other synaptic markers and synapsin II and III. Expression was quantified within a
morphologically similar slice of the PVN where a high expression of GFP or BDNFmyc
was seen. Morphological differences in the PVN in the caudal-rostral axis could still
contribute to some variation in the data (Stern, 2001). We also investigated inhibitory
signaling, looking at GABAA-alpha1, GAD67 and KCC2 expression, leaving out the
potential role of other GABAA subunits, GAD65, an enzyme responsible for the
conversion of glutamate to GABA, and the sodium potassium chloride co-transporter
(NKCC1). The effect of BDNF on GABAA-alpah1 subunit expression in the PVN was
variable, with some of the analyses showing a significant effect while others did not. The
mechanism behind the alteration of excitatory and inhibitory signaling seen in the BDNF
overexpressed rats may involve the GABAA-alpha1 subunit to some extent but might also
involve other subunits of GABAA, as well as other trafficking and phosphorylation
mechanisms that have not been studied here.
The main limitations of the RT-PCR protocol could be that the isolated PVN tissue
included tissue not affected by the vector injection, and potentially included some tissue
outside the boundary of the PVN, such as parts of the peri-PVN. Another potential
limitation of this study was the use of only male rats. Sex has been shown to influence the
development and maintenance of hypertension (Gillis & Sullivan, 2016; Sandberg & Ji,
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2012). However, the extent and impact of sex on hypertension is debated, with a recent
meta-analysis showing that there is no significant impact of sex on blood pressure
responses to antihypertensive therapy or on cardiovascular outcomes (Doumas,
Papademetriou, Faselis, & Kokkinos, 2013). The effect of BDNF signaling in the PVN on
hypertension in females has also not been conclusively determined.
This study investigated the effect of BDNF overexpression in the PVN on NMDAmediated excitatory signaling, which leaves out important roles that might be played by
AMPA receptors and mGluRs, both of which have been shown to play a role in elevating
blood pressure within the PVN previously in the literature. Microinjection of the GluR2lacking AMPAR inhibitor 1-naphthyl acetyl spermine into the PVN has been shown to
decrease blood pressure and lumbar sympathetic nerve activity in SHR but not in WKY
rats (D.-P. Li, H. S. Byan, & H.-L. Pan, 2012). While bilateral PVN microinjection of a
selective mGluR1 or mGluR5 receptor antagonist, has been shown to have no significant
effect on lumbar sympathetic nerve activity and blood pressure in WKY rats but does
decrease lumbar sympathetic nerve activity, blood pressure and heart rate in SHRs (D. P.
Li & Pan, 2010). Additionally, a PVN bilateral microinjection of a selective group I mGluR
agonist causes an increase in lumbar sympathetic nerve activity, blood pressure and heart
rate in both WKY and SHRs (D. P. Li & Pan, 2010). Further, mGluR5 in the PVN is known
to be upregulated in hypertension and contribute to the hyperactivity of PVN
presympathetic neurons through PKC- and SNAP-25-mediated surface expression of
NMDA receptors (D. P. Li, Zhu, Pachuau, Lee, & Pan, 2014). Finally, BDNF is known to
increase the surface expression of AMPA receptors in the rat nucleus accumbens core (X.
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Li & Wolf, 2011), and activation of group I mGluRs induces BDNF mRNA and protein
expression in C6 glioma cells (Viwatpinyo & Chongthammakun, 2009) while chronic
treatment of a selective mGluR5 antagonist increases BDNF mRNA levels in the
hippocampus (Legutko, Szewczyk, Pomierny-Chamioło, Nowak, & Pilc, 2006).
This study investigated the effect of BDNF overexpression in the PVN on GABAAmediated signaling. However, a potential contributor to the alteration of GABAergic
signaling in the PVN in hypertensive conditions are GABAB receptors. A PVN
microinjection of the GABAB receptor agonist baclofen has been shown to decrease
lumbar sympathetic nerve activity and blood pressure in SHRs but not in WKY and SD
rats (D. P. Li & H. L. Pan, 2007). Meanwhile, a microinjection of the GABAB receptor
antagonist CGP52432 has been shown to only increase lumbar sympathetic nerve activity
and blood pressure in SHR but not in normotensive controls (D. P. Li & H. L. Pan, 2007).
Further, stimulation of GABAB receptors has been shown to induce a calcium-dependent
release of BDNF via the PLC-PKC signaling cascade and L-type voltage-gated calcium
channels (Fiorentino et al., 2009; Kuczewski et al., 2011).
Future studies could focus on delineating the impact of BDNF overexpression on
other glutamatergic receptors such as mGluR1 and mGluR5, and the AMPA receptors in
the PVN. Additionally, the effect of BDNF overexpression in the PVN on GABAB
receptor signaling could be investigated. Other signaling components that would need to
be evaluated in the BDNF-model would be GAD65 and NKCC1 expression and signaling
in the PVN. Another key element to look at would be if BDNF expression is upregulated
in the PVN of SHRs compared to WKY rats and if an injection of a TrkB antagonist into
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the PVN lowers blood pressure in the SHRs or not. This would provide a more definitive
link between hypertension and an increase in BDNF signaling and expression in the PVN.
Furthermore, shifting focus to the development of a central TrkB antagonist to treat
hypertension could be an important avenue to pursue.
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